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SUMMARY
Nephrotic range proteinuria and chronic renal failure are associated with both 
qualitative and quantitative changes in lipoproteins and increased cardiovascular risk. 
LDL exhibits heterogeneity with increased small dense LDL (LDLIII) associated with 
increased risk of coronary heart disease (CHD). In normal populations, production of 
small dense LDL is physiologically linked to mild hypertriglyceridaemia and low 
HDL, a combination that has been labelled ‘the atherogenic lipoprotein phenotype’. 
This thesis aimed to explore abnormalities in the metabolism of triglyceride-rich 
lipoproteins in patients with chronic renal dysfunction, with particular reference to 
changes in LDL sub fraction distribution and remnant lipoprotein particles. The main 
population investigated were patients with nephrotic range proteinuria secondary to 
primary glomerular disease, however this work was extended to examine changes in 
lipoproteins in patients with proteinuria secondary to diabetic nephropathy in type 2 
diabetes, and also patients with end-stage renal failure. Our hypothesis was that in 
patients with proteinuria, hypertriglyceridaemia occurs as a result of impaired 
catabolism of VLDL. The consequence is the generation of small dense LDL 
(LDLIII) and remnant lipoproteins, both of which are pathogenic agents which may 
contribute to accelerated vascular disease and to the rate of progression of renal 
failure.
Quantitative analysis of both LDLIII and remnant lipoproteins was performed in 27 
patients with nephi'otic range proteinuria and well preserved renal function. This 
revealed a marked increased in plasma LDLIII concentration, to levels that are noted 
to be atherogenic in normal populations. This increase primarily due to a shift in 
particle size towards smaller denser particles. Remnant lipoproteins (RLP) were
V
similarly increased in proteinuric patients. The excess of both of these atherogenic 
particles was independently related to the increase in plasma triglyceride prevalent in 
this population, an increase that previously been demonstrated to result in part, from 
delayed clearance of the VLDL] subfraction of very-low density lipoprotein (VLDL).
The 27 patients studied were found to have normal in vitro lipase activity, however 
marked abnormalities in the lipid and apolipoprotein content of the VLDL] particles 
was observed. Despite apparently normal plasma concentration of both apolipoprotein 
(apo) CII and apoCIII, the patients with proteinuria possessed VLDL] particles that 
were deficient in both of these apolipoproteins. This deficiency was accompanied by a 
relative deficiency in both plasma and VLDL] apoE. VLDL] particles were also found 
to be smaller than those in the control group with a higher surface ratio of free 
cholesterol: phospholipid. The presence o f smaller, free cholesterol enriched, 
apolipoprotein deficient particles could easily account for the observed delay in 
clearance of VLDL] observed in this population.
12 patients with >1.5g/24hrs o f urinary albumin, hypercholesterolaemia and plasma 
triglyceride >1.5mmol/l were studied in a randomised crossover trial comparing the 
effects of a statin (cerivastatin) and a fibrate (fenofibrate) on the concentration of 
LDLIII and remnant lipoproteins (RLP). Fenofibrate produced a significant reduction 
in both LDLIII and RLP. Cerivastatin reduced LDLIII but not RLP, moreover the 
reduction in LDLIII was greater on fenofibrate than following cerivastatin. The two 
treatments also differed in the manner in which plasma LDLIII was reduced, thus the 
reduction in LDLIII following fenofibrate correlated with plasma triglyceride 
reduction whilst the LDLIII reduction on cerivastatin was associated with LDL-C
VI
reduction. Therefore fenofibrate seemed to reduce LDLIII by removing the excess 
triglyceride essential for formation of small dense LDL, with cerivastatin reducing 
LDLIII by decreasing the total amount of LDL present.
The association between dyslipidaemia and progression of chronic renal failure was 
studied in 30 patients with primary glomerular disease and >1.0g/24hrs of urinary 
albumin. Mean urinary albumin was found to have the strongest correlation with the 
rate of progression of renal failure, however non HDL-C was also independently 
related to the rate of progression. From amongst the spectrum of lipoproteins covered 
by non HDL-C, the only lipoprotein parameter that correlated with the rate of 
progression was VLDLi. No relationship was seen between the rate of progression of 
renal failure and the concentration of small dense LDL.
The influence of albuminuria on LDLIII concentration was examined further by 
studying patients with type 2 diabetes who had either diabetic nephropathy, 
microalbuminuria or normal urinary albumin excretion (diabetic controls). All three 
groups were compared to non-diabetic control patients. All groups were matched for 
age and sex, with the diabetic groups also matched for glycaemic control. The patients 
with diabetic nephropathy were found to have excess LDLIII compared with all three 
other groups, whilst the microalbuminuric and diabetic control patients possessed 
excess LDLIII compared with normal controls. These increases in LDLIII were found 
despite each group having a similar plasma LDL concentration. Once more, plasma 
triglyceride was the most important determinant of LDLIII concentration, however an 
independent effect of having diabetes was present and a clear relationship was seen 
between plasma LDLIII concentration and urinary albumin. As the groups were well
VII
matched, it is likely that in the patients with diabetic nephropathy, the dyslipidaemic 
environment in which excess LDLIII was formed resulted from the excess urinary 
albumin.
The final study assessed the influence of end-stage renal failure and renal replacement 
therapy on LDL subfractions. Excess LDLIII was present in the patients with renal 
failure, with plasma triglyceride and hepatic lipase activity being independent 
determinants of LDLIII. It is noteworthy that hepatic lipase activity was decreased 
compared with controls. In normal populations, a plasma triglyceride >1.5mmol/l and 
hepatic lipase activity >15umol/FA/ml/hi' is required to form atherogenic levels of 
LDLIII. As a result of the reduced lipase activity in uraemic patients, the level of 
plasma triglyceride required to form atherogenic levels of LDLIII was noted to be 
increased to approximately 2mmol/l.
In conclusion, the importance of the impaired metabolism of triglyceride-rich 
lipoproteins in patients with clii’onic renal disease has been demonstrated in this work. 
The consequence is formation of excess atherogenic particles, that are not detected by 
routine measurement of cholesterol and LDL-C but will clearly contribute to the 
excess coronary artery disease present in patients with either proteinuria, diabetic 
nephropathy or end-stage renal failure. A clear relationship was also demonstrated 
between dyslipidaemia and progression of renal failure. This clearly requires further 
investigation. Lipid lowering therapy is successful in reducing the plasma 
concentration of these particles, however due to the extent of the dyslipidaemia, 
aggressive treatment is likely to be required to achieve optimal results.
VIII
List o f  Figures
Page
1.1: VLDL particle.............................................................................................................. 18
1.2: LDL Particle................................................................................................................. 19
1.3: Endogenous Lipoprotein Metabolism: Enzymes & Receptors..............................  20
1.4: Characteristics of Stable and Unstable Plaques....................................................... 26
1.5: Vascular Risk Factors and the Plaque Stability.................. .................................... 27
1.6: Typical LDL Subfraction Profiles.............................................................................  34
3.1: Plasma Triglyceride (TG), CETP Activity and Flepatic Lipase Activity vs
LDLIII mass in Proteinuric Patients......................................................................... 59
3.2: Plasma Triglyceride, VLDLi mass and CETP Activity vs Remnant
Lipoprotein Cholesterol (RLP-C) in Proteinuric Patients....................................... 60
3.3: LDLIII mass and %LDLIII vs RLP-Cholesterol in Proteinuric Patients...............  61
4.1 : VLDLi mass vs Apolipoprotein CII, CIII and E per VLDLi particle.................  75
4.2: Triglyceride per VLDLi Particle vs Apolipoprotein CII, CIII and E per
VLDLi Particle............................................................................................................  76
4.3: FC:PL ratio vs Apolipoprotein CII, CIII and E per VLDLi particle ...................  77
5.1 : Absolute Change in %LDL Subfraction: Cerivastatin vs Fenofibrate.................  97
5.2: Percentage Change in Plasma Triglyceride and LDL-Cholesterol vs LDLIII
mass for Fenofibrate and Cerivastatin...................................................................... 98
5.3: Percentage Change in Plasma Triglyceride and VLDLI mass vs Remnant
Lipoprotein Cholesterol for Fenofibrate and Cerivastatin.....................................  99
5.4: Percentage Change Remnant Lipoprotein Cholesterol vs LDLIII mass for
Fenofibrate................................................................................................................... 100
6.1 : Distribution of Examination Period for Patients Studied....................................... 118
6.2: Urinary Albumin and Blood Pressure over Examination Period .......................... 119
6.3: Rate of Progression vs Mean Urinary Albumin over Examination Period and
Non H D L-C ................................................................................................................. 120
6.4: Rate of Progression vs VLDLi and LDLIII concentration....................................  121
7.1: Dot-Plot showing distribution of plasma triglyceride, VLDLi and VLDLi in
diabetic nephropathy, microalbuminuria, diabetic controls and normal controls.. 140 
7.2: Boxplot of LDLI, II and III in diabetic nephropathy, microalbuminuria, diabetic
controls and normal controls...................................................................................... 141
7.3: Plasma Concentration of VLDLi and LDLIII vs Urinary Albumin: Creatinine
R atio .............................................................................................................................. 142
7.4: Plasma Triglyceride, VLDLi and VLDLi Concentration vs LDLIII
Concentration..............................................................................................................  143
7.5: Plasma Triglyceride and HDL-C vs LDLIII for Diabetic Patients vs Controls ... 144
8.1. LDL Subfractions as Percentage of Total LDL: Patients vs Controls................  162
8.2: Plasma Triglyceride & Hepatic Lipase vs LDLIII concentration: All Patients ... 163
8.3: Plasma Triglyceride vs LDLIII concentration: Patients Subgroups.....................  164
8.4: Hepatic Lipase vs LDLIII concentration: Patients Subgroups..............................  165
9.1: Metabolism of Apo-B Containing Lipoproteins in Nephrotic-Range Proteinuria 177
IX
List o f  Tables
Page
1.1: Properties of Plasma Lipoproteins............................................................................ 16
1.2: The Major Apolipoproteins in P lasm a.....................................................................  17
2.1 : Density Gradient for Separation of VLDLi, VLDLi and ID L ...............................  43
2.2: Conditions for Cumulative Ultracentrifugation of VLDLi, VLDLi and IDL ..... 44
3.1: Anthiopometry, Lipids, Lipoproteins and Lipase activity.....................................  51
3.2: VLDL subfractions, IDL and LDL Subfractions...................................................  53
3.3: Lipids, Lipoproteins, VLDL & LDL Subfractions according to Renal Function . 55
3.4: Lipoprotein Compositions......................................................................................... 56
3.5: Factors associated with LDLIII and Remnant Lipoprotein Concentration  57
4.1 : Plasma Apolipoproteins: Patients vs Controls.......................................................  68
4.2: Plasma Concentration of VLDL] Apolipoproteins: Patients vs Controls  69
4.3: Apolipoprotein and Lipid content per VLDLi particle : Patients vs Controls  71
4.4: Univariate and Multivariate Analysis for Regulation of ApoCII, apoCIII
and ApoE per VLDLi particle - All Patients........................................................... 72
5.1 : Basic Lipid & Lipoproteins: Cerivastatin vs Fenofibrate......................................  93
5.2: Lipoprotein Concentrations: Cerivastatin vs Fenofibrate......................................  94
5.3: LDL Subfractions: Cerivastatin vs Fenofibrate......................................................  95
5.4: Plasma Lipoprotein Remnants and Apolipoproteins: Cerivastatin vs Fenofibrate 96
6.1: Clinical and Biochemical Data over Examination P eriod .....................................  115
6.2: Plasma Concentrations of Lipids, Lipoproteins and VLDL Subfractions at
Study D a te .................................................................................................................... 116
6.3: Plasma Concentration of LDL Subfractions at Study D ate ...................................  117
7.1 : Clinical Characteristics and Lipid Profiles of Each G roup...............................   137
7.2: Plasma Concentrations of Lipoproteins and Lipoprotein Subfractions................ 138
7.3: Lipoprotein Compositions: Total Cholesterol and Triglyceride as Percentage of
Lipoprotein M ass........................................................................................................  139
8.1: Anthropometric data, Lipids, Lipoproteins and Lipase activity: Patients vs
Controls....................................................................................................................... 154
8.2: Anthropometric data. Lipids, Lipoproteins and Lipases : Patient Subgroups vs
Controls.......................................................................................................................  156
8.3: VLDL subfractions, IDL & LDL subfractions: Patients vs Controls...........  157
8.4: VLDL subfractions, IDL & LDL subfractions: Patients Subgroups vs Controls . 159
8.5: Univariate and Multivaiiate Analysis for Regulation of LDLIII Concentration .. 160
8.6: Plasma Lipoprotein Compositions: Patients vs Controls................................ 161
X
A cknow ledgem ents
This work would not have been possible without the help of many of the staff of the 
Lipid Research Laboratory and the Renal Unit, Glasgow Royal Infirmary. In 
particular I wish to thank;
Professor Chris Packard for acting as my_^  supervisor, _%r providing excellent 
laboratory facilities in which to work, for his support, patience and guidance, for his 
stimulating advice and constructive criticism, which has and continues to be 
invaluable.
Dr Muriel Caslake for analysing the majority o f the LDL profile results in Chapter 8, 
for her help in analysing the LDL profiles in the other studies, and for teaching me the 
analytical techniques required to measure LDL and VLDL subfraction profiles. I 
would like to thank her for her ideas, discussions, constant support, and for her 
patience whilst teaching me the skills required for this work.
Michael McConnell for analysing the majority of the LDL and VLDL subtractions in 
chapter 8, along with the lipase, cholesteryl-ester transfer protein, remnant 
lipoproteins and the apolipoprotein analyses and most of the compositional analysis of 
the lipoprotein samples. I would like to thank him for teaching me the analytical 
techniques required in this work and for his patience in tolerating a novice in the 
laboratory.
Dr Michael Boulton-Jones for having the initial idea for the pilot study and for his 
enthusiasm, support, advice and criticism.
The Routine Lipid Section of the Institute of Biochemistry for carrying out the B 
quantification of lipids and lipoproteins.
The Lipid Research Staff for performing the rest of the compositional analyses, and 
Grace Stewart and Dorothy Bedford for their advice and assistance.
The patients and volunteers for freely giving their time and assistance, at no clear 
benefit to themselves.
The nursing staff in Ward 12, the CAPD unit and renal out-patient department.
Bayer and Fournier Pharmaceutical Companies for providing supplies of cerivastatin 
and fenofibrate.
The Scottish Hospital Endowment Research Trust who funded this project through a 
grant held by Professor C Packard and Dr JM Boulton-Jones.
Finally I would like to thank my wife and family for their incredible patience and 
support, without which this work would not have been possible.
XI
Author’s D eclaration
The work presented in this thesis was performed solely by the author, except where 
the assistance of others is acknowledged.
Chiistopher Deighan, October 1999
XII
D edication
To my loving wife Tricia and children Hannah and Michael
XIII
List Of Abbreviations
Apo Apolipoprotein
BMI Body mass index
BP Blood pressure
CAD Coronary artery disease
CETP Cholesteryl ester transfer protein
CHD Coronary heart disease
CrCl Creatinine Clearance
d Density
Da Daltons
DBP Diastolic blood pressure
HDL High density lipoprotein
HL Hepatic Lipase
HMG CoA 3-hydroxy,3-methyl glutaryl coenzyme A
IDL Intermediate density lipoprotein
IQR Inter-quartile range
LCAT Lecithin cholesterol acyl transferase
LDL Low density lipoprotein
Lp(a) Lipoprotein (a)
LpL Lipoprotein lipase
RLP-C Remnant lipoprotein - cholesterol
RLP-TG Remnant lipoprotein - triglyceride
SD Standard deviation
Sf Svedberg flotation units
VLDL Very low density lipoprotein
XIV
CHAPTER 1 - INTRODUCTION
1.1. MACROVASCULAR DISEASE IN PATIENTS WITH CHRONIC RENAL 
DISEASE
Across a wide range of pathological processes, the development of chronic renal 
disease is associated with a marked increase in cardiovascular morbidity and 
mortality. The presence of excess urinaiy protein is recognised to be an independent 
risk factor for cardiovascular disease [1,2] with 2 fold increase in the relative risk of 
cardiovascular disease in normal populations found to have dipstick positive 
proteinuria. [3]. In patients with chronic renal failure, there is an increased incidence 
of cardiovascular disease, accounting for more than 50% of deaths amongst patients 
on renal replacement therapy [4]. Moreover, despite the reduction in mortality from 
cardiovascular disease in the general population [5], the proportion of patients 
receiving renal replacement therapy who die of cardiovascular disease has remained 
constant [4]. Finally in both insulin dependent and non-insulin dependent diabetes, the 
development of diabetic neplnopathy with persistent proteinuria is also associated 
with increased cardiovascular mortality [2, 6].
When discussing cardiovascular disease in the context of underlying renal 
dysfunction, it is important to distinguish between: (1) atherosclerotic disease which is 
manifested primarily as myocardial ischaemia secondary to coronaiy artery disease,
(2) congestive cardiac failure which may result from myocardial ischaemia, but may 
also be secondary to fluid overload, uraemia or hypertension, (3) left ventricular 
hypertrophy, which also results from fluid overload and hypertension but is also a
consequence of chi'onic anaemia and (4) cerebrovascular disease, which may be 
secondary to atherosclerosis, but more frequently results from hypertension.
If the cardiovascular risk assessment is restricted to morbidity and mortality from 
coronary heart disease however, the increased risk remains prevalent across the 
spectrum of renal disease. In the MRFIT study, the relative risk of death from 
coronary heart disease was increased 2 fold in patients with persistent 1+ positive 
proteinuria on dipstick urinalysis [3], increasing to 2.5 times with an increase in the 
proteinuria to 2+ [3]. The relative risk continues to rise as proteinuria increases and 
studies in patients with nephrotic range proteinuria demonstrate a 3 fold increase in 
the risk of coronary death and a 5.5 times increase in the risk of myocardial infarction 
[7]. In the case of the MRFIT study, the increased risk was independent of age, initial 
cholesterol, diastolic blood pressure, smoking, antihypertensive use, change in renal 
function and race [3], whilst in the study by Ordonez [7] the risk from nephrotic range 
proteinuria was independent of both hypertension and smoking. In patients with 
chronic but not end-stage renal failure, the incidence of myocardial infarction is 2.5-3 
times higher in male patients than in the general male population [8], whilst those on 
renal replacement therapy in the United States have a prevalence of coronary artery 
disease of 40% compared with the prevalence in the general population of 5% in those 
aged 45-64 and 12% in those over 65 years [9]. Age specific death rates from 
myocardial ischaemia and infarction in patients on renal replacement therapy in the 
UK follow along similar lines and continue to be 7-10 times higher, even after 
excluding patients with diabetes mellitus [4]. In patients with diabetes mellitus, the 
impact of renal disease on morbidity and mortality from coronary heart disease is even 
more profound. Coronary artery disease is the major determinant of the excess
mortality in patients with insulin dependent diabetes mellitus (IDDM) and persistent 
proteinuria [10], with an 8 fold increase in the incidence of coronaiy arteiy disease 
compared with matched insulin dependent diabetic patients without proteinuria [11]. 
In NIDDM, although microalbuminuria is strongly associated with coronary artery 
disease, it is unclear whether this is simply a reflection of underlying vascular damage 
rather than a risk factor for the future development of coronary arteiy disease [12]. 
However, the development of heavy proteinuria in NIDDM has been shown to be 
associated with increased atherosclerosis [13]. The prognosis in diabetics with end- 
stage renal failure is even worse. Mortality from ischaemic heart disease is a further 2- 
3 times higher in diabetics compared to non-diabetic patients on renal replacement 
therapy [4], A further illustration of the extent of coronary artery disease in this 
population can be seen by comparing the mortality from myocardial infarction in 
diabetics from the MRFIT study (10 per 1000 patient/years) and diabetics on dialysis 
(65 per 1000 patient/years) [14]. These two data sets clearly demonstrate the excess 
coronary risk of having both NIDDM and end-stage renal failure.
Therefore, it is clear that not only is cardiovascular disease extremely prevalent across 
the wide spectrum of clu'onic renal disease, but coronaiy heart disease and 
atherosclerotic disease in general are major contributors to morbidity and mortality in 
this population. Indeed data from the United States Renal Data System has shown that 
overall 1 year mortality following the diagnosis of a first myocardial infarction in 
patients with end-stage renal failure is 59%, twice the mortality following acute 
myocardial infarction in the general population [15].
1.2. RISK FACTORS FOR THE DEVELOPMENT OF CORONARY HEART 
DISEASE
In normal adult populations, factors associated with increased risk of coronary heart 
disease (CHD) aie well recognised. They include hypertension, hyperlipidaemia, 
cigarette smoking, diabetes and family history. More recently additional risk factors 
have been identified e.g. fibrinogen, homocysteinaemia, lipoprotein (a) and C reactive 
protein (GRP). It is now clearly established that intervention to attenuate the effect of 
a number of these risk factors reduces morbidity and mortality from coronary heart 
disease.
Raised levels of total cholesterol, increased plasma triglyceride, and reduced HDL-C 
are established risk factors for coronaiy heart disease. These will be discussed in more 
detail later in this chapter. Coronary heart disease (CHD) is the most common 
cardiovascular disease that is influenced by hypertension. Increases in both systolic 
(SBP) and diastolic blood pressure (DBP) are major contributors to death from CHD 
[16]. From the large MRFIT sample size it is calculated that the optimal level for SBP 
is 120mmHg and for DBP SOmmHg, with a 1.5 fold increase in the risk of CHD death 
for an increase in the SBP of 20mmHg and 2.5 fold increase for a 40mmHg 
increment. Antihypertensive treatment reduces CHD by about 14% [17], with the 
benefit extended to those aged >60 years, where it has been demonstrated that 
reduction in systolic hypertension results in a 27% decrease in non-fatal MI or CHD 
death [18]. It is interesting to note that the optimal blood pressure calculated from the 
MRFIT cohort is not dissimilar to the figure obtained from randomised controlled 
studies, which suggests that the relationship between on-treatment blood pressure and 
stroke flattens out below a blood pressure of 135/85 [19].
Smoking multiplies the effect of other coronary risk factors, with the adverse effect 
seen in both men and women. This increased risk is particularly profound in women 
who smoke whilst taking oral contraceptives [20]. The absolute risk imparted by 
cigarette smoking on coronary heart disease, is greater than the absolute risk of 
chi'onic obstructive airways disease, pulmonary neoplasms or pulmonary heart disease
[21]. There is a 3-4 fold increase in the relative risk of acute myocardial infarction
[22], with the risk increasing with the duration of smoking [21] and the number of 
cigarettes smoked [22]. However the risk decreases quickly with cessation of 
smoking, even in long term smokers [23].
Diabetes increases the risk of CHD 2-4 fold [24]. This increased risk is related to the 
increased prevalence of both dyslipidaemia and hypertension [25], but is also related 
to poor glycaemic control [25]. Recent evidence has suggested that overall 
cardiovascular mortality is increased with mild asymptomatic hyperglycaemia [26], 
but whether hyperglycaemia itself contributes to CHD or simply results in worsening 
of associated risk factors, remains controversial. In insulin dependent or diabetes 
mellitus (IDDM), the development of prematine CHD is closely linked to nephropathy 
and hypertension [27]. In non-insulin dependent diabetes mellitus (NIDDM), lipid 
lowering reduces CHD death and non-fatal MI [28], and tight blood pressure control 
reduces macrovascular disease including stroke and CHD [29]. Intensive glycaemic 
control has been shown to decrease microvascular disease, however it has not been 
shown to reduce macrovascular disease [30]. Obesity is associated with several 
cardiovascular risk factors, including hypertension [31], dyslipidaemia [32] and 
glueose intolerance [33]. Waist to hip ratio (an index of central obesity) rather than
body mass index (BMI) has been shown to predict fatal ML Central obesity is part of 
the insulin resistance syndrome, which is associated with increased risk of CHD, 
however data from the Framingham cohort suggests that effect of obesity as a risk 
factor for CHD and coronary death, is also independent of conventional risk factors 
including glucose intolerance, cholesterol, SBP, smoking and left ventricular 
hypertrophy [34].
A family history of CHD is recognised to be a strong independent risk factor for CHD 
[35]. This may be mediated by genetic influence on other risk factors e.g. obesity, 
hypertension, dyslipidaemia or diabetes [36]. However there may also be an 
independent influence e.g. the deletion allele of the insertion deletion polymorphism 
of the angiotensin converting enzyme has been shown to be a risk factor in NIDDM 
patients who are at low risk of CHD due to the presence of a favourable lipid profile 
[37]. Hormonal status clearly exerts a profound influence with premenopausal women 
protected against CHD to an extent not accounted for by differences in blood pressure, 
total cholesterol and cigarette smoking.
Epidemiological studies have demonstrated that a sedentary lifestyle is associated with 
increased risk of both morbidity and mortality from CHD [38], moreover adults who 
undertake moderate physical exercise, have a lower mortality rate from CHD than less 
active subjects [39]. The beneficial effects of physical exercise on CHD result from 
improvements in blood pressure, lipids, weight and insulin resistance, however 
exercise also increases cardiac output and tissue oxygen extraction from the blood 
[40] with an independent and inverse correlation seen between physical fitness and 
cardiovascular mortality [41].
More recently clotting factors, homocysteine and inflammatory markers have been 
shown to correlate with CHD. Factors affecting both coagulation and fibrinolysis are 
important, with fibrinogen, Factor VII, Von Willebrand factor (VWF), tissue 
plasminogen activator and plasminogen activator inhibitor activity-1 (PAI-l) all being 
implicated. A number of prospective studies have identified an independent 
association between increased plasma fibrinogen and increased morbidity and 
mortality from CHD [42-44], and it has been suggested that a component of the risk of 
cigarette smoking is mediated via increased fibrinogen [42]. In hypercholesterolaemic 
patients, a high fibrinogen level increases coronary arteiy risk, whilst a low fibrinogen 
level identifies patients at low risk despite having hypercholesterolaemia [44]. 
Possible mechanisms by which fibrinogen increases coronary artery risk include 
facilitating the development of the atherosclerotic plaque, increasing plasma viscosity, 
increasing the ability of platelets to aggregate and increasing the amount of fibrin 
contained in thrombi [45].
VWF and tissue plasminogen activator have both been shown to be independent 
predictors of acute coronary events [44]. Factor VII concentration is increased in 
patients with coronary arteiy events [42,44], however this has not been found to be an 
independent risk factor [46]. Increased PAI-1 has been demonstrated to be an 
independent risk factor, particularly for secondary cardiac events [47]. 
Hyperhomocysteinaemia is associated with a 2 fold increase in coronary artery disease 
after correction for conventional risk factors [48]. Moreover, in the Physicians Health 
Study, over 5 years, a 3-4 fold increase in the risk of myocardial infarction was 
demonstrated in patients with increased homocysteine levels [49].
Evidence of inflammation after MI is associated with increased risk of recurrent 
coronaiy events [50]. Small increases in C reactive protein (CRP) are predictive of the 
development of acute myocardial infarction [51] and CRP is an independent risk 
factor for death following unstable angina or a non-Q wave MI [52]. Meta-analysis 
has demonstrated that an increase in CRP of 1.4mg/dl is associated with a 1.7 fold 
increase in the relative risk of coronary events [53]. Overall, increases in CRP are 
strongly associated with acute coronaiy events but are not determinants of chronic 
stable coronary disease [54].
1.3. NORMAL LIPID AND LIPOPROTEIN METABOLISM
(I) Lipids and Lipoproteins
The main lipids in plasma are cholesterol, cholesterol esters, triglycerides and 
phospholipids. They are found in the circulation complexed to apolipoproteins as 
lipoprotein particles. Cholesterol is required for the formation of cell membranes, 
steroid hormones and vitamin D, whilst triglycerides provide a major source of energy 
for the body. Cholesteryl ester and triglycerides are both hydrophobic neutral lipids, 
are insoluble in water, and thus are located in the core of lipoprotein particles. The 
amphipathic lipids, phospholipid and free cholesterol, form a surface monolayer in 
which proteins (apolipopoproteins) are interspersed.
Lipoproteins can be separated and classified by a number of different methods. 
Density gradient ultracentrifugation in a salt solution separates particles by their 
density and flotation characteristics, electrophoretic mobility on a gel separates
particles by the charge on the apolipoprotein content of the particles, and gel 
chromatography separates particles by their size. Separation into density classes is the 
method in most widespread use, however in recent years it has become evident that 
even within each density range, lipoproteins exhibit marked heterogeneity and can be 
separated into subgroups with distinct structures and functions [55,56].
The physical properties and apolipoprotein compositions of the various lipoproteins 
are given in table 1.1. Table 1.2 lists the main plasma apolipoproteins, the paiticles on 
which they are found, and their main functions. The largest and lightest lipoproteins 
are chylomicrons. These particles are most abundant post-prandially and are virtually 
absent in the fasting state. They are formed in intestinal epithelial cells and their main 
core lipid content is triglyceride, derived from dietaiy fat, along with lesser amounts 
of phospholipid, free cholesterol, cholesterol esters and protein. The main 
apolipoprotein (apo) is apoB48 however they also contain apo A-I, A-IV, ApoC and 
ApoE (table 1.2).
Very-low density lipoproteins (VLDL) are very similar to chylomicrons, and are the 
main triglyceride carrying lipoprotein in the fasting state. The main differences 
between VLDL and chylomicrons are the site of synthesis, the source of triglyceride 
being transported and the apolipoprotein B moiety. VLDL particles are synthesised in 
hepatocytes and their main function is the transport of endogenously synthesised 
triglyceride. VLDL contains apoB-100, apoCII, apoCIII and apoE, which are the 
apolipoproteins essential for the synthesis and clearance of the particles (fig 1.1).
ApoB is common to both chylomicrons and VLDL. It is essential for the assembly of 
both triglyceride rich lipoproteins, forming the structure around which both 
chylomicrons and VLDL are assembled. ApoB-100 and apoB-48 arise from an 
identical gene. ApoB-100, a 4563 amino acid protein, is synthesised in the liver and 
contains in its C terminal domain, the ligand region for the LDL receptor (table 1.2). 
ApoB-48 is the N-terminal 2152 amino acids of apoB-100, is synthesised in the 
intestine and does not bind the LDL receptor.
It was previously thought that intermediate-density lipoproteins (IDL) were simply 
intermediate particles in the process of forming low-density lipoprotein (LDL) from 
VLDL, however it is now evident that IDL itself has important properties and may 
contribute to atherogenesis [57]. IDL contains apoB-100 and apoE with a reduced 
triglyceride content and an increased cholesteryl ester content compared with VLDL. 
LDL is the main cholesterol cariying lipoprotein in plasma, accounting for more than 
70% of circulating cholesterol. It contains very little triglyceride and the only 
apolipoprotein in LDL is apoB-100, accounting for approximately 25% of the particle 
mass (fig 1.2). Excess LDL is associated with atherogenesis, with humans possessing 
much greater concentrations of LDL compared with other mammals.
The smallest and most dense lipoprotein is high-density lipoprotein (HDL). The main 
function of HDL is to transport cholesterol from peripheral tissues to the liver, thus 
the main lipid found in HDL is cholesteryl ester. The major apolipoproteins in HDL 
are apo A-I and apoA-II, however HDL also possesses lesser amounts of ApoC and 
ApoE. Despite being the most abundant lipoprotein particles, HDL only cairies 20%
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of the circulating cholesterol. An important inverse relationship is seen between HDL 
and coronary artery disease risk.
(II) ApoB Containing Lipoproteins and Endogenous Lipoprotein Transport
In humans, there are two main pathways for the transportation of lipids in the plasma. 
The endogenous pathway involves transport of lipids from the liver to peripheral 
tissues using apoB-100 containing lipoproteins, and then the mechanism of reverse 
cholesterol transport uses HDL to return cholesterol to the liver. The exogenous 
pathway involves transport of dietaiy fat, mainly in the form of triglycerides, in 
chylomicrons to adipose tissue and skeletal muscle and will be discussed briefly later 
in this chapter.
Fig 1.3 illustrates an outline of endogenous lipoprotein metabolism. VLDL particles 
are assembled in hepatocytes, with each particle having a triglyceride rich core and 
containing one apoB moiety along with a number of apolipoprotein C and E 
molecules. The relative importance of apoB production and the availability of 
triglyceride in regulating production of VLDL remains to be clarified. What is clear is 
that not only is apoB essential for the normal production of VLDL, as patients with 
abetalipoproteinaemia do not produce VLDL [58], but that in the presence of excess 
triglycerides, larger VLDL particles are produced [59]. Following secretion from the 
liver into the bloodstream, VLDL particles acquire apoC and apoE from HDL. They 
are then transported to peripheral tissues where they undergo lipolysis via the 
endothelial bound enzyme, lipoprotein lipase. The apoC moieties on VLDL are 
cofactors for this process. ApoCII is necessaiy to activate lipoprotein lipase, whilst 
apoCIII inhibits the enzyme. Lipolysis of the triglyceride core of the particle shrinks
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the VLDL particle and results in the fomiation of either smaller VLDL remnant 
particles or IDL. The VLDL remnant particles have 2 main fates, they can either 
undergo further lipolysis to IDL via either lipoprotein lipase or hepatic lipase, or they 
can be cleared directly from the bloodstream via hepatic receptors, which recognise 
apoE on the VLDL surface.
In addition to hydrolysis of triglyceride rich lipoproteins, a large amount of exchange 
of lipids and apolipoproteins takes place between VLDL and HDL. This process is 
facilitated by cholesteryl ester transfer protein (CETP). Cholesteryl ester is transferred 
from HDL to VLDL in exchange for triglyceride which transfers in the opposite 
direction. Thus not only do VLDL particles lose triglyceride via lipolysis, they are 
further triglyceride depleted whilst being cholesteiyl ester enriched under the 
influence of CETP. IDL is formed, which contains apolipoproteins B and E, and a 
core which has a reduced triglyceride content and greater quantities of cholesteryl 
ester. Further lipolysis of the triglyceride in IDL is mediated via hepatic lipase, the 
triglyceride content is further reduced, apoE is lost and IDL is transformed into LDL.
LDL can be regarded as the end-product of VLDL metabolism. Some direct hepatic 
secretion o f LDL occurs but the majority of LDL particles are formed from VLDL. 
LDL clearance occurs in both the liver and peripheral tissues, however in humans, the 
liver is responsible for over 70% of LDL catabolism. Clearance of LDL particles can 
take place via receptor mediated or receptor independent pathways. The LDL receptor 
recognises apoB in the LDL particle, the particle is internalised and cholesterol is 
delivered to the cell. Between 50 and 70% of LDL in normolipaemic subjects is 
metabolised this way. Not only is the LDL receptor responsible for binding LDL
12
paiticles, but along with the enzyme HMGCoA reductase, it plays an integral part in 
maintaining normal cholesterol homeostasis. If intracellular cholesterol stores are 
replete, the number of LDL receptors is reduced and HMGCoA reductase activity also 
decreases. This results in less cholesterol entering the cells via the LDL receptor and 
reduced de novo production of cholesterol by the cell. On the other hand when 
cholesterol is needed, upregulation of LDL receptors takes place and activity of the 
HMGCoA reductase enzyme increases. This increases the amount of cholesterol 
entering the cell and also increases de-novo production of cholesterol.
The alternative route by which LDL is removed from the circulation is by non­
receptor mediated routes or the so called ‘scavenger receptor’. This method involves 
phagocytosis of LDL by macrophages and is uncontrolled. LDL penetrates the 
endothelium and accumulates both in the extracellular space and in the smooth muscle 
cells of the arterial intima. LDL is often modified by oxidation pre-phagocytosis and 
the end product is the development of fatty streaks and ultimately atherosclerotic 
plaques.
(Ill) The Exogenous Lipoprotein Transport Pathway
The exogenous lipid transport pathway involves transport of dietary lipid (mainly 
triglyceride) in chylomicrons from the intestine to the liver. Chylomicrons are 
synthesised in the villi of the small intestine in response to the absorption of dietaiy 
lipid. Chylomicron synthesis is dependent upon production of apolipoprotein B-48. 
Particles are secreted from intestinal mucosal cells into the lymphatics or the portal 
circulation. The remainder of chylomicron metabolism follows along very similar 
lines to that of VLDL. Particles acquire apoC and apoE in the circulation, are
13
hydrolysed by lipoprotein lipase (which in fact preferentially binds to chylomicrons 
compared with VLDL), and surface components are transferred to HDL. Chylomicron 
remnants are taken up by the liver via receptor mediated mechanisms, with the LDL 
receptor related protein (LRP) recognising apoE on the surface of the chylomicron 
remnants.
(IV) HDL
HDL is synthesised in the liver as disc like particles known as ‘nascent HDL’. These 
contain phospholipid, free cholesterol and apoAl. HDL takes part in the process of 
reverse cholesterol transport (fig 1.3). This involves transporting cholesteryl esters 
from peripheral tissues to the liver, either directly by HDL or indirectly by transfer of 
cholesteryl ester to VLDL (and ultimately LDL) via CETP. Cholesterol that is 
transferred from peripheral tissues to HDL is converted to cholesteryl ester by the 
action of lecithin cholesterol acyl transferase (LCAT). Exchange of cholesteryl ester 
and triglyceride takes place between HDL and VLDL, with the triglyceride rich HDL 
particle that is formed, rapidly hydrolysed by hepatic lipase. As a result of this 
process, it can be seen that a low HDL-C is physiologically linked to increased VLDL, 
as the rate limiting step for transfer of cholesteiyl ester from HDL to VLDL is the 
availability of VLDL to accept the transferred cholesteryl ester. This explains why 
such a close inverse correlation is consistently found between plasma triglyceride and 
HDL-C.
(V) Lp(a) metabolism
Lipoprotein (a) is lipoprotein that consists of an LDL paiticle that is covalently linked 
to an apo(a) molecule by a disulphide bond with apoB. This particle was first
14
discovered in 1963 [60], when it was considered to be a variant of LDL. Apo(a) is a 
glycosylated protein that resembles plasminogen. Apo (a) is extremely polymorphic, 
varying in size from 300-800kDa [61]. Plasma concentration of Lp(a) is under genetic 
control and is heavily influenced by the size of the apo(a), which is inversely related 
to plasma level of Lp(a) [61]. Lp(a) and the apo(a) protein are synthesised in the liver 
with plasma levels regulated by the rate of production rather than cleai’ance of the 
particle. Less is known about mechanisms by which Lp(a) is cleared from the 
circulation. The kidney is thought to contribute, with Lp(a) concentration increased in 
renal failure, however the major sites of Lp(a) catabolism remain to be determined. 
The normal physiological role of Lp(a) is still not understood, however it is evident 
that the protein sequence of the apo(a) shows marked homology with plasminogen, 
and it has been suggested that Lp(a) may represent a bridge between the fields of 
atherosclerosis and thr ombosis [62].
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1.4. LIPIDS, LIPOPROTEINS AND CORONARY HEART DISEASE
The influence of dyslipidaemia on CHD has been recognised for some time, with a 
clear relationship between CHD risk and increasing plasma total cholesterol [63]. A 
gradient of increased risk of death from coronaiy heart disease has been shown for 
total cholesterol levels of >4.7mniol/l, with a 2-3 fold increase for a total cholesterol 
of 5-6.3mmol/l and a 5 fold increase for a cholesterol >6.3mmol/1 [16]. Furthermore, 
it is clearly established that reducing cholesterol with HMGCoA reductase inhibitors 
(‘statins’) reduces morbidity and mortality from CHD in patients with 
hypercholesterolaemia, both in the context of primaiy prevention and secondaiy 
prevention [64,65]. Moreover for secondaiy prevention, this benefit extends to 
patients with total cholesterol levels that would not be regarded as high [66,67]. It has 
also recently been demonstrated that a similar risk reduction can be obtained using 
statins as primary prevention in a population with a normal cholesterol and below 
average HDL-C levels [68].
The relationship between coronary artery disease and raised plasma triglycerides has 
not been defined as clearly as the risk of hypercholesterolaemia, nevertheless, it is 
now clear that hypertriglyceridaemia is an independent risk factor for CHD. The role 
of triglycerides has been clouded by the physiological link between raised 
triglycerides and a low HDL-C, thus confounding attempts at multivariate analysis 
when both of these closely linked variables are inserted. Both the PROCAM study 
[69] and the Helsinki Heart Study [70] have found marked increases in cardiac events 
in patients with plasma triglyceride >200mg/dl (2.3mmol/1) and a meta-analysis of 17 
studies has demonstrated that increased plasma triglyceride is a risk factor for 
coronary artery disease, even after adjusting for HDL-C [71]. Data from the Helsinki
21
Heart Study [72] has suggested that lowering plasma triglyceride leads to a reduction 
in coronaiy events. In this prospective randomised controlled study, fibrates 
(Gemfibrozil), whose main action is to increase lipolysis of triglyceride rich 
lipoproteins, reduced coronaiy events, with the benefit seen almost exclusively in the 
subgroup with raised triglycerides and a low HDL.
An inverse relationship exists between the plasma concentration of HDL-C and CHD 
[73,74], and it has been estimated that a Img/dl (0.025mmol/l) decrease in HDL-C 
increases the risk of coronary arteiy disease by 2% in men and 3% in women [75]. 
The cardioprotective role of HDL-C is thought partly to be related to its role in reverse 
cholesterol transport, as it is known that lipid rich macrophages can have cholesterol 
removed by HDL [76]. Other potential cardioprotective mechanisms include 
stabilisation of prostacyclin in the vessel wall [77] or enhancement of endothelial 
repair [78]. However given the physiological link between low HDL-C and excess 
triglyceride rich lipoproteins, and the atherogenic effect of these triglyceride rich 
lipoproteins, it is now felt that part of the cardioprotective effect of raised HDL-C is 
simply related to it being a marker for efficient lipolysis of triglyceride rich 
lipoproteins, with the resulting low plasma concentrations of these lipoproteins. It is 
suggested that, in comparison to HDL-C, the greater variability of plasma triglycerides 
on repeated testing means that when both variables are inserted into a multivariate 
analysis, HDL-C rather than triglycerides is chosen as the independent variable with a 
consistent underestimate of the contribution of triglyceride to the disease state [79].
More recently remnant lipoproteins have been implicated in atherogenesis. These 
particles are formed from chylomicron or VLDL particles which have been partially
22
metabolised by lipoprotein lipase. These remnant-like lipoproteins (RLP) are apoE 
rich, exist across a wide range of densities, and are characteristically found in patients 
with hypertriglyceridaemia [80]. It is likely that this connection results from 
hypertriglyceridaemia and increased RLP having a common origin, i.e. inefficient or 
incomplete lipolysis of triglyceride rich lipoproteins. Increased RLP have been found 
in patients with NIDDM [81] and patients on haemodialysis [82]. RLP-cholesterol 
levels are increased in men with coronary artery disease [83]. In addition a high RLP- 
cholesterol is a predictor for coronary artery stenosis [84], sudden cardiac death [85], 
and myocardial infarction in vasospastic angina [86]
Most studies show higher concentrations of Lp(a) to be an independent risk factor for 
CHD [87, 88]. The precise mechanism by which Lp(a) confers its increased coronary 
risk remains to be elucidated however it has been shown that Lp(a) promotes 
proliferation of smooth muscle cells [89], is deposited in atherosclerotic plaques [90], 
and is thrombogenic, competing with plasminogen and decreasing plasminogen 
activation [91].
1.5. VASCULAR RISK FACTORS, ATHEROGENESIS AND PLAQUE 
STABILITY
The role that established cardiovascular risk factors play either in initiating 
atherosclerosis or precipitating acute coronaiy events can be seen by examining their 
impact on either the development or the stability of the atherosclerotic plaque. Factors 
contributing to atherosclerotic plaque development include accumulation of oxidised 
LDL in the vascular wall, endothelial dysfunction, activation of macrophages,
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alteration of smooth muscle cells, platelet activation and pro-coagulant states [92]. A 
typical atherosclerotic plaque (fig 1.4) has a lipid rich core (derived from oxidised 
LDL which has been endocytosed by macrophages to form foam cells), macrophages 
(often in the form of foam cells) which surround the lipid core, and a fibrous cap 
(consisting mainly of collagen but also containing smooth muscle cells) [93]. The 
majority of acute coronary events occur in unstable plaques which rupture, resulting in 
thrombus formation and coronary artery occlusion. Unstable plaques are characterised 
by having large, highly thiombogenic, lipid rich cores, thin fibrous caps with few 
smooth muscle cells or collagen fibres, large numbers of inflammatory cells 
(including macrophages and lymphocytes) within and surrounding the cap (fig 1.4), 
and areas of endothelial denudation [93-95]. In contrast, stable plaques have a thick 
fibrous cap with large numbers of smooth muscle cells and collagen fibres, and a 
smaller lipid core with few inflammatory cells [93-95]. Vascular risk factors can help 
trigger coronary events by effecting plaque stability, by contributing to plaque rupture 
via changes in blood flow or endothelial function or by aiding propagation of 
thi'ombus.
Fig 1.5 summarises the effect of vascular risk factors on plaque stability, rupture and 
tlirombus propagation. LDL is an essential component in atherosclerotic plaque 
development. Plasma cholesterol concentration is closely related to the concentration 
of LDL in the aortic intima [96], cholesterol enrichment of an atherosclerotic plaque 
increases plaque instability, and the beneficial effects of cholesterol lowering is 
related to a reduction in the lipid-rich core of plaques [97]. Patients with 
hypertriglyceridaemia develop smaller denser LDL particles which penetrate 
endothelium more easily and are more susceptible to oxidation, both essential process
24
in the formation of atherosclerotic plaques [55,56]. Lp(a) is found in atherosclerotic 
plaques, increases local cholesterol deposition, competes with plasminogen and 
accumulates in thrombi [61]. Hypertension is associated with endothelial dysfunction, 
however evidence suggests that hypertension also plays a key role in triggering acute 
plaque disruption, causing shear stress on the arterial wall [94]. Concentrations of 
angiotensin II (a potent vasoconstrictor) are often raised in hypertensives, contributing 
to endothelial dysfunction and promoting atherogenesis by stimulating smooth muscle 
growth. [98]. The effect of cigarette smoking on coronary heart disease results from 
alteration in haemodynamics, vasomotor tone, platelet activation, increased fibrinogen 
and decreased oxygen carrying capacity of the blood [99,100]. Diabetes mellitus is 
frequently associated with dyslipidaemia and hypertension, however both insulin and 
the glycation of lipoproteins may also increase cholesteryl ester accumulation in 
macrophages and in the arterial wall [101], and both platelet activity and coagulation 
are enhanced in diabetes [94]. It is known that high homocysteine concentrations are 
associated with a protlirombotic state, homocysteine is also toxic to endothelium and 
reduces nitric oxide availability (thus impairing vasodilatation) [98], whilst increased 
levels of fibrinogen, factor VII, VWF and PAI-1 will all increase the propensity for 
thrombus to form on the vessel wall. Thus it is evident that the epidemiological 
associations between these recognised risk factors and either atherogenesis or acute 
coronary events can be explained by examining the contribution that the recognised 
risk factors make to plaque instability, rupture or to the propagation of thr ombus.
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1.6. DYSLIPIDAEMIA IN RENAL DISEASE
The prevalence, extent and origin of dyslipidaemia in clii'onic renal disease varies with 
the cause of the renal dysfunction, the level of renal impairment and the degree of 
proteinuria. One of the first reports documenting the connection between 
hyperlipidaemia and the neplnotic syndrome was published in 1917 [102], although 
the association between chronic renal disease and hyperlipidaemia has been 
recognised since the 19^ '' century [103]. In neplnotic range proteinuria both 
quantitative and qualitative changes in lipids and lipoproteins exist. Total cholesterol 
and LDL cholesterol (LDL-C) are invariably raised [104,105]. Triglycerides may also 
be increased [106] and very low density lipoprotein cholesterol (VLDL-C) is raised 
[104,105], even in patients with proteinuria, normal serum albumin and normal renal 
function [107]. This dyslipidaemia results from a combination of increased production 
and reduced clearance of apoB containing lipoproteins. VLDL is overproduced, 
lipolysis of VLDL to IDL and LDL is delayed, and receptor mediated clearance of 
LDL reduced [104].
Despite extensive animal and human study, the underlying cause of the alterations in 
the production and clearance of lipoproteins in patients with both the nephrotic 
syndrome and nephrotic-range proteinuria remains to be clarified. It has been 
postulated that the increase in production of apoB containing lipoproteins simply 
reflects a general increase in hepatic protein synthesis consequent of having excess 
loss of plasma proteins. However not only is albumin synthesis not increased in the 
neplrrotic syndrome [104] but metabolic studies have shown that changes in apoB 
synthesis do not match changes in albumin synthesis [108]. The explanation for the 
impaired clearance of VLDL also remains to be fully explained. Reported activity of
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both lipoprotein and hepatic lipase enzymes varies [104,105,109]. It has been 
postulated that loss of cofactors (e.g. apoCII) in the urine might account for the 
impaired lipolysis [110], however this would not explain the finding of normal 
clearance of chylomicrons in the context o f impaired clearance o f VLDL in patients 
with the nephrotic syndrome [104].
The extent o f dyslipidaemia in non-nephrotic patients with moderate chronic renal 
failure is less well defined. Increased plasma triglyceride and low HDL-C are the 
characteristic abnormalities in advanced renal failure however the level of renal 
function at which abnormal lipid levels become more prevalent is less clear and 
studies performed tend to have only small numbers of patients. Attman reported that 
triglycerides tended not to be increased when GFR was greater than 15-20ml/min
[111]. However Grutzmacher suggested that triglycerides may be increased when 
GFR is less than 30ml/min [112] and Arnadottir reported increased triglycerides in 26 
patients with non-nephrotic proteinuria and a GFR of 50ml/min [113]. In end-stage 
renal failure (ESRF) hypertriglyceridaemia and low HDL-C are typical [114,115], 
very-low density lipoprotein cholesterol (VLDL-C) is raised, however levels of total 
cholesterol and low-density lipoprotein cholesterol (LDL-C) are generally normal and 
may be low [114,115]. The primary metabolic defect is thought to be impaired 
catabolism of triglyceride rich lipoproteins (mostly VLDL) by the enzymes lipoprotein 
and hepatic lipase, and studies have found activity o f lipoprotein and hepatic lipase to 
be low [114]. However the precise mechanism underlying the impaired lipolytic 
activity remains to be established [114,116,117]. The lipoprotein abnormalities also 
differ according to modality o f renal replacement therapy with patients on peritoneal 
dialysis tending to have higher total cholesterol and LDL-C compared with those
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treated by haemodialysis [118].
1.7. LIPIDS IN RENAL DISEASE: CARDIOVASCULAR AND CORONARY 
RISK
In contrast to the data linking dyslipidaemia to coronary artery disease, and despite the 
high prevalence of coronary artery disease in patients with chronic renal dysfunction, 
direct epidemiological evidence linking dyslipidaemia to coronary artery disease in 
this population remains limited. This is partly due to the relatively small numbers of 
patients with chronic renal disease compared to other organ dysfunction (e.g. diabetes 
mellitus) but is also due to the extensive comorbidity present in this population. This 
has clouded links between mortality from CHD and dyslipidaemia to the extent that 
renal physicians have been reluctant to embark on lipid lowering therapy due to the 
link between a low cholesterol and decreased survival [119], a link that is now 
recognised to result from excess comorbidity in the study population.
To our knowledge, at present, no epidemiological studies have examined the 
relationship between dyslipidaemia and either cardiovascular disease or coronaiy 
arteiy disease in patients with nephrotic range proteinuria. Clearly patients with 
nephrotic range proteinuria or dipstick positive proteinuria have increased coronary 
arteiy disease [3,7], however the extent to which dyslipidaemia contributes to this 
increased risk remains to be established. No prospective trials looking at 
cardiovascular end-points in patients with proteinuria that is not secondaiy to diabetic 
nephropathy, have been undertaken. However in patients with persistent proteinuria, it
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is difficult to imagine that the significant dyslipidaemia resulting from persistent 
heavy proteinuria will not contribute to the development of atherosclerosis.
There is extensive evidence linking dyslipidaemia with cardiovascular and coronaiy 
artery disease in both IDDM and NIDDM, with raised total cholesterol, LDL-C and 
plasma triglycerides, along with a low HDL-C, all risk factors for coronaiy artery 
disease [120-129]. Moreover in insulin-dependent diabetics with proteinuria, a link 
between CHD and dyslipidaemia has been established. In patients with IDDM and 
persistent proteinuria, CHD is increased compared with those without proteinuria, 
moreover the risk of CHD is associated with high total cholesterol levels [10]. 
Similarly in NIDDM, Stephenson reported that proteinuria was associated with both 
raised cholesterol and excess cardiovascular disease (the vast majority of which were 
due to ischaemic heart disease), however the increased cardiovascular mortality was 
independent of the increased cholesterol [6]. In diabetics with end-stage renal failure, 
a low HDL-C has been found to be a risk factor for CHD in a study looking at 110 
patients with insulin dependent diabetes [130], whilst data from 412 type 1 and type 2 
diabetic patients on dialysis again found a low HDL-C to be an independent predictor 
o f cardiac and non-cardiac mortality [131], although the same authors in a study of 
coronary angiography in 105 diabetics on renal replacement therapy failed to show a 
difference in lipid profiles between patients with and without CHD [132] .
An increasing number of studies have identified dyslipidaemia as a risk factor for 
either cardiovascular disease or coronary artery disease in chronic renal failure. In a 
study looking at patients with chronic but not end-stage renal failure, Jungers found 
that patients with myocardial infarction had higher triglycerides, LDL-C,
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apolipoprotein B and Lp(a), with a lower HDL-C [8]. In this study, HDL-C was an 
independent risk factor. A number o f studies have highlighted the importance of 
triglycerides and HDL-C in patients on haemodialysis. In a study of 252 chronic 
haemodialysis patients, those with CHD had higher plasma triglyceride and lower 
HDL-C compared with those without CHD [133]. In a prospective study which 
followed 419 patients (1% diabetic) on clrronic haemodialysis for a mean follow-up of 
6 years, plasma triglyceride was found to be an independent risk factor for ischaemic 
cardiovascular' disease [134]. In a recent cross sectional study looking at 607 
haemodialysis patients (33% diabetic), independent predictors of coronary arter-y 
disease included a low HDL-C, increased plasma apoB and apo(a) phenotype [135]. 
The largest study looking at Lp(a) in end-stage renal failure prospectively followed up 
129 patients for 4 years and found that high Lp(a) levels predicted atherosclerotic 
cardiovascular events [136].
Overall, although data remains limited, the risk of coronary artery disease posed by 
dyslipidaemia in clrronic renal disease is beginning to emerge. On multivariate 
analysis, the most frequently quoted parameter contributing to increased risk is a low 
HDL-C. However most of these studies insert plasma triglyceride and HDL-C into the 
same multivariate equation and are therefore liable to the same underestimation o f the 
importance of plasma triglyceride that has been explained by Austin [79]. The 
relevance and contribution of increased plasma triglyceride as compared with reduced 
HDL-C can be illustrated by performing more detailed lipoprotein analysis in order 
assess subfractions of the lipoprotein density classes.
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1.8. HETEROGENEITY OF APOB CONTAINING LIPOPROTEINS AND 
THEIR ROLE IN ATHEROSCLEROSIS
Although the traditional classification of lipoproteins divides them according to their 
density into VLDL, IDL, LDL and HDL, within each density range these lipoproteins 
exhibit marked heterogeneity in terms of size, density and composition. The first 
studies of low-density lipoprotein heterogeneity in normal populations, divided LDL 
by size using gradient gel electrophoresis [137]. As a result it was found that LDL 
consisted of a discrete number of subfractions with particular sizes and densities. 
Patients who had LDL that was mostly large were labelled as having ‘Pattern A’, 
whilst those with small LDL had ‘Pattern B’ [55]. Alternatively, in order to quantify 
the amount o f each LDL subfraction present, LDL can be separated by density 
gradient ultracentrifugation into three main subfractions (LDLI d^l .025-1.034g/ml, 
LDLII d= l.034-1.044 and LDLIII d=L045-1.060) [138]. LDLI predominates in 
premenopausal females, the most common subfraction for males is LDLII (fig 1.6), 
whilst an increasing number o f studies have demonstrated a link between CHD and 
either the small dense LDL phenotype (Pattern B) or an increase in plasma LDLIII 
concentration. In a case control study of survivors of myocardial infarction, 50% of 
cases had pattern B compared with 26% o f controls [139]. Multivariate analysis 
demonstrated that plasma triglycerides and HDL-C were associated with formation of 
small dense LDL and contributed to the risk associated with the small dense 
subfraction pattern [139]. Thus as a result of this and other studies, the combination of 
excess small dense LDL, raised plasma triglyeerides and low HDL-C have come to be 
known as the ATHEROGENIC LIPOPROTEIN PHENOTYPE [55,56,140]. The 
risk of excess small dense LDL has been further quantified in eross-sectional studies,
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and an LDLIII level greater than lOOmg/dl has been shown to confer a seven times 
increase in the risk of myocardial infarction [141].
Fig 1.6: TYPICAL LDL SUBFRACTION PROFILES
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The atherogenic risk of small dense LDL has been further substantiated by 2 more 
recently published prospective studies. Data from the Physician’s Health Study cohort 
has shown that cases of MI have a significantly smaller LDL diameter compared with 
controls [142], whilst Gardner in the same edition o f the Journal o f the American 
Medical Association demonstrated that in men and women, LDL size is smaller in 
patients with coronary artery disease compared with controls [143]. Both of these 
studies used non-fasting samples, and in the second study LDL size was found to be 
independent of other lipid parameters, despite the close links that have been 
demonstrated between LDL size and plasma triglyceride [144].
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In addition to LDL, VLDL can also be divided into 2 subfractions. This is generally 
performed using cumulative-gradient ultracentrifugation, with VLDL subfractions 
being divided by their flotation coefficients. VLDLi (Sf 60-400) is larger, lighter and 
triglyceride rich, VLDL2 (Sf 20-60) is smaller, denser and more enriched in 
cholesteryl ester. Production o f VLDLi and VLDL2 is regulated independently. 
VLDLi production is increased in patients with hypertriglyceridaemia, in patients with 
insulin resistance [145] and following carbohydrate loading [146]. As a result excess 
VLDL] is associated with raised triglycerides [144] and excess partially metabolised 
atherogenic lipoprotein remnants. VLDL2 is overproduced in patients with raised total 
and LDL cholesterol [56]. VLDL] is slowly cleared from the circulation, VLDL2 on 
the other hand is rapidly metabolised to LDL and increased VLDL2 formation is the 
main cause of the excess LDL found in eommon types of hypercholesterolaemia [56]. 
The importance of excess VLDL] is further highlighted by looking at the 
physiological relationship between VLDL] and LDL subfractions, as formation of 
excess small dense LDL (LDLIII) requires an increase in plasma triglyceride (in the 
form of VLDL]), along with adequate plasma activity of hepatic lipase and cholesteryl 
ester transfer protein (CETP) [56].
1.9. THE ATHEROGENIC LIPOPROTEIN PHENOTYPE IN RENAL
DISEASE
(I) Background
It can therefore be seen that not only are small dense LDL, plasma triglyeerides and a 
low HDL-C physiologically linked (the atherogenic lipoprotein phenotype) but small
35
dense LDL is associated with an increase in the risk of coronaiy arteiy disease. To 
assess whether patients with proteinuria possessed excess small dense LDL, we 
performed a pilot study in 12 patients with neplii’otic range proteinuria and relatively 
well preserved renal function. The most important factor influencing LDL particle size 
is generally the plasma triglyceride level, therefore our initial hypothesis was that the 
excess of triglyceride rich lipoproteins found in this population would result in 
increased amounts of small dense LDL being present. We found that the patients 
studied had LDLIII levels twice those of the normal controls, and at a concentration 
known to be associated with increased atherogenic risk in normal populations (mean 
135mg/dl). This excess of LDLIII resulted from a shift in particle size towards smaller 
denser particles, as the total LDL concentration did not differ between the two study 
populations [109]. In this pilot study, we also demonstrated that both VLDLi and 
VLDL2 subfractions were increased in this population, confirming data previously 
published from our laboratory [104]. This study therefore suggested that in addition to 
hypercholesterolaemia, the presence of excess small dense LDL in patient with 
nephrotic-range proteinuria was an additional atherosclerotic risk factor.
(II) Triglyceride Rich Lipoproteins and Small Dense LDL
In normal populations, excess triglyceride rich lipoproteins are essential for the 
formation of atherogenic levels of small dense LDL. Current models of lipoprotein 
metabolism suggest that adequate plasma activity of hepatic lipase and cholesteiyl 
ester transfer protein are also required. A further consequence o f impaired clearance 
o f triglyceride rich lipoproteins in normal populations is the presence of excess 
remnant lipoproteins. Remnants of VLDL have not been studied in this population, 
however given the impaired VLDL clearance in patients with proteinuria, it is likely
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that these lipoproteins will be present in excess. Remnants may also contribute to the 
atherogenic risk attributed to the atherogenic lipoprotein phenotype.
(III) Dyslipidaemia and Progression
In addition to atherosclerotic disease, dyslipidaemia may contribute to progression of 
renal disease. There are pronounced pathogenetic similarities between atherosclerosis 
and glomerulosclerosis [147]. Proteinuria is the most important risk factor for 
progression o f chionic renal failure and the assoeiated dyslipidaemia may eontribute to 
this progression [148]. Several reports have suggested a relationship between 
lipoprotein abnormalities and progression of renal disease [149-151]. Thus a cyclical 
decline may occur in which renal disease generates dyslipidaemia which in turn 
aggravates the renal disease. LDL is seen as the prime candidate promoting the 
pathological changes in both the arterial wall and the kidney.
(IV) Lipid Lowering Therapy and Proteinuria
HMG CoA reductase inhibitors (statins) and fibrates have been shown to be effective 
lipid lowering agents in proteinuric dyslipidaemia, although there has been some 
concern expressed about the use of fibrates in severe hypoalbuminaemia, due to the 
extent o f their protein binding. Statins reduce total cholesterol and LDL-C by 
preventing intracellular cholesterol synthesis and as a result, upregulating the LDL 
receptor. This has the net result of increasing influx of LDL from plasma to the liver. 
It is thought that the main effect of fibrates is to suppress apolipoprotein CHI 
(apoCIII) synthesis and promote lipoprotein lipase activity [152]. Thus their action 
leads to a reduction in plasma triglyceride and triglyceride rich lipoproteins. In normal 
populations, statins reduce small dense LDL by lowering all 3 LDL subfractions in
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concert [153]. Fibrates on the other hand, promote a shift in LDL size towards larger 
lighter particles, with or without a change in total LDL [154,155]. Statins have been 
shown to reduce cholesterol and LDL-C in patients with neplu'otic dyslipidaemia 
[104]. This cholesterol lowering effect is accompanied by plasma triglyceride 
reduction and increased receptor mediated LDL clearance [156]. Small dense LDL 
formation is a consequence o f mild increases in plasma triglyceride [56], and therefore 
the triglyceride lowering effect of statins may have a beneficial effect not only on 
LDLIII concentration but also on the relative proportions of each LDL subfraction and 
on remnant lipoproteins.
(V) NIDDM, Proteinuria and Dyslipidaemia
A strong relationship exists between vascular disease and both plasma triglyceride and 
LDL-cholesterol in NIDDM. Patients with NIDDM typically have smaller LDL and 
excess quantities of LDLIII [157,158], and therefore possess the atherogenic 
lipoprotein phenotype. It has recently been suggested that patients with diabetic 
nephropathy and macroalbuminuria possess LDL that is smaller than normal diabetic 
controls [159], however the extent to which small dense LDL is formed in diabetic 
nepiu’opathy and macroalbuminuria secondaiy to NIDDM has not been quantified.
(VI) Small Dense LDL in ESRF
Proteinuria is the most consistent risk factors for progression of renal failure in 
glomerular disease. Qualitative analysis of LDL in end-stage renal failure (ESRF). 
[160,161] has been published suggesting an increase prevalence of small dense LDL 
in ESRF. Plasma triglyceride has been shown to be an independent risk factor for 
cardiovascular disease in ESRF, however the relationship between triglyceride rich
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lipoproteins, lipase activity and small dense LDL in this population has not been 
explored.
Therefore, we planned to explore in more detail lipoprotein heterogeneity in chronic 
renal disease, with a particular focus on small dense LDL in patients with proteinuric 
renal disease. In addition to the focus on the atherogenic lipoprotein phenotype, we 
hoped to highlight the importance o f detailed lipoprotein analysis in order to fully 
assess cardiovascular risk in a population with a high risk of coronaiy artery disease.
1.10. HYPOTHESIS
Our hypothesis is that in patients with proteinuria, hypertriglyceridaemia occurs 
tlnough impaired catabolism of VLDL. The primary consequence is the generation of 
small dense LDL which is a pathogenic agent contributing both to rate o f progression 
of renal failure and accelerated vascular disease. A further consequence of the 
impaired clearance of triglyceride rich lipoproteins is that excess atherogenic remnant 
lipoproteins may also be formed. These remnants may be associated with excess small 
dense LDL and contribute to the increased vascular risk attributed to small dense 
LDL.
The main population studied in this projeet were patients with excess proteinuria, 
generally secondary to primary glomerular disease, but also secondary to NIDDM. 
Given that proteinuria is consistently the most important factor influencing the renal 
prognosis in this population, a further study was performed to assess the effect of end- 
stage renal failure on the quantity and quality o f LDL.
39
1.11. AIMS
The aims of this project are encapsulated in the following questions.
1. To what extent are LDLIII and remnant lipoproteins present in patients with 
nephrotic range proteinuria? What is the origin of these abnormal lipoproteins in 
patients with neplii'otic range proteinuria? In particular we planned to investigate 
differences in plasma triglyceride, VLDL subfractions, activity of cholesterol ester 
transfer protein (CETP), hepatic and lipoprotein lipases whilst attempting to 
identify if there is any relationship between the plasma concentration of LDLIII, 
remnant lipoproteins and both renal function and proteinuria.
2. In normal populations, excess VLDLt is essential for the development of 
atherogenic levels of LDLIII. Are there specific abnormalities in the composition of 
VLDLi, that may account for the delayed clearance of the lipoprotein in patients 
with nephrotic range proteinuria? Our laboratory has previously shown activity of 
lipoprotein lipase to be normal in this population, we therefore we plaimed to 
investigate plasma and VLDLi apolipoprotein CII, GUI and E levels, along with the 
lipid composition of VLDLi particles.
3. What are the effects of treatment with lipid lowering agents, on the lipoprotein 
subfraction profile and remnant lipoproteins in patients with proteinuria. The aim 
of this study therefore, was to compare the ability of a statin (cerivastatin) and a 
fibrate (fenofibrate) to lower levels of these atherogenic lipoproteins in patients 
with nephrotic range proteinuria.
4. Is there a relationship between rate of deterioration of renal function and 
dyslipidaemia? If there is, does this relationship involve subfractions of either LDL 
or VLDL ? Examination of this issue requires further investigation into the
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relationships between lipoprotein subfraction profiles, level of renal function, and 
degree of proteinuria in patients with glomerular disease, heavy proteinuria and 
progressive renal failure.
5. Does the development o f diabetic nephropathy in NIDDM result in changes in the 
atherogenic lipoprotein phenotype? Do any changes develop with the onset of 
microalbuminuria or frank proteinuria? This study will involve assessing small 
dense LDL formation across the spectrum of NIDDM and nepliropathy, from 
normoalbuminuria to frank proteinuria, and comparison with non-diabetic controls.
6. What is the prevalence o f small dense LDL in patients with end-stage renal failure, 
and how does the quantity and quality o f LDL differ between patients who have not 
yet commenced dialysis, those on haemodialysis and those on peritoneal dialysis? 
This study will also involve assessing factors that determine LDLIII formation in 
end-stage renal faiiiue and compare VLDL and LDL subfractions in patients on 
haemodialysis and peritoneal dialysis to see if this provides further information 
regarding the origin of the different lipid and lipoprotein profiles obtained in these 
2 populations.
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CHAPTER 2 - METHODS
All analyses of lipids and lipoproteins were performed in either the lipid research 
laboratoiy or the routine lipid laboratoiy in the Department of Pathological 
Biochemistry, Glasgow Royal Infirmary University NHS Trust.
2.1. B  Q U A N T IF IC A T IO N  O F  L IP O P R O T E IN S
Plasma cholesterol, triglyceride, VLDL cholesterol, LDL cholesterol and HDL 
cholesterol were analysed by a modification o f the standard Lipid Research’s Clinics 
protocol [163]. 5ml of plasma is overlayered with d<1.006 solution and centrifuged at 
35,000 rpm for 16 hours. The solution is split into an upper VLDL fraction and a 
lower fraetion eontaining LDL and HDL. Heparin and Manganese Chloride is used to 
precipitate LDL in the lower fraction leaving HDL in solution. Cholesterol 
measurements are performed on the total plasma, the top VLDL fraction, the total 
bottom fraction, and the bottom fraction with the precipitate removed (following 
centrifugation). Thus LDL is a calculated measured value, i.e. Total Cholesterol - 
(VLDL cholesterol + HDL eholesterol).
2.2 . V L D L , V L D L  S U B F R A C T IO N S  A N D  ID L
VLDLi (Sf 60-400), VLDL] (Sf 20-60) and IDL (Sf 10-20) were isolated from fresh 
plasma by a modification of the cumulative-gradient ultracentrifugation procedure 
[164]. Stock solutions of density 1.006g/ml and 1.182g/ml were prepared using NaCl, 
NaBr and Na]EDTA. These were used to make up 6 density solutions, which ranged 
from 1.0588 to 1.0988g/ml. The density of 2mls of plasma was adjusted to 1.118g/ml
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by the addition of 0.341 g NaCl. The density solutions were then carefully overlayered 
on the plasma as detailed in table 2.1. Ultracentrifugation of the sample was 
performed, with the speeds and times shown in table 2,2. At the end o f each run, 
samples were carefully removed using a long-tipped glass pipette. VLDLi is removed 
in 1ml, with VLDL] and IDL removed in 0.5ml aliquots.
Table 2.1: Density Gradient for Separation of VLDL,, VLDL] and IDL
Solution Density (mg/1) Volume (mis) Position
__ 1.0588 2 Top
5 1.0641 2
4 1.0722 2
3 1.0790 2
2 1.0860 1
1 1.0988 1
Plasma 1.118 (adjusted) 2
1.182 0.5 Bottom
Adapted with permission from Ref #162
2.3. LOW DENSITY LIPOPROTEIN
LDL was isolated from fresh plasma by sequential ultracentrifugation [162]. The 
density of 2mls of plasma was increased to 1.109g/ml by the addition of a solution of 
density 1.182g/ml. The resulting solution was overlayered using 1.019g/ml salt 
solution and the sample underwent centrifugation overnight for 18hrs on a fixed angle 
rotor at 15^C, 35000ipm. The top 2mls (containing VLDL and IDL was removed).
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further 1.182g/ml solution was added followed by overlayering with 1.063g/ml 
solution. Again, the sample was spun overnight at 15°C, 35000rpm and the top 1ml 
removed (LDL d 1.019-1.063 g/ml).
Table 2.2: Conditions for Cumulative Ultracentrifugation of VLDLj, VLDL] and 
IDL
Sf Speed (rpm) Time (hours:min)
VLDLi 60-400 39 ,000  L 38
VLDL] 20-60 18,500 15:41
IDL 12-20 39,000 2:35
Adapted with permission from Ref #162
2.4. CHOLESTEROL, TRIGLYCERIDE, PHOSPHOLIPID AND PROTEIN
The triglyceride, free cholesterol, eholesteryl ester, phospholipid and protein content 
of the VLDLi, VLDL], IDL and LDL collected, were assayed and the lipoprotein 
concentrations were calculated as the sum of these components (concentration = 
protein + free cholesterol + esterified cholesterol + phospholipid). Protein was 
analysed by a modification of the method by Lowry et al. [165]. Cholesterol in plasma 
is present in esterified and free form. Free cholesterol is 22-30% o f total cholesterol. 
Total cholesterol was measured by enzymatic hydrolysis of cholesterol esters to form 
free cholesterol, with subsequent oxidation to give hydrogen peroxide, which is 
quantitated by formation of a coloured product (quinineimine) at 505nm (Boehringer 
Mannheim, Germany, Kit No: 1491458). Free cholesterol was assayed using the same 
method but omitting the enzyme cholesterol esterase (which would otherwise react
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with the cholesterol esters: Boehringer Mannlieini, Germany Kit No: 310328). 
Cholesterol ester was calculated as the total cholesterol - free cholesterol. Triglyceride 
was assayed by enzymatic hydrolysis with subsequent enzymatic determination of 
liberated glycerol by colorimetry at 505 nm (Boehringer Mannheim, Germany, Kit 
No: 1730711). Phospholipid was determined by a enzymatic colorimetric assay 
method measuring absorbance at 500nm (Boehringer Mannheim, Germany, Kit No: 
691844), absorbance is proportional to the amount of phospholipids present. Note this 
kit only measures phosphatidyl choline, the most abundant phospholipid, and so the 
values obtained are estimates of total phospholipid content.
2.5. LDL SUBFRACTIONS
Three LDL subfractions were isolated from fresh plasma by nonequilibrium density 
gradient ultracentrifugation as previously described [138]. Following centrifugation 
for 24h at 40,000rpm and 23 °C in a swinging bucket rotor, the contents of the 
centrifuge tube were eluted by upward displacement and the presence o f 3 fractions 
(LDL I d 1.025-1.034 g/ml, LDL II d 1.034-1.044 g/ml and LDL III d 1.044-1.063 
g/ml) were detected by continuous monitoring at 280nm. The individual subfraction 
areas were quantified, corrected for previously calculated extinction coefficients and 
expressed as percentage of total LDL. The lipoprotein mass of LDL (d 1.019-1.063 
g/ml) was determined as above and used to generate individual subfraction 
concentrations in mg lipoprotein per 100ml plasma.
2.6. LIPOPROTEIN AND HEPATIC LIPASE
Lipoprotein and hepatic lipase activities were measured in post-heparin plasma 
incubated with a gum arabic-stabilized triglyceride emulsion containing glycerol tri(l-
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*"^ C) oleate at a specific activity of 30pCi/mmol triglyceride fatty acids as substrate 
[166]. For the specific assay of LPL, plasma was preincubated with sodium dodecyl 
sulfate to inhibit HL, and pooled pre-heparin plasma was added to the incubation as a 
source of cofactor apoCII to activate the LPL enzyme. HL was assayed in the presence 
of 1.0 mol/1 NaCl to inactivate LPL. Enzyme activities are expressed in pmol of fatty 
acids released per hour per ml of plasma.
2.7. CHOLESTERYL ESTER TRANSFER PROTEIN
Cholesteryl Ester Transfer Protein (CETP) was assayed using a CETP assay kit from 
Roar Biomedical Inc. HDL containing fluorescein labelled cholesteryl ester was 
ineubated with plasma from the subjects studied. The fluorescent labelled lipid is 
contained in the core of the HDL particle. CETP mediated transfer of cholesteryl ester 
from HDL to VLDL was determined by the increase in fluorescence as the labelled 
lipid is moved from the core of the HDL particle to the acceptor VLDL particle. The 
assay was read in a fluorescence spectrometer. The activity is expressed as pmol 
cholesteryl ester transferred per ml of plasma.
2.8. REMNANT-LIKE PARTICLES
The cholesterol and triglyceride in remnant like partieles (RLP-C, RLP-TG) were 
measured using a diagnostic reagent kit from Japan Immunoresearch Laboratories 
(JIMRO), Takasaki, Japan. Remnant lipoproteins were separated from other 
lipoproteins by an immunoaffinity gel containing monoclonal antibodies to human 
apoBlOO and human apoAl [167]. The cholesterol and triglyceride contents of the 
unbound fraction was measured using very sensitive enzymatic spectrophotometric 
assays.
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9. APOLIPOPROTEINS
Apolipoproteins B, CII, CHI and E were analysed from EDTA plasma and the VLDLi 
fraction using kits purchased from Wako Pure Chemical Industries (Japan).
2.10. URINARY ALBUMIN
Urinary Albumin is measured by an automated (Hitachi 911) immunoturbidimetric 
method using a monoclonal antibody produced by SAPU.
2.11. STATISTICS
Statistical analyses were performed by using MINITAB lOX for Windows (Minitab 
Inc.), SPSS statistics package and Microsoft Excel 7 for Windows 95 (Microsoft 
Corp.). Statistical methods used in each study are outlined in the appropriate chapters. 
Factors that were not normally distributed were subjected to log transformation. 
Results are shown as means and standard deviations or as medians and interquartile 
ranges.
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CHAPTER 3 - 
The A therogenic Lipoprotein Phenotype: 
Sm all D ense LDL and Lipoprotein R em nants 
in Nephrotic Range Proteinuria
3.1. INTRODUCTION
Normal populations require raised triglycerides (in the form of triglyceride rich VLDLi) 
and adequate activity of hepatic lipase and eholesteryl ester transfer protein (CETP) to 
form atherogenic levels of LDLIII [56]. Excess lipoprotein remnants (REP) are a 
characteristic finding in patients with hypertriglyceridaemia [80]. There is increasing 
evidence to suggests that excess lipoprotein remnants (RLP) are atherogenic [168] and a 
risk factor for coronary artery disease [83]. RLP have not previously been studied in 
patients with nephrotic range proteinuria however given the delayed clearance of 
triglyceride-rich lipoproteins found in this population, excess RLP are likely to be 
present and may contribute to the atherogenicity of nephrotic dyslipidaemia.
The aim of this study was to assess factors determining formation of both small dense 
LDL and remnant lipoproteins (RLP) in patients with nephrotic range proteinuria. We 
aimed to study triglyeeride rich lipoproteins, lipoprotein lipase and hepatic lipase 
activity, and cholesteryl ester transfer protein. At the same time, this would allow us to 
confirm our previous finding of excess LDLIII in this population, clarify the influence of 
renal dysfunction, plasma and urinaiy albumin on LDLIII and RLP, and examine the 
relationship between lipoprotein remnants and the atherogenic lipoprotein phenotype in
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proteinuric renal disease.
3.2. METHODS 
Subjects
27 patients (22 males, 5 females) were recruited consecutively from the out-patient 
clinic of the Glasgow Royal Infirmary Renal Unit, according to the following inclusion 
criteria (a) urinaiy albumin excretion >2.0g/24hi's (b) serum creatinine <300umol/L (c) 
primaiy glomerular disease. They were compared to 27 age and sex matched controls. 
Patients suffering from other diseases or on treatment that might influence their lipid 
profile were exeluded, specifically patients with underlying liver disease, diabetes 
mellitus, amyloid, any neoplastic disorder, systemic lupus erythematosis or taking 
thiazide diuretics, fat soluble beta blockers, corticosteroids or other immunosuppressive 
agents. Treatment with other antihypertensives or diuretics was permitted. Patients 
receiving lipid lowering therapy had their lipid lowering medication stopped for a period 
of 4 weeks prior to inelusion in the study. All patients had a biopsy proven diagnosis. 
They were compared to 27 age and sex matehed controls who were either relatives of 
patients attending the renal unit or laboratory staff members. All controls were free of 
acute illness with normal serum creatinine, albumin and liver function tests. Any patient 
or control with a bleeding diathesis or with a recent history of peptic ulceration was 
excluded. All patients and controls gave written consent before participating. The study 
was approved by the Ethics Committee of Glasgow Royal Infirmaiy. Patients and 
controls attended after an overnight fast. An intravenous cannula was inserted and 
samples were taken for the estimation o f lipids and lipoproteins, LDL and VLDL
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subfractions, remnant lipoproteins, cholesteiyl ester transfer protein, serum creatinine 
and albumin. 70units/kg body weight of intravenous heparin was then given followed by 
further sampling 10 minutes later for hepatic and lipoprotein lipase measurement. All 
patients collected a 24 hour urine for analysis of urinary albumin excretion.
Statistics
Statistical analyses were performed by using MINITAB lOX for Windows (Minitab 
Inc.). Any factors that were not normally distributed were subjected to log 
transformation. These included: BMI, plasma TG, VLDL-C, HDL-C, LPL, HL, total 
VLDL and VLDL subfractions, total LDL and LDL subfractions and lipoprotein 
remnants. Results are shown as either median and interquartile range (IQR) or as mean 
and standard deviation. Samples were compaied using the two-sample /-test. Simple 
regression analysis was performed to identify significant correlations. Stepwise 
regression was used for multivariate analysis.
3.3. RESULTS
Anthropometry, Diagnoses and Renal Function
The patients were well matched for age and body mass index (table 3.1). The mean 
creatinine was 139pmol/l (range 85-290). Creatinine clearance (CrCl) was greater than 
50ml/min in 20 patients (calculated using the Cockcroft & Gault formula [169]), and 
greater than 70ml/mln in 15 patients. Urinaiy albumin excretion was 3.9g/24hrs (range 
2.0-11.4). Serum albumin was well preserved at 35.0+6.7g/i (6 patients had a serum 
albumin <32g/l). The diagnoses were membranous neplii'opathy (8 patients) IgA
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nephropathy (7 patients), with 3 cases each of mesangiocapillary glomerulonephritis, 
minimal change, focal and segmental glomerulosclerosis, and chronic 
glomerulonepMtis.
Table 3.1: Anthropometry, Lipids, Lipoproteins and Lipase activity: (Median+IQR)
PATIENTS
n=27
CONTROLS
n=27
P
Age 48.0 (29.0-62.0) 45.3 (30.1-60.5) nsd
Sex (M: F) 22 : 5 22 : 5 nsd
Body Mass Index 26.5 (25.1-30.2) 24.5 (22.8-28.6) nsd
Creatinine (pmol/1) 120(100-180) 100 (95-120) <0.006
Cholesterol (mmol/1) 6.8 (5.6-7.5) 5.1 (4.6-5.8) <0.0001
Triglyceride (mmol/1) 2.2(1.6-3.2) 1.0 (0.8-1.3) <0.0001
VLDL-C (mmol/1) 1.0 (0.5-1.3) 0.3 (0.2-0.4) <0.0001
LDL-C (mmol/1) 4.2 (3.7-5.4) 3.4 (2.8-4.0) <0.002
FIDL-C (mmol/1) 1.0 (0.8-1.2) 1.2 (1.0-1.6) <0.003
Lipoprotein Lipase (pmolFA/ml/hr) 3.7 (2.9-5.Ô) 4.0 (3.4-5.4) nsd
Hepatic Lipase (pmolFA/ml/hr) 16.2(10.1-24.3) 13.8(9.6-16.1) nsd
Lipids, Lipoproteins and Post-Heparin Lipase Activity
The results for basic lipids, lipoproteins and post-heparin lipase activity are shown in 
table 3.1. Cholesterol, plasma triglyceride and VLDL-C, were all higher in patients with
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proteinuria compared with controls (all p<0.0001), LDL-C was similarly raised 
(p<0.002) with HDL-C redueed in the patients (p<0.003). Comparing the two groups 
revealed no difference in activity of either lipoprotein or hepatic lipase. Urinaiy 
albumin correlated with plasma cholesterol (r^=22% p<0.02), LDL-C (r^=15% p<0.05) 
and negatively with HDL-C (r^=21% p<0.02). Plasma albumin was also negatively 
correlated with cholesterol (r^=41% p<0.001) and LDL-C (r^=41% p<0.001). There was 
no observed relationship between either plasma creatinine or CrCl and any lipid 
parameter, within the range of the population studied.
VLDL Subfractions, IDL and LDL concentration
There was a 3-4 fold inerease in total VLDL (table 3.2, p<0.001), due to an increase in 
the concentration of both VLDLi and VLDL] in proteinuric patients (both p<0.001). 
IDL mass in the patients was double that of the controls (p<0.0001), and total LDL mass 
(p<0.02) was also increased. Urinaiy albumin was weakly associated with inereasing 
IDL mass (r^=17% p<0.04) but not LDL mass. Low plasma albumin was associated 
with both IDL (r^=27% p<0.006) and LDL (r^=19% p<0.03). No relationship was 
observed between renal ftinction and any o f the lipoproteins.
LDL Subfractions
A marked shift in LDL subfraction profile was observed. Proteinurie patients had a 
reduced eoncentration of laige light LDLI and LDLII with a large increase in LDLIII 
mass (p<0.0001, table 3.2). LDLIII mass was greater than lOOmg/dl in 74% of the 
patients studied, compared with 4% of controls. Similarly, the percentage of LDL that 
was LDLIII was increased in the patients (p<0.0001), with a corresponding decrease in
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the %LDLI (p<0.0001) and %LDLII (p<0.0003, table 3.2), indicating that the difference 
in LDL profile was independent o f the LDL mass.
Table 3.2: VLDL subfractions, IDL and LDL subfractions: (Median + IQR)
PATIENTS CONTROLS P
11=27 n=27
VLDL Total mg/dl 236(172-364) 79 (52-113) <0.0001
VLDL; mg/dl 156 (57-212) 43 (24-74) <0.0001
VLDL] mg/dl 109 (75-140) 30(21-43) <0.0001
IDL mg/dl 80 (63-113) 44 (34-60) <0.0001
LDL Total mass mg/dl 351 (298-440) 292 (252-349) <0.02
LDLI mass mg/dl 36 (24-43) 69 (46-101) <0.0005
LDLII mass mg/dl 124 (79-220) 178 (129-236) <0.04
LDLIII mass mg/dl 182 (84-267) 31 (26-62) <0.0001
%LDLI 9 (7-12) 19(15-33) <0.0001
%LDLII 36(21-63) 63 (53-69) <0.0003
%LDLIII 57 (22-72) 11 (8-19) <0.0001
Effect of Renal Function and Plasma Albumin
The CrCl was >70ml/min in 15 o f the 27 patients studied. These patients had a 
creatinine of 100 (90-120)pmol/l (median + IQR) and a CrCl of 90nil/min. Direct 
comparison of the two subgroups based on a CrCl greater than or less than 70, revealed 
no difference in urinary albumin (CrCl >70: 2.7 (2.1-4.9) vs CrCl <70: 2.9 (2.2-
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6.1g/24hrs), plasma albumin (35±6 vs 35±7g/l) or any lipoprotein parameter (table 3.3). 
When the CrCl >70 subgroup was eompared with the control population, the total LDL 
mass was not increased (probably as a result of inter-patient variability). All other 
results were similar to those achieved with the entire proteinuric group. The mass and 
percentage of LDLIII were both increased (both p<0.0005) with corresponding 
reductions in the mass and percentage o f LDLI (both p<0.0005) and LDLII (mass 
p<0.03, percentage p<0.005). No correlation was observed between renal function 
(using either CrCl or reciprocal o f creatinine), and the mass or percentage o f LDLIII.
21 of the 27 patients studied had a plasma albumin >32g/l. If the patients with 
hypoalbuminaemia were omitted, the results remained similar to that for the whole study 
group, with the only that difference being that LDL mass was not significantly elevated 
(patients 347 (301-416) vs controls 292 (252-349) mg/dl). The proteinuric but 
normoalbuminaemic patients had a mean LDLIII mass of 174 (67-274)mg/dl, with 50% 
o f the LDL in these patients in the form of LDLIII. No relationship was observed 
between plasma albumin and LDLIII mass although albumin was negatively eorrelated 
with LDLI (r^=29% p<0.004) and LDLII mass (r^=21% p<0.02). No relationship was 
observed between urinaiy albumin and LDL subfractions. The 12 patients with a 
creatinine clearance >70 and a normal plasma albumin had a mean LDLIII mass of 165 
(35“286)mg/dl with 48% of the LDL present in the form of LDLIII.
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Table 3.3: Lipids, Lipoproteins, VLDL & LDL subfractions according to renal 
function. (Median + IQR)
Patients: 
Creatinine Clearance >70 
(n=15)
Patients: 
Creatinine Clearance <70 
(n=12)
Choi (mmol/1) 6.9 (5.5-7.4) 6.6 (5.7-S.4)
Trig (mmol/1) 2.3 (1.4-3.2) 2.6(1.8-3.4)
VLDL-C (mmol/1) 1.0 (0.6-1.3) 0.9 (0.5-2.2)
LDL-C (mmol/1) 4.2 (3.2-5.3) 4.4 (3.8-5.9)
HDL-C (mmol/1) 1.0 (0.8-1.3) 0.9 (0.8-L2)
VLDL Total (mg/dl) 236 (143-375) 227(178-356)
VLDLi (mg/dl) 159(66-191) 125 (79-148)
VLDL] (mg/dl) 109 (62-137) 103 (79-148)
IDL (mg/dl) 78 (63-113) 82 (64-114)
LDL Total (mg/dl) 329 (279-451) 368 (323-440)
LDL I mass (mg/dl) 33 (24-37) 41 (17-50)
LDL II mass (mg/dl) 115 (76-197) 135 (80-256)
LDL III mass (mg/dl) 195 (49-288) 149 (88-258)
%LDLI 9(7-12) 11 (8-18)
%LDLII 36 (21-65) 37 (23-62)
%LDLIII 57(17-72) 51 (23-70)
Cholesteryl Ester Transfer Protein (CETP) Activity & Lipoprotein Compositions
CETP activity was increased in the proteinuric patients (patients 59.4+21.0 vs controls
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45.8+11.1 pmoles CE/ml plasma, p<0.005). In keeping with the excess CETP activity, 
both VLDLi and VLDL] were found to be cholesterol enriched and triglyceride deplete 
compared with controls, whilst LDL was cholesterol deplete and triglyceride enriched 
(table 3.4).
Table 3.4: Lipoprotein Compositions: (Mean + SD)
Patients (n=27) Controls (n=27) P
VLDLi % Cholesterol 10.7 ±3.1 7.3 + 2.2 <0.0001
VLDLi % Triglyeeride 64.2 ±4.1 67.1 ±4.5 <0.0001
VLDL] % Cholesterol 24.2 ± 4.2 18.8 ±3.9 <0.0001
VLDL] % Triglyceride 38.1 ±5.5 42.3 ±7.8 <0.03
IDL % Cholesterol 35.7 ±4 .2 36.3 ±3.2 nsd .:y
IDL % Triglyceride 17.0±5.9 15.2 ± 3.4 nsd
LDL % Cholesterol 37.6 ±3.6 39.6 ± 1.2 <0.02
LDL % Triglyceride 8.9 ±3.4 6.7± 1.1 <0.004
Remnant Lipoproteins
Proteinuric patients had increased RLP-Cholesterol (RLP-C, Patients: 18.8 (10.9-26.8) 
vs Controls: 7.6 (5.9-8.8) p<0.0001) and RLP-Triglyceride (RLP-TG: 35.8 (11.8-54.7) 
vs 7.1 (4.3-10.0) p<0.0001, all mg/dl, median + IQR). No relationship was observed 
between RLP and urinary albumin, plasma albumin or renal function. Similar results 
were obtained for the patients with a CrCl >70 compared with those <70ml/min (RLP- 
C: 18.8 (8.0-25.3) vs 20.0 (12.1-41.9), RLP-TG: 35.8 (9.4-47.0) vs 32.1 (12.6-67.6), all
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mg/dl). Proteinuric patients with normal serum albumin levels had significantly more 
remnant lipoproteins compared with controls (RLP-C 18.8mg/dl (10.3-25.8), RLP-TG 
35.8 (11.6-54.2), both p<0.0001 vs controls).
Table 3.5: Factors associated with LDLIII and Remnant Lipoprotein 
concentration
LDLIII mass
(r"%)
%LDLIII
(r^%)
RLP-C
(r^%)
RLP-TG
(r"%)
Triglyceride 45.7" 54.9" 85.2" 87.5 "
VLDLi mass 29.7'' 57.9" 68.8" 85.4"
VLDL] mass 39.1 " 20.2^ 27.6" 18.3^
LDL mass 24.3" 0.0 0.0 0.1
HDL-C 38.0 (-)'' 32.9(-)'' 39.2" 45.0"
CETP 24.6" 20.2 46.0" 39.3"
Lipoprotein Lipase 0.0 0.5 0.4 1.6
Hepatic Lipase 0.5 5.4 0.2 3.5
r % = coefficient of determination p<0.001, ^< 0 .005 , "p<0.01, “'p<0.05
Factors determining LDLIII and Lipoprotein Remnants in Proteinuric Patients
LDLIII mass was correlated with plasma triglycerides, CETP activity (both fig 3.1), 
VLDLi, VLDL] and total LDL (table 3.5). An inverse relationship was seen with HDL- 
C. No relationship was observed between LDLIII mass and activity of lipoprotein or
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hepatic lipase (fig 3.1). Multivariate analysis revealed plasma triglycerides and LDL 
mass to be independent predictors of LDLIII mass accounting for 62.2% of the variance 
(TG 45.7%, LDL mass 16.5%). The %LDLIII was related to plasma triglyceride and 
VLDLi with a weaker relationship with VLDL2 and CETP activity. An inverse 
relationship was seen with HDL-C, with no correlation seen with total LDL or lipase 
activity. On multivariate analysis plasma triglyeeride (r^= 54.9%) was the only 
independent predietor of %LDLIII.
RLP-C and RLP-TG were closely correlated with plasma triglyceride, VLDLi 
concentration and plasma CETP activity (table 3.5, fig 3.2). An inverse correlation was 
noted with HDL-C. No relationship was observed between remnant lipoproteins and 
lipase activity or LDL. On multivariate analysis plasma triglyceride was the only 
predictor o f RLP-C mass (r^=85.2%), with plasma triglyceride, VLDLi mass and 
VLDL2 mass independent factors determining RLP-TG level (total r^=94.1%: 
triglyceride 87.5%, VLDLi 5.1%, VLDL2 1.5%). A elear relationship was observed 
between the mass and percentage of LDLIII and RLP. LDLIII mass was associated with 
both RLP-C (r^=31.3% p<0.003, fig 3,3) and RLP-TG (i-^=33.6% p<0.003), with a 
closer relationship between %LDLIII and both RLP-C (r^=46% P<0.001, fig 3.3) and 
RLP-TG (r^=55.5% p<0.001).
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Fig 3.1: Plasma Triglyceride (TG), CETP Activity and Hepatic Lipase Activity vs
LDLIII mass in Proteinuric Patients
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Fig 3.2: Plasma Triglyceride, VLDLi mass and CETP Activity vs Remnant
Lipoprotein Cholesterol (RLP-C) in Proteinuric Patients
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Fig 3.3: LDLIII mass and %LDLIII vs RLP-Cholesterol: Patients
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3.4 . D IS C U S S IO N
This study demonstrates that remnant lipoproteins are present in excess in patients 
with neplii’otic range proteinuria. The data also confirms the original findings of our 
pilot study suggesting that small dense LDL is present in quantities that are associated 
with significantly increased cardiovascular risk in normal populations. This analysis 
has been extended, demonstrating that the excess of both RLP and LDLIII is not 
related to mild renal impairment and that no direct relationship was discernible with 
either urinaiy or plasma albumin. The results suggest that plasma triglyceride is the 
most important factor determining LDL size phenotype (i.e. % LDLIII) and RLP 
formation, with plasma triglyceride and total LDL determinants of LDLIII mass.
Comparing the RLP results with those obtained from the Framingham Heart Study, 
reveals that the proteinuric patients have levels of RLP-C and RLP-TG that are 2-3 
fold higher than the reference value for males [170]. The control RLP-C data 
corresponded closely to reference values however the RLP-TG control data was lower 
than comparable male data. Four o f the 5 women studied were premenopausal and the 
mean age of the patients was lower than the Framingham Offspring Study, given that 
younger patients and pre-menopausal women have lower RLP levels, this may account 
for the difference from reference males [170]. In keeping with other dyslipidaemic 
populations, plasma triglyceride was the most important determinant of RLP-C and 
RLP-TG mass present [80]. This excess of plasma triglyceride results from increased 
VLDLi and VLDLi concentration, which is primarily related to impaired clearance of 
these triglyceride-rich lipoproteins [108,171]. It is therefore likely, that the impaired 
clearance of VLDLi and VLDLi is related to the excess of RLP observed. As in vitro 
lipase activity was not reduced, it is unsurprising that lipase activity was not
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associated with RLP concentration. It has been suggested that the defective clearance 
of VLDL may result from deficiencies in plasma or VLDL apolipoproteins [105].
The current theory describing the formation o f atherogenic levels of LDLIII require 
the presence of excess triglycerides and adequate levels of hepatic lipase (found in 
males and post-menopausal females). Triglyceride is passed via CETP from VLDL; to 
LDL in return for cholesteiyl ester. A triglyceride enriched LDL pailicle is formed 
which is hydrolysed by hepatic lipase, sluinking the paiticle and forming small dense 
LDL [56]. The results obtained in this study suggest that LDLIII formation in 
proteinuric patients probably follows similar lines. Increased triglyceride is related to 
LDLIII mass and %LDLIII. Plasma CETP activity is increased and related to the mass 
and percentage o f LDLIII. It is likely that hepatic lipase was not rate limiting due to 
the extent of the hypertriglyceridaema. Finally VLDL] concentration is increased and 
is cholesteiyl ester enriched. Moreover, the LDL present is triglyceride rich, a 
characteristic finding for small dense LDL [172]. Thus, in proteinuric patients it 
appears that the LDL phenotype is determined by the plasma triglyceride, with both 
plasma triglyceride and the total LDL mass determining the LDLIII mass.
There is increasing evidence to link both lipoprotein remnants and small dense LDL 
with coronary artery disease, RLP-C levels are increased in men with coronary artery 
disease [83], high RLP-C is a predictor for coronary arteiy stenosis [84] and sudden 
cardiac death [85], RLP induces platelet aggregation [173], is associated with 
coronary artery endothelial cell dysfunction [174] and can promote lipid accumulation 
by macrophages [168]. Prospective and retrospective studies have established that 
increased small dense LDL is associated with enhanced cai'diovascular risk [142,143],
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and patients with an LDLIII mass of >100mg/dl have a seven fold increase in the risk 
of myocardial infarction [141]. Using this criteria, 20 of the 27 patients studied have a 
high risk of developing a myocardial infarction irrespective o f other cardiovascular 
risk factors. A number of theories have been proposed regarding the cause of the 
increased atherogenicity of small dense LDL, these include: (i) decreased affinity for 
the LDL receptor with increased uptake by the scavenger receptor, [175] (ii) increased 
susceptibility of small dense LDL to oxidation, partly as a result of longer residence 
time in plasma due to decreased LDL receptor uptake [176,177], (ill) increased 
filtration by the endothelium due the smaller size of the LDL particles [56] and (iv) 
greater affinity for binding to arterial wall proteoglycans [178]. Each of the above 
factors will increase the likelihood of LDL being located in the subendothelial space 
and initiate the formation of the atherosclerotic plaque.
Patients with end-stage renal failure have increased small dense LDL [160] and RLP 
[82]. The data in this study does not suggest that mild renal dysfunction has 
contributed to the increase in small dense LDL or RLP observed in the proteinuric 
patients. The lack of correlation between either LDLIII or RLP and plasma or urinaiy 
albumin in this population is also noteworthy. The atherogenic lipoprotein phenotype 
consists of raised triglycerides, low HDL-C and increased small dense LDL. Plasma 
triglycerides have the closest association with LDLIII and reported relationship 
between plasma triglycerides and proteinuria vary significantly [105]. An inverse 
relationship was observed between albuminuria and HDL-C (r^=21.2% p<0.02) 
suggesting that a relationship may exist between urinary albumin and one aspect of the 
atherogenic lipoprotein phenotype.
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The central role of triglycerides and triglyceride rich lipoproteins in determining the 
extent of RLP and LDLIII formation is clearly demonstrated in this study. To our 
knowledge small dense LDL and atherogenic remnants have not been analysed in the 
same study population. The close conelation between RLP and both plasma 
triglycerides and LDLIII, suggest that RLP are likely to contribute to the increased 
cardiovascular risk attributed to the atherogenic lipoprotein phenotype. We suggest 
that the definition o f the atherogenic lipoprotein phenotype may require modification 
to include RLP along with small dense LDL, mild hypertriglyceridaemia and a low 
HDL. The finding of excess small dense LDL and lipoprotein remnants, highlights the 
need to clarify the nature o f the defective clearance o f triglyceride rich lipoproteins 
that has been demonstrated in this population [108,171]. Clearly excess of both RLP 
and LDLIII add to the spectrum of cardiovascular risk factors that are likely to 
contribute to the increased atherogenesis present in proteinuric patients.
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CHAPTER 4 -
R aised Very-Low D ensity  Lipoprotein  
(VLDL) In Nephrotic Range Proteinuria Is 
A ssociated  With R elative D eficiency Of 
Apolipoprotein C And E On VLDL Particles
4.1 INTRODUCTION
Patients with nephi*otic range proteinuria have an increase in plasma concentration of 
both VLDL, and VLDLi [104,109]. Metabolic studies suggest that the increase in 
VLDL, results from delayed clearance of the lipoprotein whilst the rise in VLDLi 
results both from delayed clearance and enlianced hepatic production [108,171]. 
Excess plasma triglyceride in the form of VLDL, appears essential for the formation 
of small dense LDL [56,144], a form of LDL that is atherogenic [55] and associated 
with inereased cardiovascular risk [139,140,142,143]. We have shown that patients 
with nephrotic range proteinuria possess excess quantities of both small dense LDL 
[109] and remnant lipoproteins, and postulate that the delayed VLDL, clearance and 
resultant hypertriglyceridaemia is a significant contributor to the atherogenic 
dyslipidaemia prevalent in patients with nephi'otic range proteinuria.
The two methods of clearing VLDL, particles from the circulation are by hydrolysis 
using lipoprotein lipase to form VLDL% and then IDE, and by direct hepatic uptake of 
VLDL via the VLDL receptor which recognises apolipoprotein E [179]. Our 
laboratory has previously demonstrated impaired VLDL clearance but normal 
chylomicron clearance in the neplnotic syndrome [180], with normal in-vitro activity
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of lipoprotein lipase [109,180]. Activation o f lipoprotein lipase depends upon the 
cofactor apolipoprotein CII on the VLDL particle, whilst apolipoprotein CIII inhibits 
this process [181]. The aim of this study therefore, was to measure the apolipoproteins 
CII, CIII and E, in the plasma and VLDL, compartments, along with VLDL lipid 
compositions to clarify the potential cause of the impaired clearance leading to the 
excess VLDL, in the plasma of patients with neplu'otic range proteinuria.
4.2 SUBJECTS AND METHODS 
Subjects
Fasting plasma and the VLDLi fraction o f plasma from the 27 patients and controls 
that were studied in Chapter 3, was stored at a temperature of -50°C. After 
recruitment of all the patients and controls, apolipoproteins B, CII, CIII and E were 
analysed from the EDTA plasma and the VLDLi fraction.
Statistics
Statistical analyses were performed using MINITAB lOX for Windows (Minitab Inc.). 
Any factors that were not normally distributed were subjected to log transformation. 
These included the VLDL, concentration and the majority of apolipoprotein results. 
Results are shown as either median and interquartile range (IQR) or mean and 
standard deviation (SD). Samples were compared using the two-sample /-test. Simple 
regression analysis was performed to identify significant correlations. After fitting 
regression lines, the slopes for patients and controls were compared firstly to assess if 
they were parallel and then to see if their intercepts differed. This was done using a 
general linear model (GLM). Multivariate analysis of linear variables was performed
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using stepwise regression. A GLM was used to perform multivariate analysis if a 
categorical variable was involved.
4.3 RESULTS
The data on renal function, urinary albumin, plasma albumin, lipids and lipoproteins 
is shown in chapter 3. There was a 4 fold increase in VLDLi concentration (patients 
156mg/dl (57-212) vs controls 43mg/dl (24-74) p<0.0001, median + IQR) which 
persisted even if patients with hypoalbuminaemia or a creatinine clearance of 
<70ml/min were excluded.
Table 4.1: Plasma Apolipoproteins: Patients vs Controls (All Median + IQR)
PATIENTS (n=27) CONTROLS (n=27) P
Apo B (mg/dl) 146(112-179) 90 (68-98) <0.0001
Apo CII (mg/dl) 6.2 (4.4-7.9) 3.1 (2.5-4.4) <0.0001
Apo CIII (mg/dl) 30.0 (27.1-37.2) 17.7 (15.9-21.7) <0.0001
Apo E (mg/dl) 4.3 (3.3-6.8) 3.5 (2.9-4.1) <0.002
ApoCII / B (mg/mg xlO'^) 4.2 (3.3-5.6) 3.9 (2.8-4.4) nsd
ApoCIII / B (mg/mg xlO"^) 21.1 (19.1-26.0) 22.2 (17.7-26.5) nsd
ApoE / B (mg/mg xI0 ‘^ ) 3.1 (2.8-3.8) 3.9 (3.5-4.8) <0.03
Plasma Apolipoproteins.
Table 4.1 shows the results for the plasma apolipoproteins. In keeping with the 
increased in total lipoproteins present, the total mass of apolipoprotein B (apoB), 
apolipoprotein CII (apoCII), apolipoprotein CIII (apoCIII) and apolipoprotein E
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(apoE) were all increased in the patients with proteinuria. Each VLDL, IDL and LDL 
particle carries one moiety of apoB, thus using this as a reference, a crude estimate of 
the amount of apoCII, CIII and E moieties per lipoprotein particle in the plasma was 
obtained, ignoring the apoC present on HDL. The results suggest that taking into 
account the excess of particles present, the amount of CII and CIII per lipoprotein 
particle did not differ between the patients and controls (table 4.1). However, the mass 
of apoE per particle was reduced in the patients compared with controls (p<0.03).
Table 4.2: Plasma Concentration of VLDL, Apolipoproteins: Patients vs 
Controls (All Median + IQR)
PATIENTS (n=2I) CONTROLS (n=19)
ApoB (mg/dl) 13.0(6.1-26.2) 3.7 (Q.9-6.3) <0.003
Apo CII (mg/dl) 1.20 (0.49-1.87) 0.51 (0.33-0.77) <0.002
Apo CIII (mg/dl) 4.14 (2.43-5.42) 1.57 (0.94-2.83) <0.001
ApoE (mg/dl) 0.14(0.09-0.19) 0.13 (0.10-0.16) nsd
VLDL, Apolipoproteins & Compositions: Patients vs Controls
The concentration of apolipoproteins present in the plasma VLDL, fraction are seen in 
table 4.2. The analysis of the VLDL, apolipoproteins was performed on 21 patients 
and 19 controls, due to the concentration of VLDL, being too low in some patients 
and controls to allow accurate measurement of either apoCII, apoCIII or apoE. If one 
of the VLDL, apolipoproteins was umecordable due to low VLDL, concentration then 
all the apolipoprotein and composition results for that patient were ignored to avoid 
bias in any results. In keeping with the increase in total VLDL, concentration, apoB
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(p<0.003), apoCII (p<0.002) and apoCIII concentration (p<0.001) were all increased 
in the patients compared with controls. However VLDL, apoE was not increased. To 
assess the quantity of apolipoprotein CII, CIII and E on each VLDL, particle, the 
molar ratio of each apolipoprotein to apolipoprotein B was calculated (table 4.3). This 
revealed each VLDL, particle in the patients with proteinuria to be deficient in apoCII, 
CIII and E. In the case of apoE, this deficiency was present to such an extent that it 
could be calculated that between only one in three and one in five VLDL, particles 
possessed an apoE moiety. The VLDL, particles in the proteinuric group also had a 
significantly lower triglyceride content (p<0.05) with a trend towards lower surface 
phospholipid (p<0.07). The total and free cholesterol content o f the particles did not 
differ between the 2 groups.
The relative proportions of apolipoproteins to phospholipid on the surface of the 
VLDL, particles further demonstrated the relative deficiency of VLDL, 
apolipoproteins. The ratio of apoCII to phospholipid (3.7+1.7 vs 5.8+2.1 p<0.002), 
apoCIII to phospholipid (12.1+4.9 vs 16.7+6.6 p<0.03) and apoE to phospholipid 
(0.16+0.13 vs 0.35+0.22 p<0.02, all xlO'^) were all significantly reduced compared 
with controls. In contrast the ratio of free cholesterol to phospholipid (FC:PL) was 
increased in the proteinuric patients (0.55+0.17 vs 0.40+0.18 p<0.002, all mean+SD).
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Table 4.3: Apolipoprotein and Lipid content per VLDL, particle : Patients vs 
Controls (all moles per particle -  Median + IQR)
PATIENTS(n=21) CONTTlOLS(ii=19) P
ApoCII 4.2 (3.1-8.2) 9.9 (7.4-23.2) <0.0004
ApoCIII 16.6(9.1-27.2) 29.3 (18.5-69.4) <0.02
ApoE 0.17(0.08-0.44) 0.48 (0.31-1.31) <0.006
Triglyceride 4896 (3025-7912) 6979 (4590-15687) <0.05
Total Cholesterol 1758 (1393-2808) 1667(1312-2885) nsd
Free Cholesterol 814(515-1028) 759 (562-1474) nsd
Phospholipid 1209 (977-2186) 1783 (1277-4091) nsd
Relationship between VLDLi compositions and VLDLi concentration
Strong negative correlations were observed between the plasma VLDL, concentration 
and the number of moles of apoCII and apoCIII per VLDLi particle (fig 4.1). Thus for 
all the patients studied, as VLDL, mass increased from 25mg/dl to lOOOmg/dl, the 
number o f moles of apoCII per VLDL, particle decreased from 53 to 1 and apoCIII 
per VLDL, particle decreased from 150 to 3. A similar negative relationship was also 
observed between the moles per VLDLi of apoE and VLDL, concentration, with apoE 
per particle decreasing from 5 to 0.02 (i.e. one particle in fifty) as VLDL, mass 
increased (fig 4.1). A strong negative relationship was observed between the moles of 
triglyceride per VLDL, particle (an index o f particle size) and the VLDL, mass (all 
subjects r^=52.2% p<0.001, patients r^=41.5% p<0.003, controls r^=71.1% p<0.001), 
indicating that as VLDL, mass increased, the size of the VLDL, particles decreased. 
Weaker relationships were observed between VLDL, concentration and the FC:PL
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ratio (all subjects r^=30.2% p<0.001, patients r^= ll.l%  p=nsd, controls r^=25.7% 
p<0.03).
Table 4.4: Univariate (U) and Multivariate (M) Analysis for Regulation of 
ApoCII, apoCIII and ApoE per VLDL, particle - All Patients
ApoCII ApoCIII ApoE
U r^% M r^% U r^% M r^% U r^% M r^%
TG per particle 61.5“
FC:PL 41.6“
Subject Group .
24.9
5.2
5.3
75.8 “ 36.7
38.8 “ 2.8
2.5
58.2 “ 
11.7 '
p<0.001, ° p<0.01, p<0.05,  ^p=0.05 r'^=coefficient of determination
43.3“
nsd
4.2^
Regulation of VLDLi apolipoprotein CII and CIII composition
To assess determinants of apoCII and apoCIII content per VLDL, particle, the 
relationship between apoCII and apoCIII per VLDL, particle and lipoprotein 
composition was analysed. As triglyceride per particle increased from 2x10^ to 32x10^ 
moles so did apoCII and apoCIII per particle (fig 4.2, table 4.4). Conversely an inverse 
relationship was seen between FCiPL (increasing from 0.17 to 0.98) and both apoCII 
and apoCIII per particle (fig 4.3, table 4.4). An interaction was also observed between 
triglyceride per particle and FC:PL (all subjects r^=22.7 p<0.003). We proceeded to 
multivariate analysis to assess factors determining apoC per particle. We analysed 
linear variables by stepwise regression and noted that for all subjects, triglyceride 
(TG) per particle and FC:PL were independent predictors of apoCII per particle (total 
r^=71.1%) and apoCIII per particle (total r^=80.5%). Multiple regression analysis
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using a general linear model to include the categorical variable ‘subject group % 
revealed that particle size, FC:PL and ‘subject group’ were all independent predictors 
of both apoCII and apoCIII per particle (table 4.4). From the equation obtained from 
multiple regression analysis, it could be estimated that the ‘subject group’ accounted 
for a mean difference o f 1.5moles of apoCII per VLDL, and 1.3moles of apoCIII per 
VLDL,.
Regulation of VLDLi apolipoprotein E composition
The relationship between apoE per particle and triglyceride per particle was similar to 
that found for apoC, indicating that as particle size increased, so did the apoE content 
(table 4.4, fig 4.2). However although analysing all subjects revealed a weak 
relationship between apoE per VLDL, and FCtPL (r^=11.7 p<0.05), no relationship 
was seen if the analysis was performed for either patients or controls (fig 4.3). On 
multivariate analysis, triglyceride per particle and subject group but not FC:PL ratio 
were independent predictors of apoE per VLDL, particle. Despite the low coefficient 
of variation for subject group, from the equation obtained from multiple regression 
analysis it could be estimated that the ‘subject group’ had a profound effect on apoE 
per particle accounting for a mean difference o f 1.7moles of apoE per VLDL, (range 
of apoE per VLDL,: patients 0.04 -2.0, controls 0.02 -S.Omoles/particle).
Effect of Renal Function and Hypoalbuminaemia
In the patients with proteinuria, the relationship between the VLDL, compositions and 
apolipoproteins did not seem to be affected by renal function (as measured by 
creatinine or creatinine clearance -  CrCl), or plasma albumin. Weak relationships 
were seen between urinary albumin and plasma apoB (r^=23.5% p=0.01) and apoE
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(r^==23.5% p=0.03), whilst plasma albumin exhibited an inverse relationship with 
plasma apoB (r^=25.3% p<0.009). However, no other relationships were observed and 
there was no correlation between renal function and either plasma or VLDL, 
apolipoprotein content. 15 patients had a CrCl greater than 70, with 12 less than 70, 
whilst amongst those patients whose VLDL, apolipoproteins could be measured, CrCl 
was greater than 70 in 12, and less than 70 in 9. Comparing the 2 subgroups revealed 
no differences in their plasma or VLDL, apolipoprotein content. Moreover comparing 
the subgroup with CrCl greater than 70 with the control group, revealed similar results 
to those obtained using all the proteinuric patients. Plasma albumin was >32g/dl in 21 
patients and <32 in only 6, (>32 in 16 and <32 in only 5 in those patients whose 
VLDL; apolipoproteins could be accurately measured). Excluding the 
hypoalbuminaemic patients did not significantly change the comparison of patients 
and controls.
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Fig 4.1: V L D L i mass (mg/dl) vs Apolipoprotein C II , CIII and E per V L D L i 
particle (all moles/particle)
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Fig 4.2:Triglyceride per V L D L i particle vs Apolipoprotein C II, C III and E per 
V L D L i particle (all moles/particle)
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Fig 4.3: FC:PL ratio vs Apolipoprotein CII, CIII and E per VLDL, particle (all 
inoles/particle)
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4.4 DISCUSSION
The data presented here suggest that patients with proteinuria have plasma apoCII and 
CIII levels that are increased but apparently proportionate to the excess of lipoprotein 
particles. However the data also suggest that there is a relative deficiency in 
circulating apoE. We planned to explore the causes o f the VLDL difference. Given 
that we have demonstrated that heparin releasable lipoprotein lipase activity was not 
reduced in proteinuria [109], we hypothesised that the impaired clearance of VLDL, 
that has been noted previously [108,171] may result from a relative lack of 
apolipoproteins on the VLDLi particle, particularly apoCII the lipoprotein lipase 
cofactor. As a result, we have shown that the VLDL, paxUcles in this population are 
deficient in apoCII, apoCIII and apoE. The study has also suggested that the 
deficiency in apolipoprotein C is related to a combination of the presence of smaller 
VLDL, particles, and VLDL, particles which are relatively enriched in free 
cholesterol, with an increased ratio of free cholesterol to phospholipid (EC:PL) on 
their surface. The VLDL apoE deficiency was related to the presence of smaller 
VLDL, particles but was not explained by altered lipid composition.
Patients with nephi'otic range proteinuria are markedly heterogeneous in terms of their 
clinical diagnosis, renal function and plasma albumin. Indeed some studies looking at 
dyslipidaemia in the nephrotic syndrome require the patients only to have nephrotic 
range proteinuria, without necessarily being hypoalbuminaemic [156,182]. Metabolic 
studies have shown that VLDL, clearance is reduced and VLDL2 production increased 
in a group of patients with nephrotic range proteinuria who were predominantly 
normoalbuminaemic [171]. More recently VLDL, concentration has been shown to be 
increased two-fold, with a four-fold increase in VLDL2 and reduced VLDL,, VLDL2
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and IDL clearance in a population with neplnotic syndrome and normal renal function 
[108], In our study, neither the heterogeneity in renal function or plasma albumin, 
seem to have had a major influence on the lipoprotein apolipoprotein compositions. 
As a result the proteinuric patients were treated as a whole group.
A clear relationship is seen between the number of moles of apoCII, apoCIII and apoE 
per VLDL, particle and the VLDL, mass. Thus in both patients and controls, as the 
VLDL, mass increases, the apolipoprotein content of VLDL particles decreases. 
However, there is also a clear tendency for the patients with proteinuria to have 
smaller VLDL, particles compared with controls. Given the relationship between the 
apolipoprotein content of each particle and the particle size (i.e. triglyceride per 
particle), it is important to decide if particle size and the presence of proteinuria were 
independent factors. From our data we concluded that for apoCII, apoCIII, and apoE, 
particle size and lipid composition (i.e. FC:PL ratio) did not appear to explain all of 
the differences in apolipoprotein content between the patients and controls, and that 
there appeared that to be an additional effect of being in the proteinuric group. We 
proceeded to explore the relationships between lipoprotein size, lipid and 
apolipoprotein content not only for what they told us about hyperlipidaemia in 
neplnotic range proteinuria, but also to identify the factors that might regulate the 
apolipoprotein content of large triglyceride rich VLDL,.
Despite apparently adequate plasma levels of apoC, both apoCII and apoCIII per 
VLDL, particle were reduced in the proteinuric patients. Moreover, as VLDL particle 
size decreased or FC:PL increased, the apoCII:CIII ratio remained constant. This is in 
contrast to the reported situation in other hypertriglyceridaemic conditions, where
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apoCIII increases and apoCII decreases with a decrease in the apoCII:CIII ratio as 
plasma triglyceride and VLDL, mass increase [183,184]. It is also noteworthy that the 
compositional data obtained for the controls corresponded closely to those obtained by 
other authors [185]. The compositional abnormalities seen in the patients with 
nephrotic range proteinuria, may cast light on the nature of the hypertriglyceridaemia 
observed in this population. ApoCII is a cofactor which activates lipoprotein lipase 
(LpL). ApoCIII is thought to inhibit the lipolysis of triglyceride rich lipoproteins and 
may, if  present in excess, cause hypertriglyceridaemia [181]. We have demonstrated 
that in nephrotic range proteinuria, inefficient lipolysis cannot he related to this as 
apoCIII is not increased. Therefore it is likely that the lack of apoCII causes the 
hypertriglyceridaemia associated with impaired catabolism of VLDL, to VLDL2 [171].
These data also indicate that within the discrete density class of VLDL,, across a wide 
range of VLDL, mass, the increase in VLDL, size (increased triglyceride per particle) 
leads to an increase in the surface area of the lipoproteins and a greater ability to 
accumulate apolipoprotein CII, CIII and E. Apart from apolipoproteins, the main 
surface constituents of lipoproteins are free cholesterol and phospholipid. The apoCII 
and apoCIII content per particle was independently associated with the surface FC:PL 
ratio. We hypothesise that the reduction in apoC observed, as FC:PL increases is due 
to the changing nature of the phospholipid layer as it becomes enriched in free 
cholesterol [186]. Free cholesterol will form a hydrogen bond with phospholipid and a 
phospholipid layer is saturated when FC:PL approaches 1.0 [187]. It is therefore 
interesting to observe that in fig 4.3 that as this ratio approaches unity, the number of 
apoCs per VLDL, reduces dramatically. Thus it may be that the lack of low molecular 
weight apolipoproteins in the patients VLDL, is also due to the saturation of the
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phospholipid layer with free cholesterol. The mechanism underlying this association 
may be as follows. Small apolipoproteins such as apoC are known to bind to VLDL 
by penetrating the surface phospholipid matrix of lipoproteins and embedding their 
amphipathic helical structures in the phospholipid layer [181]. If the phospholipid 
layer is not fluid enough, due to the excess FC, then it is likely that apoCs will not be 
able to bind. We postulate therefore that even in the VLDLi range, the free cholesterol 
emichment of the surface leads to an inability to incorporate apoC by exchange from 
HDL, and this, as a result, has consequences for efficient processing of VLDLi 
particles. There is evidence to suggest that free cholesterol is overproduced in the 
neplnotic syndrome [188], however indirect assessment of cholesterol synthesis does 
not support this evidence [189]. We hypothesise that patients with nephrotic range 
proteinuria may be secreting VLDL which given the smaller particle size, has a 
relative excess of surface free cholesterol and a high FCiPL. However further studies 
are required to assess whether this is related to excess free cholesterol production. It is 
interesting to note that despite the differences in particle size and FC:PL, having 
proteinuria remained an independent predictor of apoC per particle. Whether this is 
related to a relative deficiency of apoC, not identified by assessing the plasma apoC/B 
ratio, to the spread of the FC:PL results obtained in both patients and controls or to 
another as yet unidentified mechanism, remains to be determined.
Apolipoprotein E per VLDL, particle was determined by particle size and subject 
group. In the case of apoE, we suggest that the group effect is likely to reflect the 
relative plasma deficiency of apoE that was present in patients with proteinuria. The 
reduction in apoE per particle seen in the patients is likely to have major consequences 
for clearance of VLDL by the VLDL receptor, LDL-receptor related protein, or LDL
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receptor, all of which are thought to use apoE as their ligand [179]. Indeed it can be 
calculated that between 67-80% of the VLDL, particles in the patients are devoid of 
apoE. It is unclear why a specific plasma deficiency of apoE was found in patients 
with neplirotic range proteinuria. All three apolipoproteins: apoE (34000 daltons), 
apoCII and apoCIII (8800 daltons), are smaller than albumin (65000 daltons) and thus 
could easily be lost in the urine. It may be that the plasma is deficient in all tluee 
apolipoproteins or that a specific deficit in plasma apoE is present due to varying 
affinity of the apolipoproteins to the lipoproteins, failure of the liver to produce apoE, 
or accelerated apoE catabolism. Elucidation of the precise mechanism will require 
further study. The observation that there was no independent association between 
apoE per particle and FC:PL suggests that inter-lipoprotein transfer in plasma is less 
important for apoE. It is interesting to note that recent evidence suggests that apoE has 
a role in VLDL production and apoE deficient hepatocytes produce smaller VLDL 
than controls [190]. It may be that the relative deficiency of apoE found in the 
proteinuric patients plays a role in the appearance of smaller VLDL, in this study.
In summary we have shown that patients with nephrotic range proteinuria possess 
VLDL, particles that are deficient in apolipoprotein CII, CIII and E. We have 
suggested two mechanisms that would potentially explain the hypertriglyceridaemia in 
patients with neplii'otic-range proteinuria and explain previous observations that there 
is a primary clearance failure in this population [108,171]. The lack of apoCII on the 
VLDL particles will, it is predicted, result in inefficient lipolysis, and may effect not 
only VLDL, but also VLDLz. The decreased plasma and VLDL apoE is likely to result 
in reduced receptor mediated catabolism of VLDL particles. The compositional 
analysis indicates that the abnormal generation in the liver of a smaller VLDL, particle
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which is relatively enriched in free cholesterol and deficient in apoE might be 
sufficient explanation for the abnormalities observed in the VLDL, density range. The 
resulting hypertriglyceridaemia is of clinical importance as it is a major determinant of 
other aspects of lipoprotein abnormalities particularly the presence of both small 
dense LDL and remnant lipoproteins with their associated increased cardiovascular 
risk.
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CHAPTER 5 - 
Com parative E ffects o f  C erivastatin and  
Fenoflbrate on th e  A therogenic Lipoprotein  
Phenotype in Proteinuric Renal D isease
INTRODUCTION
It is now established that pharmacological lipid lowering with either HMG CoA 
reductase inhibitors (statins) or fibrates reduces cardiovascular morbidity and 
mortality [64-68, 70, 191]. However the majority of patients with coronary arteiy 
disease do not have hypercholesterolaemia, with a large proportion having a pattern of 
mild hypertriglyceridaemia, low HDL and excess small dense LDL [97] - the 
atherogenic lipoprotein phenotype [140]. In normal populations, statins will reduce the 
plasma concentration of atherogenic small dense LDL particles by lowering all 3 LDL 
subfractions in concert [153]. Fibrates promote a shift in LDL size towards larger 
lighter particles, with or without a change in total LDL [154,155], with recent data 
suggesting that fibrates reduce coronary events in patients with coronary heart disease, 
low HDL-C and raised triglycerides, without altering LDL-C concentration [191].
We have demonstrated that not only do patients with nephrotic range proteinuria 
possess atherogenic quantities of LDLIII [109], they also have excess quantities of 
atherogenic lipoprotein remnants. In patients with nephrotic range proteinuria, statins 
have been shown to reduce cholesterol and LDL-C [104]. This cholesterol lowering 
effect is accompanied by plasma triglyceride reduction and increased receptor 
mediated LDL clearance [156]. Given the link between increases in plasma
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triglyceride and both small dense LDL formation [56] and concentrations of remnant 
lipoproteins [80], the triglyceride lowering effect of statins may have a beneficial 
effect not only on LDLIII concentration but also on the relative proportions of each 
LDL subfraction, and on remnant lipoproteins. The aim of this study therefore, was to 
compaie the ability of a statin (cerivastatin) and a fibrate (fenoflbrate) to lower levels 
of these atherogenic lipoproteins in patients with nepluotic range proteinuria. A 
secondary aim was to assess changes in VLDL subfractions and plasma 
apolipoproteins, to help identify mechanisms underlying any changes in the 
atherogenic lipoproteins.
SUBJECTS & METHODS 
Subjects
12 patients (10 males, 2 females) were recruited from the out-patient clinic of the 
Glasgow Royal Infirmary Renal Unit according to the following inclusion criteria:
(a) primaiy glomerular disease
(b) urinary albumin excretion >1.5g/24hrs (equivalent to 3 g proteinuria per 241n's)
(c) serum creatinine <250umol/l.
(d) plasma cholesterol >6.5mmol/l
(e) plasma triglyeeride >1.5mmol/1.
Any patient with a significant deterioration in their renal function during the 6 months 
prior to the study was excluded. Patients suffering from other diseases or on treatment 
that might influence their lipid profile were excluded, specifically patients with 
diabetes mellitus or amyloid, or taking thiazide diuretics, fat soluble beta blockers,
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corticosteroids or other immunosuppressive agents. Treatment with other 
antihypertensives or diuretics was permitted. Any patient receiving lipid lowering 
therapy had their lipid lowering medication stopped for a period of 4 weeks prior to 
inclusion in the study. All patients had a biopsy proven diagnosis.
The study had a randomised, erossover design and lasted 5 months. 6 patients were 
randomised (using random numbers) to receive cerivastatin, 1 OOmicrograms (ug) for 1 
month increasing to 200ug for the next month, or fenoflbrate 200mg for 2 months. At 
the end of 2 months, the drug was stopped, patients were given a month off lipid 
lowering treatment as a wash-out period and then given the alternative treatment for 2 
months. Patients were seen on a monthly basis, attending after an overnight fast. At 
each visit blood was sampled for creatinine, albumin, liver function tests (LFTs), 
creatine kinase (CK), lipids and lipoproteins, VLDL and LDL subfractions. A 241n 
urine collection was taken at each visit for creatinine clearance and urinary albumin. 
The study was approved by the Ethics Committee of the Glasgow Royal Infirmary. All 
patients gave written consent before participating.
Statistics
Statistical analysis were performed by using MINITAB lOX for Windows (Minitab 
Inc.) and SPSS statistics package. Results are shown as means and standard 
deviations. Baseline and endpoint data was compared using ANOVA repeated 
measures of analysis. If this showed a significant difference then the 2 treatment 
modalities were further compared using paired ^-test. Data before and after treatment 
was compared using paired r-test. Simple regression analysis was performed to 
identify significant correlations.
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RESULTS 
Baseline data
Ten males and 2 females were recruited. The diagnoses were IgA nephropathy (n=4), 
membranous nephropathy (n=3), minimal change nephropathy (n=2), 
mesangiocapillary glomerulonephritis (n=2) and focal and segmental 
glomerulosclerosis (n=l). The baseline data obtained before treatment with either 
cerivastatin or fenoflbrate is shown in tables 5.1-5.4. Values at the beginning of each 
treatment phase (baseline and washout) did not differ for any parameter studied. The 
patients had a body mass index of 27.7+3.6. Serum albumin was 35.8+5.5g/l, 3 
patients had a serum albumin <32g/l, however only one patient had significant 
oedema. Average blood pressure was 143/87mmHg, with 9 patients receiving 
antihypertensives. Only 3 of the 12 patients before cerivastatin and 2/12 before 
fenoflbrate treatment had a serum creatinine >150umol/l. Compared to the normal 
population, the mean cholesterol, triglyceride, VLDL-C, and LDL-C were all raised, 
whilst HDL-C was reduced (Table 5.1). Total VLDL concentration and both VLDL 
subfractions were increased 4-5 times normal [144]. IDL concentration and total LDL 
concentration were increased 2 fold [144] (Table 5.2). LDLIII was the most prevalent 
LDL particle (Table 5.3) with a marked shift in subfraction distribution towards small 
dense LDL. Ten of the 12 patients in each group had an LDLIII concentration 
>100mg/dl. Compared with normal reference values, remnant lipoprotein cholesterol 
and triglyceride were both raised at baseline [170] (Table 5.4).
Biochemistry, Renal function, Blood pressure, Lipids & Lipoproteins
Changes in lipids and lipoproteins following treatment with cerivastatin and
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fenoflbrate are seen in Table 5.1. Cerivastatin produced a significant fall in cholesterol 
(21%), triglyceride (14%) and LDL-C (23%). The reduction in VLDL-C just failed to 
reach significance (16% reduction, 95% Cl -36:4), and no change in HDL-C was 
observed. One patient developed myalgia on 200ug of cerivastatin which resolved on 
decreasing to a lOOug dose. No increment in CK was found. No change in serum 
creatinine, ereatinine clearance, LFTs or CK was observed on cerivastatin treatment. 
Fenoflbrate reduced plasma triglyceride (41%) and VLDL-C (52%). A significant 
reduction in plasma cholesterol (19%) was also seen, with a 19% increase in FIDL-C. 
There was no consistent change in LDL-C. Fenoflbrate treatment was associated with 
a 14% increase in serum creatinine (p<0.01) but no change in creatinine clearance was 
observed. There was also no significant change in CK following fenoflbrate treatment 
(mean increase 78u/l, 95%CI: -105:261). One patient developed abnormal LFTs and a 
rise in CK after 2 months on fenoflbrate. These values returned to normal after 
stopping the drug as planned.
Despite the greater reduction of LDL-C by cerivastatin, there was no significant 
difference in cholesterol or LDL-C at the end of each treatment period (Table 5.1). 
Plasma triglyceride (p<0.01) and VLDL-C (p<0.05), were lower after treatment with 
fenoflbrate compared with cerivastatin. The absolute decrease in triglycerides (TG) 
and VLDL-C was also greater following fenoflbrate compared with cerivastatin (mean 
difference TG 0.8mmol/l, 95% Cl 0.4:1.3, VLDL-C 0.5mmol/l, 95% Cl 0.1:0.9). 
HDL-C was higher after fenoflbrate (p<0.05) with the response to fenoflbrate being 
0.15mmol/l greater than cerivastatin (95% Cl 0.06:0.25). The on treatment serum 
creatinine was higher following fenoflbrate, however there was no difference in 
creatinine clearance (Table 5.1).
VLDL, VLDL subfractions, IDL and LDL concentration
Cerivastatin produced a significant reduction in total VLDL concentration (26%) and 
total LDL concentration (18%). Changes in VLDL subfractions and IDL were less 
clear-cut with an 18% reduction in VLDLi (mean decrease 80mg/dl 95% Cl 19:141), a 
14% reduction VLDL% (mean decrease 29mg/dl 95% Cl -4:61), and a non-significant 
reduction in IDL concentration (20%, table 5.2). Fenoflbrate produced a much greater 
reduction in the triglyceride rich lipoproteins with large decreases in total VLDL 
(55%), VLDLi (57%), and VLDL2 (47%). There was no significant reduction in IDL 
or LDL concentration.
Comparing the final results achieved (table 5.2) reveals that concentrations of total 
VLDL (p<0.01), VLDLi (p<0.05) and VLDL% (p<0.05) were all lower following 
treatment with fenoflbrate compared with cerivastatin. The absolute reduction in total 
VLDL, VLDLi and VLDL2 was also greater on fenoflbrate, with a difference of 
118mg/dl for total VLDL (95% Cl 29: 207), and 39mg/dl for VLDL2 (95% Cl 12: 66). 
The difference in the absolute reduction of VLDLi concentration did not quite reach 
significance (mean difference 79mg/dl, 95% Cl -13: 170). LDL concentration was 
lower following cerivastatin however the difference was not significant. The on 
treatment IDL results were similar for both treatments.
LDL Subfractions
Cerivastatin reduced LDLIII concentration by 27% (table 5.3), The quantity of LDLI 
present was very low and there was a negligible change in LDLII concentration. The 
relative pereentage of each LDL subfraction did not change. Following fenoflbrate
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treatment LDLIII concentration decreased by 49% with a corresponding 138% 
increase in the concentration of LDLI. The relative proportions of each LDL 
subfraction therefore changed on this drug with a shift in particle size towards larger 
lighter particles. %LDLIII decreased from 60 to 33% (95% Cl 12:41, p<0.01), whilst 
the %LDLI and %LDLII both increased (%LDLI: 8% to 19%, 95% Cl 3:19, p<0.05; 
%LDLII 32% to 48%, 95% Cl 1:30, p<0.05).
On treatment LDLIII concentration was lower (p<0.05) and LDLI concentration 
higher (p<0.01) on fenoflbrate compared to cerivastatin. The absolute response to 
treatment also differed for LDLI and LDLIII. Fenoflbrate increased whilst cerivastatin 
decreased LDLI concentration (mean difference 33mg/dl, 95% Cl 4:62). The absolute 
decrease in LDLIII concentration following fenoflbrate was greater than that achieved 
with cerivastatin (although not quite reaching statistical significance - mean difference 
63mg/dl, 95% Cl -134:7, p<0.07). A similar finding was seen with the relative 
proportions of each LDL subfraction. At the end of each treatment, the %LDLI was 
higher (p<0.03) and the %LDLIII lower (p<0.03) following fenoflbrate compared with 
cerivastatin (fig 5.1).
A close correlation was observed between the plasma triglyceride reduction and both 
the decrease in VLDL, (r^=70.5% p<0.001) and LDLIII concentration (r^==67.5% 
p<0.001, fig 5.2) following fenoflbrate. The correlation between VLDL, reduction and 
the reduction in LDLIII concentration just failed to be statistically significant (r^=30% 
p<0.07). No correlation was noted between reduction in LDLIII and either LDL-C (fig 
5.2) or LDL concentration. Following cerivastatin the triglyceride reduetion was not 
associated with the decrease in either VLDL, or LDLIII concentration (fig 5.2),
90
neither was VLDL, reduction associated with the change in LDLIII concentration. 
However, there was an association between the reduction in LDL-C and LDLIII 
concentration (r^=33.7% p<0.05, fig 5.2), with weaker associations between VLDL2 
reduction and LDLIII (r^=23% p=0.1) and between VLDL2 reduction and LDL-C 
(r^=31%p=0.06).
Rem nant Lipoproteins
Cerivastatin treatment did not result in a significant reduction in levels of remnant 
lipoprotein cholesterol (RLP-C mean decrease 9mg/dl, 95%CI -8:26 ) or triglyceride 
(RLP-TG, mean decrease 20mg/dl, 95%CI -32:73, Table 5.4). The 65% increase in 
RLP-TG noted in table 5.4 was heavily skewed by one outlier. However if this outlier 
was removed, no difference in the results was obtained (RLP-C 13% decrease 95%CI 
-21:47, RLP-TG 1% decrease 95%CI -54:56). The change of both RLP-C and RLP- 
TG on cerivastatin treatment was associated with the change in VLDL, concentration 
(RLP-C r^=39.5% p<0.03 (fig 5.3), RLP-TG r^=40.0% p<0.04), but not triglyceride 
reduction (RLP-C r^=15.0% p=nsd (fig 5.3), RLP-TG r^=12.1% p=nsd). Fenoflbrate 
reduced RLP-C by 35% (mean decrease 16mg/dl, 95%CI 8:25) and RLP-TG by 44% 
(43mg/dl 95%CI 9:77). Fenoflbrate induced RLP reduction was associated with 
VLDLi reduction (RLP-C r^-60.7% p<0.004 (fig 5.3), RLP-TG r^=68.3% p<0.002), 
and plasma triglyceride reduction (RLP-C r^=58.2% p<0.005 (fig 5.3), RLP-TG 
r^^55.5% p<0.005). A relationship was also observed between the reduction in LDLIII 
concentration and both RLP-C (r^=44.6% p<0.02, fig 5.4) and RLP-TG (r^=35.0% 
p=0.05) following fenoflbrate. Despite fenoflbrate appearing to produce a greater 
reduction in RLP-C and RLP-TG, the on treatment RLP-C and RLP-TG 
concentrations did not differ between the two drugs.
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Apolipoproteins
Cerivastatin treatment reduced plasma apoB (21%) and apoE (20%). Smaller 
reductions were seen in plasma apoCII (10%) and apoCIII (7%). Fenoflbrate resulted 
in a reduction in plasma apoB (27%), apoE (32%), apoCII (29%) and apoCIII (26%). 
The on treatment plasma apoB and apoE concentrations did not differ between the two 
drugs, however plasma apoCII (p<0.01) and apoCIII (p<0.01) were lower following 
fenoflbrate compared with cerivastatin. No significant correlations were observed 
between plasma apolipoprotein reduction and reduction in either LDLIII or remnant 
lipoproteins, however weak associations were noted between RLP-C reduction on 
fenoflbrate and the decrease in plasma apoCII (r^=31.5% p<0.06) and plasma apoCIII 
(r^=26.8% p<0.09).
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DISCUSSION
In this study we have demonstrated that in patients with nephiotic range proteinuria, 
both fenoflbrate and cerivastatin signiflcantly reduce plasma concentrations of small 
dense LDL. However the two treatments seem to differ in the means by which they 
alter LDL subfractions. Cerivastatin reduced LDLIII concentration by reducing 
circulating LDL concentration, without any effect on the LDL pattern. Fenoflbrate 
however, had no overall effect on LDL concentration but produced marked LDLIII 
reduction by shifting LDL size towards less atherogenic larger lighter particles. 
Fenoflbrate also resulted in a lower final concentration of LDLIII and proved more 
effective in lowering potentially atherogenic remnants of triglyceride rich lipoproteins. 
Despite successful lipid reduction, with 27% and 49% reductions in LDLIII, 
atherogenic levels of LDLIII remain on both drug regimens.
The main effect of fenoflbrate was on plasma triglyceride, VLDL-C and HDL-C 
levels, with a significant reduction in plasma cholesterol, but not LDL-C. This 
response is similar to that found in non-proteinuric populations where it is known that 
the ability of fibrates to lower LDL-C is related to baseline triglyceride concentrations, 
with the greatest decreases in LDL seen in patients with initially normal plasma 
triglyceride levels [154,192]. In mixed hyperlipidaemia, as here, fibrates often fail to 
reduce LDL-C [192,193]. This response has been reported with other fibrates in 
nephi'otic dyslipidaemia [194]. Cerivastatin redueed cholesterol and LDL-C, with a 
lesser, but still significant effect on triglycerides. This lipid lowering effect follows a 
similar pattern to that found with the drug in non-proteinuric populations, and with 
other statins in the large scale intervention studies [65,66].
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In keeping with the marked reductions in triglycerides and VLDL-C, fenoflbrate 
decreased both VLDL subfractions by 50%. It is thought that the main effect of 
fibrates is to suppress apolipoprotein CIII (apoCIII) synthesis and promote lipoprotein 
lipase activity [152]. ApoCIII inliibits lipolysis of VLDL by lipoprotein lipase and 
interferes with hepatic uptake of VLDL via apolipoprotein E. Thus flbrate therapy is 
likely to improve lipolysis and increase hepatic uptake of VLDL. In this context it is 
interesting to note that fenoflbrate reduced potentially atherogenic lipoprotein 
remnants by 35-45%. This supports the theory that fibrates improve lipolysis and 
clearance of triglyceride rich lipoproteins. Metabolic studies suggest that the effect of 
statins on VLDL subfractions is partly dependent upon the dyslipidaemia present. In 
hypercholesterolaemic populations (with raised VLDL2 but not VLDLi), statins 
generally increase the fractional catabolic rate of VLDL2 and therefore lower VLDL2 
concentration. VLDLi metabolism is generally unchanged [153]. However in mixed 
hyperlipidaemia, of which proteinuria is an example, statins appear to increase 
catabolism of all VLDL subfractions [195, Packard CJ - unpublished data]. Our study 
is in keeping with this hypothesis with cerivastatin treatment resulting in a reduction 
in triglyceride rich VLDLi with a modest (but not quite significant) reduction in 
cholesteryl ester enriched VLDL2 . That the statin failed to effect signiflcantly the 
remnant lipoproteins is surprising since these drugs are effective in type III 
hyperlipidaemia, where remnants accumulate in the circulation [196]. Changes in 
remnant lipoproteins following statin treatment were associated with the changes in 
VLDLi concentration. Given the observed association between the reduction in 
VLDLi and RLP on both drug regimens, it is likely that the laek of significant remnant 
reduction observed following statin treatment results from the heterogeneity of the 
change in VLDLi (ranging from a 70% decrease to a 63% increase following
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cerivastatin treatment).
Fenoflbrate, while not consistently reducing total LDL concentration, did provide a 
dramatic shift in the quality of the LDL in the circulation. The predominant LDL 
subfraction at the beginning of therapy was LDLIII, however following treatment, the 
proportion that was LDLIII was reduced so that larger lighter LDLII became the major 
species present. Cerivastatin in contrast despite producing a decrease in both 
triglycerides and VLDLi, did not shift the size distribution. All three subfractions 
decreased in concert. This is possibly because the VLDLi concentration, which 
according to published models [56], is critical in determining LDLIII, was less 
affected than on fenoflbrate. Thus, comparing treatments, fenoflbrate had a greater 
effect on LDLIII with a larger reduction and lower final LDLIII concentration 
compared with the statin.
Potential mechanisms underlying the change in LDLIII following treatment with 
fenoflbrate and cerivastatin are further elucidated by examining the relationship 
between the changes in plasma triglycerides, LDL-C, VLDL subfractions and LDLIII 
concentration. Following fenoflbrate therapy there is a strong association between 
triglyceride reduction and the decrease in both VLDLi and LDLIII concentration, a 
weak relationship was also seen between VLDLi reduction and the decrease in LDLIII 
concentration. Excess triglycerides (in the form of VLDLi) promote formation of 
small dense LDL, by allowing the triglyceride enricliment of LDL (via CETP 
mediated exchange), thus making LDL a better substrate for lipolysis by hepatic lipase 
[56]. The association between triglyceride reduction and LDLIII reduction, supports 
the role of hypertriglyceridaemia in LDLIII formation. Following cerivastatin
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treatment, the reduetion in LDL-C is associated with the decrease in LDLIII. This 
suggests that the drug is reducing LDLIII by reducing the amount of LDL available for 
conversion to LDLIII and therefore lowering small dense LDL by a different 
mechanism to fenoflbrate.
The ehanges in remnant lipoproteins (RLP) following treatment parallel those changes 
seen with the LDL phenotype. It is recognised that plasma triglycerides are the best 
marker for high levels of RLP [80]. Fenoflbrate, by improving lipolysis, reduces 
remnants by 35-45%, with a close association between RLP reduction and triglyceride 
reduction. This hypothesis is further supported by noting the association between the 
reduction in RLP on fenoflbrate, and the fenoflbrate induced reduction in plasma 
V L D L i , apolipoprotein CII and apolipoprotein CIII. A clear link is also established 
between RLP reduction and a decrease in LDLIII concentration. This is unsurprising 
given the common link of hypertriglyceridaemia but does suggest that some of the 
cardiovascular risk attributed to the atherogenic lipoprotein phenotype, may result 
from excess lipoprotein remnants.
Although fenoflbrate treatment resulted in an increase in serum creatinine, no change 
in creatinine clearance was observed. Serum creatinine has been shown previously to 
increase in patients with impaired renal function treated with fenoflbrate, however this 
increment is not associated with changes in either creatinine clearance or GFR and 
therefore does not seem to represent any loss of renal function [197]. Given that 
urinary creatinine also increases [197], it is likely that this increment represents an 
increase in the production of creatinine from muscle. Fenoflbrate did not result in any 
myalgia and no significant increase in creatine kinase was observed. It remains to be
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seen if this change in serum creatinine is of clinical importance. It is noteworthy that 
previous dose response studies have noted that increases in serum creatinine are
105
transient despite continued therapy [198].
■5
IIt is now accepted that heavy proteinuria increases the risk of vascular disease. It is 
evident that simply looking at the plasma cholesterol and LDL-C does not allow full 
assessment of the cardiovascular risk posed by dyslipidaemia in patients with
;
nephrotic range proteinuria. In addition to hypercholesterolaemia, raised plasma 
.triglyceride is well recognised in nephi'otic range proteinuria [199], with reports of
67% [104] and 71% [106] of patients having a plasma triglyceride greater than
2mmol/l and 2.3mmol/1 respectively. Thus the atherogenic lipoprotein phenotype is a 
.common finding that is not necessarily expressed as an increase in LDL, but is
nevertheless highly atherogenic. We have demonstrated that both statins and fibrates 
successfully reduce LDLIII concentration in a selected population with neplu’otic 
range proteinuria and dyslipidaemia and further provided evidence that increased 
remnant lipoproteins are a component of the atherogenic lipoprotein phenotype that 
responds to fibrate but not to statin therapy. Despite significant lowering of lipids, 
lipoproteins and reductions in the concentration of LDLIII of 27% and 49% on the 
statin and fibrate respectively, atherogenic levels of small dense LDL remain. Ten 
patients had an LDLIII concentration >I00mg/dl at baseline. Of these ten, only 3 
patients following fenoflbrate treatment, and no patients following cerivastatin had 
their LDLIII concentration reduced to less than lOOmg/dl. The differing relationships 
between LDLIII reduction and (i) triglyceride reduction following fenoflbrate and (ii) , K;
LDL-C reduction following cerivastatin in addition to the differing effects on LDL 
phenotype suggest a potential role for combined therapy to achieve greater reduction
in LDLIII concentration. We suggest that cardiovascular protection should aim not 
only to reduce total cholesterol but also reduce concentrations of small dense LDL and 
remnant lipoproteins.
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CHAPTER 6 -
The A ssociation o f L ipoproteins w ith  
Progression of Renal Failure in Glom erular 
Disease
INTRODUCTION
It is now clearly established that dyslipidaemia contributes to increased 
atherosclerosis. There are many similarities between atherosclerosis and 
glomerulosclerosis [147] and it has been hypothesised that ‘any condition resulting in 
albuminuria and hyperlipidaemia could establish self perpetuating renal damage’ 
[148]. Experimental data has demonstrated that mesangial cells are susceptible to 
lipoprotein indueed damage [148,200] and a number of animal models have 
demonstrated an association between dyslipidaemia and glomerular injury [114]. 
Studies looking at the relationship between dyslipidaemia and progression of renal 
disease in humans are less numerous. In diabetic nephropathy, increases in both 
cholesterol and triglyceride are independently associated with increased risk of renal 
failure [149,150,201]. Data in non-diabetic disease is less extensive, however 
recently, baseline levels of cholesterol, triglyceride, LDL-C, apoB and apoE have all 
been associated with progression of renal insufficiency in patients with glomerular 
disease [151]. These observations have been extended, with evidence to suggest that 
triglyceride rich apoB containing lipoproteins promote progression of human chionic 
renal failure [202].
Given the close association between excess triglyceride rich lipoproteins and 
progression, the importance of hypertriglyceridaemia in the production of excess
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quantities of small dense LDL, we aimed to assess if dyslipidaemia and particularly 
small dense LDL and the subtractions of VLDL were associated with progression of 
renal failure in patients with proteinuric glomerular disease.
SUBJECTS AND METHODS 
Subjects
30 patients with chronic glomeruloneplnrtis were recruited from the out-patient clinics 
of the Royal Infirmary and Western Infirmary Renal Units in Glasgow. To be 
included, patients had to have, at the time of study:
(a) urinary albumin excretion >1 .Og/24hi's,
(b) a creatinine clearance between lOml/min and 80ml/min,
(c) a reduction in creatinine clearance over the previous year of follow-up.
Our aim was to investigate patients with a broad range of initial creatinine clearance, 
all of whom had deteriorating renal function as a result of glomerular disease. Patients 
whose glomeruloneplri'itis was being actively treated with corticosteroids or 
immunosuppressive agents were excluded. Patients suffering other diseases or on 
treatment that might influence their lipid profile were excluded, specifically patients 
with underlying liver disease, diabetes mellitus, amyloid, systemic lupus 
eiythematosis or any neoplastic disorder. Patients receiving lipid lowering therapy, 
thiazide diuretics or fat soluble beta blockers were included if their therapy was 
unchanged (i.e. either the drug or dose) over period of retrospective and prospective 
analysis (^examination period). All patients gave written consent before participating. 
The study was approved by the Ethics Committee of Glasgow Royal Infirmary. On the
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study date (month = 0, fig 6.1), patients provided a fasting blood sample for lipid and 
lipoprotein analysis, measurement of LDL and VLDL subfractions, serum creatinine 
and albumin, and a 24 hour urine for urinary albumin excretion. (The date of 
lipoprotein analysis is referred to as the study date, month = 0, the entire period of 
study, retrospective and prospective is referred to as the examination period.)
Rate of Progression
Rate of progression of renal failure was calculated using linear regression from the 
slope of the plot of creatinine clearance vs time and is expressed in ml/min/month. A 
minimum of 5 serial measurements of creatinine clearance and a minimum 
examination period of 1 year was used to calculate a slope. Creatinine clearance was 
calculated from the serum creatinine using the Cockcroft and Gault formula [169]. 
Systolic blood pressure, diastolic blood pressure and 24hi* urinary albumin data was 
also collected over the same period. The examination period was terminated 9 months 
after recruitment of the last patient, with prospective data restricted to a maximum of 
18 months after the study date for each individual patient. If any patient was 
commenced on, or had a change in the dose of lipid lowering therapy, was prescribed 
nephrotoxic medication or if they developed an intercurrent illness which resulted in 
an additional deterioration in their renal function, the examination period was 
terminated early. To minimise the effect of changes in renal function or proteinuria on 
plasma lipids and lipoproteins over the examination period, the time over which data 
was extracted was restricted to a maximum of 2.5yrs. To minimise the effect of 
malnourishment from advanced uraemia, patients with a creatinine clearance 
<10mi/min at the time of study were excluded.
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Statistics
Statistical analyses were performed by using MINITAB lOX for Windows (Minitab 
Inc.) and Microsoft Excel for Windows 95 (Microsoft Corp.). Results are shown as 
means and standard deviations or as median and interquartile range (IQR). Samples 
were compared using the two-sample Mest. Variables that were not normally 
distributed were compared by Ki'uskall-Wallis test. Changes in albuminuria or blood 
pressure over follow-up were compared using analysis of variance and paired /-test for 
paired samples. Linear regression analysis was performed to identify significant 
correlations. P values less than 0.05 were considered significant. Stepwise regression 
and a general linear model was used for multivariate analysis. For regression analysis, 
any factors that were not normally distributed were subjected to log transformation.
RESULTS 
Clinical data, renal function, blood pressure and albuminuria
30 patients with progressive chronic renal failure and albuminuria >lg/24hrs 
(equivalent to 1.5-2g of total urinary protein/day) were recruited. Clinical data for the 
patients is shown in table 6.1. Diagnoses were: IgA nephropathy (n=l 1), membranous 
nephropathy (n=6), chronic glomerulonephritis (n=5), focal and segmental 
glomerulosclerosis (n=4), mesangiocapillaiy glomerulonephritis (n=4). There were 27 
males and 3 females. Fig 6.1 shows the length of prospective and retrospective periods 
of study for the 30 patients. The average total length over which creatinine clearance 
was examined was 1.9yrs (range 1.2-2.5yrs), with a examination period 
retrospectively of l.lyrs, and prospectively of O.Syrs. Four patients were commenced 
on lipid lowering therapy after measurement of their lipid profiles, and as a result the
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rate of progression was analysed using retrospective data only. The other 26 patients 
had almost identical lengths of prospective and retrospective periods (ll.Smonths (8- 
13) vs ll.Omonths (11-13) respectively - median and IQR). Creatinine clearance 
(CrCl) at the study date was 40±21ml/min. The mean earliest recorded CrCi during 
the retrospective period was 47±22ml/min, with the final CrCl at the end of the 
prospective period 33+19ml/min (all mean+SD). The percentage reduction in 
creatinine clearance (CrCl) over the examination period was 32% (range 10-60%). 
Rates of progression ranged from -0.14 to -1.7ml/min/month, with a skewed 
distribution (mean -0.59ml/min/mth, median -0.52ml/min/mth). The median 
correlation coefficient for the regression line used to calculate rate of progression was 
0.82 (interquartile range 0.67-0.93), and 93% of the regression lines had a correlation 
coefficient >0.5.
Fig 6.2 shows the data for albuminuria and blood pressure across the entire period of 
examination. Urinaiy albumin did not significantly differ across the period of study, 
with no difference between the first and last urinary albumin measurements available 
for individual patients as analysed by paired t-test (mean change: -26mg/241n*s 95% Cl 
-602: 549). Urinaiy albumin averaged over the entire period of examination correlated 
with the rate of progression (r^=22.0 p<0.01, fig 6.3a, table 6.1) and was found to be 
more accurate in predicting the rate of progression than the earliest available urinary 
albumin or the urinary albumin measured at the study date (r^=l 1.2 p<0.07). Dividing 
patients into slow and fast progressors based on the median rate of progression of 
0.5ml/min/mth, revealed similar results. The patients with the faster rate of 
progression had a higher urinary albumin over the period of follow-up (p=0.005) and a 
higher urinary albumin at the study date (p<0.03).
I l l
From earliest retrospective data, 24 of the 30 patients were hypertensive or receiving 
antihypertensive drugs; the mean number of antihypertensive drugs taken at this point 
was 1.1, compared to 1.6 at the end the examination period. Eleven patients at the 
beginning of the examination period and 18 at the end were receiving angiotensin 
converting enzyme inhibitors. Systolic blood pressure varied little over the 
examination period (fig 6.2) and the average of the first 2 readings did not differ from 
the last 2 readings (by paired t-test). Overall mean DBF did not differ across the entire 
examination period, there was however a significant reduction in the diastolic BP of 
individual patients (by paired t-test - mean reduction 3.7mmHg (95% Cl 0.6- 
6.8mmHg). This is consistent with the increased use of antihypertensives. No 
correlation was noted between the rate of progression of renal failure and the mean 
systolic or diastolic blood pressure (table 6.1), and no there was no difference in blood 
pressure between slow and fast progressors.
Lipids, Lipoproteins and VLDL subfractions.
The results of the lipid and lipoprotein profiles are shown in table 6.2. The lipid 
profiles were typical for patients with proteinuria, normal serum albumin levels and 
mild to moderate chionic renal failure. Plasma cholesterol was marginally elevated, 
plasma triglyceride was increased and accompanied by a low HDL-C. LDL-C was 
normal. As a result, the ratio of cholesterol to HDL-C was markedly increased. Total 
VLDL and both VLDL subfractions showed a 2 fold increase compared to normal 
male values [144]. Similarly plasma concentration of IDL was increased 2 fold, 
whereas LDL concentration was normal.
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Plasma cholesterol correlated with the rate of progression of renal failure, with a 
stronger relationship observed with the non HDL-cholesterol fraction and progression 
(r^=18.4% p<0.02, fig 6.3b). The lipoprotein fraction that appeared to account for the 
relationship between plasma lipids and rate of progression was VLDL2 (fig 6.4a), with 
no significant correlation noted between the other lipoproteins and the rate of 
progression. Dividing the patients into slow and fast progressors resulted in no 
significant differences in the lipids or lipoproteins between the 2 groups (table 6.2). 
There was no observed trend in non HDL-C or VLDL2 across the range of creatinine 
clearance studied. No correlation was identified between either non HDL-C or VLDL2 
and urinaiy albumin or creatinine clearance at the study date.
Plasma concentration of LDL and LDL Subfractions
Table 6.3 shows the plasma concentration of LDL and LDL subfractions in the 
patients studied. The plasma concentration of LDLIII was increased 2 fold compared 
with normal male values [144] and the relative distribution o f LDL was shifted 
towards the atherogenic smaller denser particles. Forty-six percent of the LDL present 
was in the form of LDLIII and 17 of the 30 patients studied (57%) were found to have 
an LDLIII concentration greater than lOOmg/dl, a level associated with a marked 
increase in coronary heart disease risk. There was no correlation between LDLIII 
concentration and either CrCl or urinary albumin. Further, no correlation was found 
between either the concentration or percentage of LDLIII and the rate of progression 
of renal failure (fig 6.4b, table 6.3). There was also no association between the larger 
lighter LDL subfractions and the rate of progression. Dividing the patients into slow 
and fast progressors resulted in no significant differences between the two groups 
(table 6.3).
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Parameters Determining Rate of Progression
Multivariate analysis using stepwise regression identified mean urinary albumin over 
the examination period and non-HDL cholesterol at the study date to be independent 
predictors of the rate of progression of renal failure (total r^=33.9%, albuminuria 
22.0%, non HDL-C 11.9%). Both these parameters were significant using a general 
linear model (albuminuria p<0.02, non HDL-C p<0.04). The association between the 
rate of progression of renal failure and both albuminuria and non HDL-C was 
independent of renal function (either measured at the study date or on the earliest visit 
during the examination period). The correlation between VLDL2 and rate of 
progression was not independent of albuminuria (p=0.085).
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Fig 6.3: Rate of Progression vs Mean Urinary Albumin over Examination
Period and Non HDL-C
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Fig 6.4: Rate of Progression vs VLDL: and LDLIII
VLDL2 vs Rate of Progression
(log:log plot)
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DISCUSSION
In this study, involving patients with glomerular disease, proteinuria and a broad 
spectrum of renal function, we have demonstrated a relationship between 
dyslipidaemia and the rate of progression of renal failure. Non HDL-C correlated with 
the rate of progression, a relationship that was independent of both the degree of 
proteinuria and renal function as measured at the study date. Non HDL-C includes all 
apoB containing lipoproteins (i.e. VLDL, IDL and LDL). Within this spectrum the 
lipoprotein fraction associated most clearly with progression was VLDL:. Contrary to 
our initial hypothesis, there was no observable relationship between small dense LDL 
and progression of renal failure.
One of the difficulties in establishing an association between dyslipidaemia and 
progression of renal failure is that the quantity and quality of lipoproteins will change 
as the glomerular filtration rate (GFR) falls. In glomerular disease, as GFR falls, less 
albumin is filtered (and therefore albuminuria may fall), plasma triglyceride and 
triglyceride rich lipoproteins increase and lipase activity is reduced [203]. As a result 
initial lipoprotein profiles may bear little resemblance to the lipoprotein profiles 
during long term follow-up, and the contribution of lipoproteins to renal failure 
progression may differ as GFR falls. To limit the effect of profound changes in lipids 
over follow-up, we limited the maximal period of examination to 2.5 years and 
collected data on renal function both retrospectively before and prospectively after the 
study date at which lipoproteins were evaluated. Thus the lipid and lipoprotein 
profiles represent approximate mid-point values during the period of renal function 
decline. This hopefully allowed the lipoprotein analysis to be representative of the
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lipoprotein profile over the whole period of examination and also allowed a long 
enough period to calculate the rate of progression. In addition, to limit the effect of 
severe uraemia, no patients with a creatinine clearance of less than lOml/min were 
studied and at the end of the examination period only one patient had a creatinine 
clearance which had fallen to <10ml/min. Over the examination period, we found no 
significant difference in urinaiy albumin or systolic blood pressure, and although 
diastolic blood pressure fell over the examination period, the rate of progression of 
renal failure remained linear, with good correlation coefficients obtained for the slopes 
of creatinine clearance vs time.
Proteinuria is the most consistent risk factor for progression of renal failure in 
glomerular disease. We have previously demonstrated that patients with nephrotic 
range proteinuria have atherogenic levels of LDLIII and therefore we hypothesised 
that in the context of pre-existing glomerular damage, small dense LDL (LDLIII) may 
contribute to renal injury. For these reasons we chose to study small dense LDL in a 
population who had evidence of progression of renal failure resulting from glomerular 
disease associated with significant albuminuria i.e. a fairly representative population 
with progressive glomerular injury. However, a relationship between LDLIII and 
progression was not identified. There are theoretical reasons and experimental 
evidence to implicate LDLIII in causing glomerular damage. Due to its smaller size, it 
is more easily filtered by damaged endothelium and can therefore access the 
subendothelial space [204]. It is readily oxidised [177] and not only has oxidised LDL 
been implicated in the pathogenesis of glomerulosclerosis [200] but it has been 
identified in human renal biopsies, with increased oxidised LDL accumulation 
associated with more advanced renal disease [205]. Possible explanations for the lack
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of association between LDLIII and progression in this study are (1) the small number 
of patients studied and (2) the study population investigated.
The number of patients studied was indeed small. Clearly this can result in false 
negative results. It is notable in this context that diastolic blood pressure which is well 
recognised to contribute to progression of renal failure [206], was not correlated with 
progression in this study. This may partly be explained by the extensive use of ACE 
inhibitors, however it does suggest that the small numbers involved may have hidden 
weaker but important associations. The study population was chosen within a specific 
range of proteinuria, and it is recognised that if the range of data in a study population 
is restricted, apparent associations and correlations may be missed. There was 
however, a wide variation in both rates of progression (-0.14 to -1.7ml/min/mth) and 
LDLIII concentration (5 to 310mg/dl), and therefore it is unlikely that the selection 
criteria applied to the study population resulted in a significant association between 
LDLIII concentration and rate of progression being overlooked.
Although no association was observed with LDLIII, there was an independent 
relationship between non HDL-C and the rate of progression. Non HDL-C consists of 
the entire spectrum of apolipoprotein B containing lipoproteins and apolipoprotein E 
rich remnant lipoproteins. Within this spectrum, increased VLDL: was found to be 
associated with faster progression. Plasma triglyceride has been shown to be 
independently associated with progression in nephropathy secondary to non-insulin 
dependent diabetes mellitus [150] and recently published data has suggested that 
‘complex’ triglyceride rich apoB containing lipoproteins are associated with 
progression of renal failure in non diabetic renal disease [202]. Complex triglyceride
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rich apoB containing lipoproteins are generally found in the density range of VLDL (d 
<L006g/ml), with cholesterol rich apoB containing lipoproteins generally in the 
density range of IDL and LDL. This recent study is therefore in agreement with the 
present data.
In glomerular disease, endothelial damage and areas of basement membrane 
denudation allow filtration of macromolecules including lipoproteins and result in 
interaction between lipoproteins and both mesangial and visceral epithelial cells 
[207]. Most experimental studies have concentrated on the effect of LDL or oxidised 
LDL on glomerular mesangial or epithelial cells. However glomerular apoE 
deposition has been identified in human renal biopsies [208], and given that LDL does 
not possess apoE, the apolipopoprotein must originate from larger lighter lipoproteins. 
A number of studies have reported on the interaction between both VLDL and 
triglyceride rich lipoprotein remnants on glomerular mesangial and epithelial cells. 
Human mesangial [209] and visceral epithelial cells [210] possess receptors for apoE 
containing lipoproteins. ApoE rich lipoproteins have a greater affinity for glomerular 
cells and inhibit uptake of apoB containing lipoproteins [209]. Cholesteryl ester rich 
VLDL stimulates proliferation and expansion of mesangial cells [211] and 
accumulation of apoE rich lipoproteins by glomerular cells exceeds their ability to 
degrade the lipoproteins [212]. Thus mechanisms exist where glomerular mesangial 
and epithelial cells can accumulate triglyceride rich apoB and apoE containing 
lipoproteins (such as VLDL:), resulting in glomerular lipid deposition, macrophage 
uptake and ultimately glomerulosclerosis. The association between triglyceride rich 
lipoproteins and renal injury has also been noted in animal models. In the obese 
Zucker rat increased VLDL is associated with glomerulosclerosis [213] and increased
125
lipid content in VLDL and IDL is associated with the development of proteinuria in 
the female analbuminaemic rat [214].
In conclusion, this study has demonstrated that there is an independent association 
between non HDL-C and progression of renal failure. The data suggests that 
triglyceride rich lipoproteins may be particularly implicated, with a correlation 
between VLDL: and progression. No association was observed between excess small 
dense LDL and progression of renal failure. Further study is required to assess the role 
that VLDL subfractions and partially metabolised atherogenic apoE rich VLDL 
remnant particles may have in contributing to progressive renal injury.
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CHAPTER 7  - 
The Effect o f  Proteinuria on Sm all D ense LDL 
C oncentration in Type 2 D iabetes M ellitus
INTRODUCTION
The increased risk of coronaiy heart disease in patients with type 2 diabetes mellitus [24] 
is attributed to an increase in the prevalence of established risk factors including 
hypertension, dyslipidaemia, obesity and insulin resistance [25]. A strong relationship 
exists between vascular disease and both plasma triglyceride and LDL-cholesterol in this 
population [123,124,157], and subgroup analysis of large scale intervention studies 
indicates that lipid lowering with HMGCoA reductase inhibitors reduces the rate of death 
from coronary heart disease and non-fatal MI in patients with type 2 diabetes [28]. The 
development of diabetic nephropathy, with macroalbuminuria, results in a further 
increase in cardiovascular risk compared to diabetic patients who exhibit 
microalbuminuria or normal urinaiy albumin levels [6].
The characteristic dyslipidaemia of type 2 diabetes consists of raised plasma triglyceride 
and low HDL-cholesterol, with plasma cholesterol and LDL-cholesterol generally within 
the normal range [157,215]. This dyslipidaemia results from increased production and 
impaired clearance of triglyceride rich lipoproteins [157], and is closely related to both 
insulin resistance and glycaemic control [157]. Patients with type 2 diabetes typically 
have smaller LDL and excess quantities of LDLIII [157,158], and therefore possess the
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atherogenic lipoprotein phenotype. It has recently been suggested that patients with 
diabetic nephropathy and macroalbuminuria possess LDL that is smaller than normal 
diabetic controls [159]. The aim of this study therefore, was to quantify the extent of 
small dense LDL (LDLIII) formation in patients with diabetic nephropathy and 
macroalbuminuria, comparing these patients with both microalbuminuric and normal type 
2 diabetic patients with similar glycaemic control, and also with non-diabetic controls. A 
secondary aim was to identify factors determining the extent of LDLIII formation in type 
2 diabetes with and without nephropathy, whilst assessing if these factors accounted for 
differences in small dense LDL between diabetic and non-diabetic populations.
METHODS 
Subjects
Four groups of patients were studied. 12 patients with type 2 diabetes, diabetic 
neplir'opathy and macroalbuminuria (diabetic nephropathy group), 12 with type 2 diabetes 
and microalbuminuria, 12 normal type 2 diabetic controls and 24 non-diabetic controls. 
The diabetic patients were recruited consecutively from the joint diabetic-renal clinic and 
diabetic clinic of Glasgow Royal Infirmary. The normal controls were either relatives of 
patients attending the renal unit or members of the laboratory staff. All four groups were 
matched for age and sex, with the diabetic groups also matched for HbAlc. Type 2 
diabetes was defined as having diabetes diagnosed above the age of 40 or having a 
minimum of 6 months between the diagnosis of diabetes and commencement of insulin. 
Diabetic nephropathy was diagnosed as either: (1) the presence of macroproteinuria with
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retinopathy, normal size kidneys on ultrasound and the absence of significant haematuria 
or other multisystem disease; or (2) macroproteinuria and biopsy confirmation of diabetic 
nepln’opathy. Microalbuminuria was defined as a urinaiy albumin:creatinine ratio of 3- 
30mg/mmol [216] (approximately equivalent to a urinaiy albumin level of 20-200mg/l).
Patients were studied before commencement of lipid lowering therapy. Patients suffering 
from other diseases or on other treatment that might influence their lipid profile were 
excluded, specifically patients with underlying liver disease, amyloid, any neoplastic 
disorder, systemic lupus erythematosis or taking thiazide diuretics, fat soluble beta 
blockers, corticosteroids or other immunosuppressive agents. Patients were excluded if 
the serum creatinine was >180umol/l (2mg/dl). All patients were free of acute illness at 
the time of study. No patient had suffered a vascular event in the previous 4 months. The 
study was approved by the Ethics Committee of Glasgow Royal Infirmary. All patients 
and controls gave written consent before participating. Patients and controls attended 
after an overnight fast and samples were taken for the estimation of lipids and 
lipoproteins, LDL and VLDL subfractions, serum creatinine and albumin. All patients 
with diabetic nephropathy collected a 24 hour urine for analysis of urinary albumin 
excretion. Urinary albumin in microalbuminuric or control diabetic patients was 
measured on aliquots of early morning urine. In the patients with normal urinary albumin 
and microalbuminuria, all recent urinalysis at routine follow-up had been consistently 
within the normal or microalbuminuric range respectively.
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Statistics
Statistical analysis were performed by using MINITAB lOX for Windows (Minitab Inc.). 
Any factors that were not normally distributed were subjected to log transformation. 
These included: BMI, plasma TG, VLDL-C, HDL-C, total VLDL and VLDL 
subfractions, total LDL and LDL subfractions. Results are shown as means and standard 
deviations or as median and inter-quartile range. Samples were compared using a one­
way analysis of variance (ANOVA) with Fisher’s comparison employed to identify 
differences among the groups if the ANOVA was significant. Simple regression analysis 
was performed to identify significant correlations. Stepwise regression was used for 
multivariate analysis involving linear variables. If a categorical variable was involved 
then multivariate analysis was performed using a general linear model.
RESULTS 
Patient Characteristics
Age, body mass index (BMI) and renal function are given in Table 7.1. The ages of all 4 
groups were closely matched, with the ratio of males to females in each group being 1:1. 
The body mass index (BMI) of all 3 diabetic groups was greater than the normal controls, 
however the increase in the microalbuminuric patients did not reach significance. Renal 
function in the patients with nephi’opathy was well preserved, with a mean creatinine 
clearance (CrCl - calculated from the Cockcroft and Gault formula [169]) of 60ml/min. 
Only 3 patients had a CrCl <50 (range 30-94). The serum creatinine however, was 
increased in the patients with nephropathy compared with those with microalbuminuria
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(p<0.005), diabetic controls and normal controls (both p<0.001). Renal function in the 
microalbuminuric patients, diabetic controls and normal controls did not differ.
Four of the 12 diabetic nephropathy patients, 4 of the 12 microalbuminuric patients and 
one of the diabetic controls were receiving insulin. As measured by HbAlc, overall 
glycaemic control was good and did not differ between the three diabetic groups (table 
7.1). Urinaiy albumin/creatinine ratio in the patients with nephropathy ranged from 52- 
755mg/mmol (urinary albumin concentration range 500-5800mg/l), in the 
microalbuminui'ic group from 3.1-26.1mg/mmol (32-200mg/l) and in the diabetic 
controls from 0.5-2.7mg/mmol (6-14mg/l). Despite being well within the normal range, 
mean serum albumin was reduced in the patients with nephropathy (40+3.5g/l) compared 
with both micro albuminuric (44+3 g/1 p<0.005) and diabetic control patients (44+2g/l 
p<0.001), however no patient had a serum albumin <35g/1.
Lipids and Lipoproteins
Plasma cholesterol did not differ across the four groups (table 7.1). Plasma triglyceride 
(TG) and VLDL-C were substantially increased in the patients with neplii'opathy 
compared with all tlii'ee other groups. Although plasma triglyceride was higher in the 
microalbuminuric and diabetic control patients compared with the normal controls, the 
difference was not significant (both p=0.11). LDL-C was similar across the four groups. 
HDL-C was reduced in the nephropathy patients compared with all three other groups. In 
addition, both the microalbuminuric patients and diabetic controls exhibited a 
significantly lower HDL-C compared with the normal controls. As a result of these
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differences, the patients with diabetic nephropathy had a substantial increase in 
cholesterol:HDL ratio compared with the other study populations.
Total VLDL mass was increased in the patients with diabetic nephi'opathy compared with 
microalbuminuric patients, diabetic controls and normal controls (table 7.2). This resulted 
primarily from a 2 fold increase in VLDL:, which was present in greater quantities in the 
patients with nephropathy compared with the three other groups (fig 7.1). In contrast 
although the median VLDLi was also increased 2 fold in the nephropathy patients, the 
results were very heterogeneous and as a result, this increase was only significant when 
compared with the non-diabetic controls. The masses of IDL and LDL were similar 
across all four study groups.
LDL Subfractions
The mass of LDLIII in the patients with diabetic nephropathy was increased 2-3 fold 
compared with the microalbuminuric and diabetic control patients (both p<0.05), with a 5 
fold increase compared with the normal controls (p<0.001, table 7.2, fig 7.2). There was a 
concomitant reduction in the concentration of large light LDLI (p<0.001 vs normal 
controls, p<0.05 vs both microalbuminuric and diabetic control patients, fig 7.2) and 
LDLII (p<0.001 vs normal controls, p<0.05 vs diabetic control patients, fig 7.2). 75% of 
patients with nephropathy had an LDLIII mass greater than lOOmg/dl (a level associated 
with greatly increased risk of coronary heart disease [141]) compared with 33% of 
microalbuminuric patients, 25% of diabetic controls and 4% of normal controls. 
Compared to the normal controls, both microalbuminuric (p<0.05) and diabetic control
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patients (p<0.05) had a 2 fold increase in LDLIÏI concentration, with a reduction in larger 
lighter subfractions.
The relative proportions of the LDL subfractions followed along similar lines. The 
patients with nephiopathy had an increase in the percentage of LDLIII compared with all 
three other groups. Similarly, %LDLI was reduced in the diabetic nephiopathy patients 
compared with all thiee other groups, whilst the %LDLII was reduced compared with the 
diabetic controls and normal controls. Both the microalbuminuric (p<0.01) and the 
diabetic control patients (p<0.05) had an increase in %LDLIII compared with the normal 
controls (table 7.2, fig 7.2).
Lipoprotein composition
Within the density range of triglyceride rich VLDLi, the patients with nephropathy 
possessed VLDLj particles that were cholesterol enriched and triglyceride deplete 
compared with both microalbuminuric patients and normal controls (table 7.3). In 
contrast, the LDL particles in the patients with neplnopathy were triglyceride enriched, 
and all three diabetic groups possessed LDL that was relatively cholesterol deplete 
compared with the non-diabetic controls. There was no observed difference in the 
cholesterol or triglyceride content of VLDL2 or IDL.
Urinary Albumin and Dyslipidaemia
Amongst all 36 diabetic patients, urinary albumin/creatinine ratio correlated with 
chol/hdl-c ratio (r^=31.5% p<0.001), total cholesterol (r^=16.1% p=0.02), VLDL-C
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(r^=17.5% p<0.02), and inversely with HDL-C (r =16.8% p<0.02). Urinaiy
albumin/creatinine ratio was also correlated with serum creatinine (r^=21.0% p=0.005), 
and inversely related to serum albumin (r^=43.6% p<0.001). Assessing the relationships 
between albuminuria and the lipoprotein subtractions revealed that urinaiy 
albumin/creatinine ratio was associated with the concentration of the VLDL2 subfraction 
(r^=26.9% p=0.001, fig 7.3), but not that of VLDL, (r^=9.3% p=nsd). An increasing 
urinary albumin/creatinine ratio correlated with increasing LDLIII mass (r^=14.6% 
p<0.03, fig 7.3) and % LDLIII (r^=18.0% p=0.01).
Determinants of Small Dense LDL in NIDDM and Diabetic Nephropathy
Factors regulating the concentration of small dense LDL in the diabetic patients were 
assessed by performing regression analysis on the entire diabetic study population. This 
revealed a strong correlation between LDLIII and plasma triglyceride (r^=46.1% 
p<0.001,fig 7.4), VLDLi (r^=49.2% p<0.001, fig 7.4) and VLDL2 (rM o.3.%  p<0.001, fig 
7.4), with an inverse correlation to HDL-C (r^=28.9% p<0.002). The %LDLIII was 
similarly correlated to plasma triglyceride (r^=65.9%), VLDLi (r^=63.2%), and VLDL2 
(r^=49.2%, all p<0.001), with an inverse relationship seen with HDL-C (r^=21.2% 
p=0.005). The relationship between small dense LDL and urinary albumin/creatinine ratio 
has already been noted. No correlation was observed between either LDLIII concentration 
or %LDLIII and creatinine clearance, BMI, albumin or HbAlc.
Stepwise regression revealed that in the 36 diabetic patients, plasma triglyceride, HDL-C 
and LDL mass accounted for 65.7% of the variance of LDLIII concentration (TG 46.1%,
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HDL-C 10.6%, LDL mass 10.0%), with all three parameters significant on multivariate 
analysis using a general linear model (TG p<0.001, HDL-C p=0.003, LDL mass 
p=0.007). Plasma triglyceride (p<0.001) and HDL-C (p<0.05) were independent 
determinants of %LDLIII in the diabetic patients, accounting for 69.7% of the variance on 
stepwise regression. After accounting for the differences in plasma triglyceride and HDL- 
C, the development of nephropathy did not independently effect either LDLIII 
concentration or %LDLIII in NIDDM. A plasma triglyceride of 1.8mmol/I had a 
sensitivity of 87% and a specificity of 80% for atherogenic concentrations of small dense 
LDL (>100mg/dl), reducing the triglyceride to 1.5mmol, increased the sensitivity to 94% 
but decreased the specificity to 70%.
Small Dense LDL: Type 2 Diabetes vs Non-Diabetic Controls
To assess the effect of having a diagnosis of type 2 diabetes on LDLIII concentration, we 
repeated the regression analysis using all 60 subjects studied. The univariate analysis was 
similar to that found in the diabetic population, with a strong correlation between LDLIII 
concentration and plasma triglyceride (r^=50.4%), VLDLi (r^=47.3%) and VLDLi 
(r^=44.2%, all p<0.001), and an inverse conelation to HDL-C (r^=36.0%). A relationship 
was also observed between LDLIII mass and BMI (r^=18.6% p<0.002). On multivariate 
analysis, plasma triglyceride (p<0.001), LDL mass (p=0.003), HDL-C (p<0.05) and BMI 
(p<0.05) were independent determinants of LDLIII concentration, accounting for 66.2% 
of the variance (TG 51.1%, HDL-C 6.8%, LDL mass 4.6%, BMI 3.7%). Without the 
inclusion of body mass index into the regression equation, there was an independent 
effect of having a diagnosis of type 2 diabetes on the concentration of LDLIII (p<0.04),
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with the relationship between LDLIII and both plasma TG (p<0.02, fig 5) and HDL-C 
(p<0.04, fig 5) differing between the diabetic and non-diabetic patients. After adding BMI 
into the multiple regression equation, the independent effect of having type 2 diabetes no 
longer achieved statistical significance (p=0.06).
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Fig 7.2: Boxplot of LDLI, II and III in diabetic nephropathy (macroalb), 
microalbuminuria (microalb), diabetic controls (normoalb) and normal controls
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Fig 7.3: Plasma Concentration of VLDL2 and LDLIII vs Urinary Albumin: Creatinine Ratio
LDLIII mass vs Urinary Albumin:Creatinine 
- Diabetic Patients
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Fig 7.4: Plasma Triglyceride, VLDLi and VLDL2 Concentration vs LDLIII Concentration
Trig lyceride vs LDLIII mass: Diabetic Patients
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Fig 7.5: Plasma Triglyceride and HDL-C vs LDLIII for Diabetic Patients vs Controls
TG vs LDLIII mass; Diabetic Patients vs Controls
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DISCUSSION
This study demonstrates that in type 2 diabetes, the presence of diabetic nephropathy 
and macroalhuminuria is associated with a 2-3 fold increase in LDLIII mass when 
compared with both microalbuminuric patients and diabetic controls matched for age, 
sex and HbAlc. Moreover, when compared with non-diabetic controls, patients with 
diabetic nephropathy have a 5 fold increase in LDLIII. This increase in small dense 
LDL occurs despite patients with diabetic nephropathy having levels of total 
cholesterol and LDL-cholesterol that are comparable to the other diabetic and control 
populations. As found previously in both normal and type 2 diabetic populations 
[139,142,144,158], the main determinant of LDLIII concentration was plasma 
triglyceride, with both HDL-C and total LDL concentration being additional factors. 
After accounting for differences in lipids, the degree of proteinuria was not 
independently related to LDLIII concentration. However, as the diabetic groups were 
matched for age, BMI and glycaemic control, it is likely that the variation in plasma 
lipids, especially triglyceride, resulted from the differing levels of proteinuria and so 
proteinuria was ultimately responsible for the high levels of small dense LDL. 
Determinants of LDLIII mass also differed between diabetic and non-diabetic patients 
suggesting that additional factors contribute to formation of small dense LDL in type 2 
diabetes.
The current theories of lipoprotein metabolism suggest that both plasma triglyceride 
and hepatic lipase activity are rate limiting factors in the formation of LDLIII [56]. 
The data obtained from the patients with proteinuria secondary to glomerular disease 
(chapter 3) suggested that the processes involved in formation of LDLIII in 
proteinuria were similar to those seen in normal populations. This study provides
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further support for these conclusions with plasma triglyceride being the most 
important determinant of LDLIII concentration in all subjects. Moreover VLDLi in the 
nephiopathy patients was cholesterol rich and triglyceride deplete, whilst LDL was 
triglyceride rich and LDL deplete, consistent with extensive CETP mediated neutral 
lipid exchange. However we also found that the microalbuminuric and normal 
diabetic control patients had an increase in plasma LDLIII concentration despite 
having small, non-significant differences in VLDLi and plasma triglyceride. There 
also appeared to be an independent effect of having diabetes when all 60 subjects were 
included in the multivariate analysis assessing determinants of LDLIII concentration. 
Addition of body mass index to the statistical model accounted for some, if  not all, of 
this effect. Body mass index and other markers of obesity (e.g. waist: hip ratio) are 
known to be associated with insulin resistance. They are also correlated with hepatic 
lipase activity [144,217]. It has previously been suggested that the delayed post­
prandial clearance of triglyceride rich lipoproteins in insulin resistant subjects 
contributes to small dense LDL formation in NIDDM [158]. This may explain the 
findings in our diabetic patients. However, we favour the possibility that BMI is acting 
as a marker of increased hepatic lipase activity, which would promote LDLIII 
formation once the elevated plasma triglyceride has made the LDL particles 
triglyceride rich.
The concentration and percentage of LDLIII present in the diabetic patients was 
related to urinary albumin, with a marked increase in LDLIII in the patients with 
diabetic neplnopathy and macroalbuminuria. There was also a strong correlation 
between VLDL2 and both urinary albumin/creatinine ratio and LDLIII. It is notable 
from figure 1, that there is a marked increase in VLDLi in the patients with
146
macroalbuminuria, with the distribution of VLDLi in the other 3 groups being very 
similar. The differences in VLDLi distribution between the diabetic groups are less 
distinct. Admittedly, there is a trend for VLDLi to increase when non-diabetic and 
diabetic patients are compared, however no clear correlation was observed between 
VLDLi and urinary albumin, and any difference in VLDLi concentration in the 
patients with diabetic neplnopathy compared with the other diabetic patients can be 
accounted for by the 2 outlying patients with an extremely high VLDL] concentration. 
We suggest that the rise in plasma triglyceride that results in the increase in LDLIII 
concentration present in the patients with diabetic nephropathy compared with the 
other diabetic patients, is due to the increase in VLDL2 concentration, and that this 
increase in VLDLi is a result of the development of macroalbuminuria. In normal 
populations VLDLi is rapidly metabolised to LDL, with increased VLDLi production 
the main cause of the excess LDL found in most types of hypercholesterolaemia [56]. 
In patients with glomerular disease and neplii'otic range proteinuria, VLDLi has been 
shown to be increased due to a combination of increased production and impaired 
clearance [108,171]. In this situation, we speculate that excess VLDLi results in 
increased LDLIII either as a result of increased total LDL formation or from VLDLi 
providing an alternative source of triglyceride for neutral lipid exchange via CETP.
The plasma LDLIII concentrations in this study are similar to those obtained in the 27 
non-diabetic patients with proteinuria secondary to glomerular disease. However in 
comparison to the patients with glomerular disease, the concentration of LDLIII may 
be underestimated as this current study had a higher percentage of females (and it is 
recognised that females have lower concentrations of LDLIII [144]) and urinary 
albumin was lower in the diabetic patients compared with the patients with glomerular
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disease (chapter 3). The diabetics patients studied also had better than average 
glycaemic control. Given that glycaemic control is closely correlated with plasma 
triglyceride, this study may also underestimate the extent of LDLIII formation in the 
general population of type 2 diabetic patients with diabetic nephropathy.
Patients with type 2 diabetes have a marked increase in coronaiy artery disease 
compared with age and sex matched non-diabetic patients [24]. A raised plasma 
triglyceride is strongly associated with increased coronaiy risk in type 2 diabetes 
[124]. The strong association between plasma triglyceride and small dense LDL 
demonstrated, suggests that the excess small dense LDL contributes to the excess 
cardiovascular risk seen with increasing plasma triglyceride. The development of 
diabetic nephropathy and proteinuria leads to a further increase in cardiovascular 
mortality, independent of age, blood pressure and cholesterol [6]. Not only did the 
patients with diabetic nephiopathy have a marked increase in LDLIII compared with 
non-diabetic controls but a further 2-3 fold increase in LDLIII was observed in 
comparison to both microalbuminuric patients and diabetic controls. This ‘double 
jeopardy’ was primarily related to the marked increase in triglyceride, and was present 
despite the microalbuminuric and diabetic control patients having comparable 
glycaemic control, body mass index and LDL mass.
We observed no difference between the microalbuminuric patients and normal 
diabetic controls with respect to any parameter studied. Although more patients in the 
microalbuminuric group were treated with insulin compared with the normal diabetic 
controls, the overall glycaemic control and BMI in the two groups was not different. 
These results are in keeping with the majority of studies, where lipid profiles do not
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differ between microalbuminuric and diabetic patients with normal urinary albumin, if 
the populations are matched in terms of age, BMI and glycaemic control or insulin 
levels [218,219]. It has been suggested that microalbuminuric patients have smaller 
LDL than normal diabetic controls [159], however this finding is not universal [220]. 
Our data suggests that once glycaemic control and BMI are controlled for, the 
development of microalbuminuria is not associated with excess LDLIII. Although our 
numbers are small, the observation that in large scale studies of type 2 diabetes [218], 
plasma triglyceride does not differ between microalbuminuric patients and diabetic 
controls supports this conclusion.
In summaiy, in this study we have demonstrated that the development of diabetic 
nephropathy with its associated macroalbuminuria results in large increases in the 
plasma concentration of small dense LDL. The excess of this atherogenic lipoprotein 
is not expressed as an increase in LDL-C but is associated with increased plasma 
triglyceride and a low HDL-C (the atherogenic lipoprotein phenotype). The primary 
determinant of the LDLIII concentration is plasma triglyceride, however we suggest 
that the excess triglyceride and LDLIII in the patients with nephropathy results from 
an increase in the concentration of VLDLi. There also seemed to be an independent 
effect of having type 2 diabetes. Previous data has suggested that patients with type 2 
diabetes continue to have a preponderance of small dense LDL even after removal of 
patients with raised triglycerides (TG >2.25) [159]. The relationship between 
triglyceride and LDLIII in this study suggests that LDLIII becomes predominant at 
levels of plasma triglyceride greater than 1.5mmol/l, i.e. at levels not normally 
regarded as hypertriglyceridaemic. Clearly measurement of total cholesterol and LDL- 
C is insufficient in addressing the cardiovascular risk posed by the dyslipidaemia in
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this population, and the excess LDLIII is likely to be a major contributor to the 
increase in cardiovascular morbidity and mortality present in patients with type 2 
diabetes and nephiopathy.
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CHAPTER 8 - 
The A therogenic L ipoprotein Phenotype in 
End-Stage Renal Failure: Origin and  E x ten t 
o f Small Dense LDL Form ation
INTRODUCTION
The characteristic dyslipidaemia of end-stage renal failure (ESRF) consists of raised 
plasma triglyceride and low HDL-C [114,115]. VLDL-C is increased however levels 
of total cholesterol and LDL-C are generally normal and may be low [114,115]. The 
primary metabolic defect is thought to be impaired catabolism of triglyceride rich 
lipoproteins (mostly VLDL) by the enzymes lipoprotein and hepatic lipase. However 
the precise mechanism underlying the impaired lipolytic activity remains to be 
established [114,116,117]. The lipoprotein abnormalities also differ according to 
modality of renal replacement therapy with patients on peritoneal dialysis tending to 
have higher total cholesterol and LDL-C [118].
Dyslipidaemia is an independent risk factor for atherosclerosis in ESRF [8,134,221], 
however with cholesterol and LDL-C levels being normal in ESRF, coupled with the 
lack of long term lipid lowering studies in this population, the debate continues as to 
the role of lipid lowering therapy in ESRF and particularly to whom it should be 
targeted. Two published studies have demonstrated that LDL size is smaller in 
uraemic patients compared with control populations [160,161]. To date however, the 
analysis of LDL phenotype in this population has been qualitative in nature and 
clearly in the context of normal or low levels of LDL, the quantity of small dense LDL
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present requires to be estimated in order to fully evaluate the extent to which LDL 
phenotype may influence cardiovascular risk in end-stage renal failure.
The primary aim of our study was to identity the extent to which small dense LDL 
(LDLIII) is formed in patients with ESRF and by analysing VLDL subfractions and 
post-heparin lipase activity, to identify the factors contributing to LDLIII formation in 
this population. A secondary aim was to clarify possible origins of the differences in 
lipids and lipoproteins between patients treated with peritoneal and haemodialysis.
SUBJECTS AND METHODS 
Subjects
75 patients (45 male, 30 female) and 40 controls (24 male, 16 female) were recruited 
for the study. 50 patients were receiving renal replacement therapy (25 treated by 
haemodialysis (HD) and 25 treated by peritoneal dialysis (PD)) another 25 patients 
were 'pre-dialysis’ (PreD - defined as patients with chronic renal failure and a serum 
creatinine greater than 500umol/l, but not yet receiving renal replacement therapy). 
Patients on renal replacement therapy had been stable on their form of dialysis for 
more than 6 months. Patients suffering from other diseases or on treatment that might 
influence their lipid profile were excluded, specifically patients suffering from 
diabetes mellitus, amyloid, or any neoplastic disorder or patients taking thiazide 
diuretics, fat soluble B blockers, corticosteroids or immunosuppressants. Patients 
taking lipid lowering medication were also excluded. However, at the time of the 
study only 2 patients out of a dialysis population of ahout 130 were on lipid lowering 
medication, therefore it was not felt that this would bias any results. These patients
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were compared to 40 normal controls who were either relatives of patients attending 
the renal unit or members of the laboratory staff. The mean ages and proportion of 
males: females of the two populations were identical. All patients were free of acute 
illness at the time of study and no patient had suffered an acute vascular event in the 
preceding 3 months. The haemodialysis patients were all receiving between 12 and 15 
hours a week dialysis and were seen immediately before their regular dialysis session. 
CAPD patients were all receiving four exchanges of dextrose based dialysis solutions 
per day. All subjects were seen after an overnight fast. An intravenous cannula was 
inserted and samples taken for analysis of lipids, LDL and VLDL subfractions, serum 
creatinine and albumin. 70 units/kg of intravenous heparin was administered followed 
by sampling 10 minutes later for assessment of lipoprotein and hepatic lipase activity. 
The study was approved by the Ethics Committee of Glasgow Royal Infirmary.
Statistical analysis
Statistical analyses were performed using Minitab version lOX (Minitab Inc). 
Variables that were not normally distributed were subject to log transformation 
namely: BMI, plasma TG, VLDL-C, HDL-C, total VLDL concentration, VLDLi , 
VLDLi , IDL concentration, LDL concentration, LDLI, II and III concentration. 
Tabulated results are shown as median + interquartile range (IQR) or as mean + 
standard deviations. Patients and controls were compared using two sample t-test. 
Patient subgroups and controls were compared using a one-way analysis of variance 
(ANOVA) with Fisher’s comparison employed to identify differences among the 
groups if the ANOVA was significant. Regression analysis was performed to identify 
univariate correlations, multiple regression analysis was performed using a general 
linear model.
153
RESULTS 
Anthropometric data, lipids, lipoproteins and lipases.
All Patients
The results for anthiopometric data, lipids, lipoproteins and lipase activity are shown 
in table 8.1.
Table 8.1; Anthropometric data. Lipids, Lipoproteins and Lipase activity: 
Patients vs Controls (Median + IQR)
Patients Controls P
(n=75) (n==40)
Sex (M:F) 45 :30 24 : 16 nsd
Age 51 (38-59) 53 (36-60) nsd
Body Mass Index 24.4 (21.8-27.5) 25.0 (23.0-29.3) nsd
Cholesterol (mmol/l) 5.1 (4.4-6.2) 5.1 (4.6-5.S) nsd
Triglyceride (mmol/l) 1.7 (1.2-2.3) 1.0(0.8-L4) <0.0001
VLDL-C (mmol/l) 0.75 (0.5-1.1) 0.32 (0.2-0.4) <0.0001
LDL-C (mmol/l) 3.4 (2.5-3.9) 3.4 (2.8-4.0) nsd
HDL-C (mmol/l) 0.9 (0.8-1.2) 1.3 (1.0-1.5) < 0.0001
Choi / HDL 5.4 (4.1-6.9) 3.7 (3.1-4.7) <0.0001
Lipoprotein Lipase (umolFA/ml/hr) 3.5 (2.2-4.2) 3.9 (3.2-5.2) < 0.002
Hepatic Lipase (umolFA/ml/hi') 9.8 (5.9-14.3) 11.4 (9.3-15.4) <0.02
The age and body mass index (BMI) of the patients was comparable to that of the 
control population. Patients had higher plasma triglyceride, VLDL-C and Chol/HDL
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ratio (all p<0.0001). HDL-C (p<0.0001) and activity of both lipoprotein and hepatic 
lipase enzymes was lower in renal failure (LpL p<0.002, HL p<0.02). There was no 
difference in cholesterol or LDL-C between the two groups.
Patient Subgroups vs Controls
Table 8.2 shows the antlnopometric data, lipids, lipoproteins and lipase activity 
divided according to patient subgroup. There were differences in the ratio of males to 
females in the treatment groups, with patients on PD having the highest ratio of 
females: males. Plasma triglycerides and VLDL-C were raised in all three patient 
groups compared with controls, similarly HDL-C was reduced in all three groups. 
Cholesterol and LDL-C were only raised in patients treated with PD with LDL-C 
actually being reduced in HD patients. The reduction in lipoprotein lipase activity was 
significant in the two groups on renal replacement therapy, whereas hepatic lipase was 
only significantly reduced in the pre-dialysis patients.
Effect of Mode of Dialvsis
Comparing patients treated with PD and HD revealed that there were more females in 
the peritoneal dialysis group. The mean age, BMI, plasma triglyceride, VLDL-C, 
HDL-C, lipoprotein and hepatic lipase activities were all similar (table 8.2), however 
plasma total cholesterol and LDL-C were higher in patients on PD compared with 
haemodialysis patients (both p<0.001).
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Table 8.2: Anthropometric data, Lipids, Lipoproteins and Lipases : Patient 
Subgroups vs Controls (Median + IQR)
Peritoneal Dialysis Haemodialysis Pre- Dialysis
(n=25) (n=25) (n=25)
Sex M/F'" 11/14 18 / 7 1 6 / 9
Age 53 (43-58) 47 (30-58) 54 (39-61)
BMI 25.2 (21.8-29.5) 23.0 (20.6-26.2)* 24.6 (22.3-27.5)
Cholesterol (mmol/l) 5.9 (5.1-6.5)*** 4.6 (3.6-5.3) 5.1 (4.4-6.3)
Triglyceride (mmol/l) 2.0(I.3-3.0)**** 1.7(1.5-2.0) **** 1.3 (1.0-2.3)***
VLDL-C (mmol/l) 0.8 (0.5-1.5) **** 0.7 (0.6-1.0) **** 0.6 (0.4-1.1)***
LDL-C (mmol/l) 3.9 (3.5-4.3) * 2.8 (2.0-3.6) ** 3.0 (2.4-4.2)
HDL-C (mmol/l) 0.8 (0.7-1.1) **** 1.0 (0.8-1.2) **** 1.0(0.8-1.4) *
Choi / HDL 6.7 (5.4-8.3)**** 4.6 (3.7-S.6) * 5.1 (3.4-6.7) **
Lipoprotein Lipase 3.8 (2.0-4.4) * 3.0(1.9-3.8)**** 3.6 (2.8-4.4)
(umolFA/ml/hr)
Hepatic Lipase 9.3 (6.5-14.9) 10.4 (5.1-14.0) 9.7 (6.1-12.6)*
(umolFA/ml/lii')
****p<0.001 ***p<0.005 *"^p<0.01 *p<0.05 comparing subgroups vs control
test for comparison of sex
VLDL, VLDL Subfractions, IDL & LDL Subfractions
All Patients
There was a two fold increase in total VLDL, VLDLi, VLDL] and IDL concentration 
in the patients compared with controls (table 8.3). The total concentration of LDL did
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not differ between the patients and controls, however the concentration and percentage 
of the LDL subfractions differed markedly. The concentration of LDLIII was 
increased in the patients whereas the concentration of the larger lighter LDLI & LDLII 
subfractions was reduced (table 8.3). Similarly the percentage of LDL that was small 
& dense (LDLIII) increased in the patient group (30+26 vs 14+10% p<0.0001), with a 
corresponding decrease in the percentage of LDLII (47+18 vs 62+11% p<0.0001, fig 
8 .1).
Table 8.3: VLDL subfractions, IDL & LDL subfractions: Patients vs Controls: 
Median + IQR ( Mean + SD)
PATIENTS CONTROLS P
VLDL Total (mg/dl) 178(107-238) §^T(55H2) _ _ _ _ _
VLDLi (mg/dl) 80(40-137) 47 (27-70) < 0.0005
VLDL] (mg/dl) 84 (58-125) 34 (25-52) < 0 . 0 0 0 1
IDL (mg/dl) 71 (51-94) 44 (35-60) < 0 . 0 0 0 1
LDL Total (mg/dl) 279 (213-325) 286 (243-345) nsd
LDLI (mg/dl) 55 (25-93) 59 (45-98) <0.04
LDLII (mg/dl) 134 (85-183) 173 (134-220) < 0 . 0 0 0 1
LDLIII (mg/dl) 50 (25-122) 31 (26-54) <0.03
%LDLI 23 ±15 24±  11 nsd
%LDLII ^ 4 7 + 1 8 62+11 <0 . 0 0 0 1
%LDLIII 30 + 26 14±10 <0 . 0 0 0 1
Patient Subgroups vs Controls
The results comparing patient subgroups with controls are seen in table 8.4. The
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concentration of total VLDL, VLDL2 and IDL were increased in all tliree patient 
subgroups. VLDLi was increased in the PD and HD groups but not in the predialysis 
patients. LDL concentration was reduced in the patients treated with haemodialysis. 
The LDL subtraction distribution was similar for each patient group with an increase 
in the percentage of LDLIII and a decrease in the percentage LDLII. The concentration 
of each LDL subfraction followed a similar pattern, but was clearly also influenced by 
the total LDL concentration. Therefore the concentration of LDLIII was only 
significantly increased in the PD patients with a non-significant increase in the 
patients treated with haemodialysis due to the lower total LDL concentration in this 
group. There was however, marked heterogeneity in the plasma concentration of 
LDLIII in each group. As a result, 40% of patients treated by peritoneal dialysis, 28% 
treated by haemodialysis and 28% of predialysis patients possessed a plasma LDLIII 
concentration >100mg/dl compared with only 2.5% of the control population 
(p=0.002, test). The concentration of larger lighter LDLII was lower in the HD and 
pre-dialysis patients.
Effect of Mode of Dialysis
Comparing PD and HD patients revealed that the VLDL2 subfraction was increased in 
PD patients (p<0.005), with levels of total VLDL, VLDLi and IDL being similar. 
Total LDL concentration was also increased in PD patients, however the LDL 
subtraction distribution did not differ between the treatment modalities.
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Table 8.4: VLDL subfractions, IDL & LDL subfractions: Patients Subgroups vs 
Controls -Median + IQR ( Mean+SD)
Peritoneal Dialysis Haemodialysis Pre- Dialysis
(11=25) (11=25) (n=25)
VLDL Total (mg/dl) 208(109-333)**** 185 (120-210)**** 122 (79-224) ***
VLDLi (mg/dl) 8 8  (40-190)**** 102 (59-134) *** 51 (30-119)
VLDL2 (mg/dl) 113 (68-164)**** 6 8  (57-102) **** 82 (48-99) ****
IDL (mg/dl) 73 (60-95) **** 65 (48-84) *** 73 (41-98) ***
LDL Total (mg/dl) 310 (268-336) 243 (172-300) *** 249(186-355)
LDLI (mg/dl) 46 (22-97) 41 (24-78) * 72 (31-102)
LDLII (mg/dl) 162 (109-193) 115(78-151) **** 126 (73-170) ***
LDLIII (mg/dl) 84 (29-160)* 64 (25-114) 30 (18-120)
% LD L f 19 + 13 21 ± 15 29 ±17
% LD L if 48+ 21 *** 4 9  4 . 45 + 17 ***
% LD LIlf 33 + 29 *** 30 + 22 ** 26 + 27 **
****p<0 . 0 0 1  '^*'*'p<0.005 **p<0 . 0 1 *p<0.05 comparing subgroups vs control
Factors regulating LDLIII production
The results of univariate and multivariate analysis for factors regulating LDLIII 
concentration are seen in table 8.5. Figs 8.2-8.4, show the correlation between either 
plasma triglyceride or hepatic lipase and LDLIII concentration. For all patients with 
chronic renal failure, there is a close correlation with the plasma triglyceride (fig 8 .2 , 
p<0 .0 0 1 ), with a weaker but significant correlation with hepatic lipase (fig 8 .2 ,
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p<0.03). On multivariate analysis plasma triglyceride (p<0.001) and hepatic lipase 
(p<0.04) were seen to independently conelate with LDLIII concentration. The 
coiTelation with plasma triglyceride was seen across each of the patient subgroups (fig 
8.3), with plasma triglycerides being an independent predictor of LDLIII in PD and 
HD patients (p<0.001). The correlation between LDLIII concentration and hepatic 
lipase was only present in PD and PreD (fig 8.4), with hepatic lipase activity rather 
than plasma triglyceride being an independent predictor of LDLIII concentration in the 
predialysis patients.
Table 8.5 Univariate (U) and Multivariate (M) Analysis for Regulation of LDLIII 
Concentration (r^%)
All Patients 
U r^% M i'2%
Peritoneal Dialysis Haemodialysis 
UrVo MrVo
PreDialysis 
U r^% M
Triglyceride 38.4* 35.5* 45.2* 32.8* 47.9* 47.3* 25.8+ 1 1 . 1
Hepatic Lipase 6.7** 3.8'"'' 19.7** 7.3 3.3 2.7 28,4+ 13.8**
*p<0 . 0 0 1  p<0 . 0 1 p<0.03 p<0.04
Lipoprotein Compositions
The lipoprotein compositions obtained aie shown in table 8 .6 . The most consistent 
changes seen were in the cholesteryl ester and triglyceride compositions of the 
lipoproteins. Patients with renal failure had VLDLi and VLDL2 that was cholesteiyl 
ester rich and triglyceride deplete compared with controls. In contrast IDL and LDL 
were cholesterol deplete and triglyceride enriched in the patients compared with 
controls. There were no major differences in the percentage of protein or phospholipid
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in each lipoprotein fraction. The lipoprotein compositions of each patient subgroup 
followed a similar pattern to the entire renal failure group. Lipoprotein compositions 
in patients treated with PD and HD were identical with the exception of VLDL2 which 
was cholesteryl ester rich in PD patients (PD 23.7+3.6% vs HD 20.8+2.6% p<0.005) 
and IDL which was cholesteryl ester rich and triglyceride deplete in PD patients 
(Cholesteryl ester; PD 34.2+3.8% vs HD 32.0+4.2% p<0.05, Triglyceride: PD 
18.6+4.0% vs HD 21.1±4.2% p<0.05).
Table 8.6: Plasma Lipoprotein Compositions: Patients vs Controls (Mean+SD)
PATIENTS CONTROLS P
VLDLi% Total Cholesterol 9.8+  3.3 6.9 ±2.1
VLDL 1 % Triglyceride 65.1 ±4 .0 67.4 ±3.9 < 0.005
VLDL2 % Total Cholesterol 22.7 ±3 .7 18.7 ±3.6 < 0 . 0 0 0 1
VLDL2 % Triglyceride 39.8 ±5.1 42.5 ± 6 . 8 <0.03
IDL % Total Cholesterol 34.0 ±4.1 35.8 ±3.3 < 0 . 0 0 1
IDL % Triglyceride 18.5 ±4 .6 15.6 ±3.7 < 0 . 0 0 1
LDL % Total Cholesterol 36.2 ±3 .9 39.5 ±1.5 < 0 . 0 0 0 1
LDL % Triglyceride 10.4±3.1 6.9 ±1.4 < 0 . 0 0 0 1
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Fig 8.2: Plasma Triglyceride & Hepatic Lipase vs LDLIII: All Patients
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Fig 8.3: Plasma Triglyceride vs LDLIII concentration: Patients Subgroups
Plasma Triglyceride vs LDLIII mass; Haemodialysis
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Fig 8.4: Hepatic Lipase vs LDLIII concentration: Patients Subgroups
Hepatic Lipase vs LDLIil m ass: Haemodiaiysis
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DISCUSSION
Although two previous studies have shown that the LDL size in patients with end- 
stage renal failure (ESRF) is smaller than control populations [160,161], the extent to 
which small dense LDL is formed and the precise metabolic origin of this species in 
uraemic patients, has not been assessed. This study demonstrates that atherogenic 
small dense LDL is present in greater quantities in patients with ESRF. This increase 
in concentration of small dense LDL has occurred due to a shift in pattern of LDL 
towards smaller denser particles, with a corresponding reduction in the larger lighter 
LDLII both in terms of concentration and as a percentage of total LDL.
The increased concentration of LDLIII is seen despite the total concentration of LDL 
being slightly lower in ESRF. The shift in particle size was seen across the patient 
groups with patients treated with peritoneal dialysis (PD), haemodialysis (HD) and 
pre-dialysis patients all having a higher percentage of LDLIII and decreased 
proportion of larger lighter LDLII. The increase concentration of LDLIII however was 
only significant in the PD group as both the pre-dialysis and particularly the 
haemodialysis patients had a lower concentration of total LDL. There was however, 
marked heterogeneity in the concentration of LDLIII present in each population. 
Patients whose LDLIII concentration is greater than lOOmg/dl has been shown to have 
a seven fold increase in cardiovascular risk in non-uraemic populations [141]. In the 
patients studied, LDLIII concentration was greater than lOOnig/dl in 32% of the 
patients compared with 2.5% of controls. 40% of PD patients and 28% of both HD 
and pre-dialysis patients had an LDLIII concentration >100mg/dl. The percentage of 
patients with ESRF and atherogenic levels of LDLIII may also be underestimated in 
this study as previous authors have estimated that 50% of patients on renal
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replacement therapy have triglyceride levels >2.25mmol/l [115], and we found fasting 
triglycerides to be >2.25mmol/l in only 30% (PD 44% HD 16% ). This may in part be 
due to the exclusion of patients with diabetes.
The results obtained by density gradient ultracentrifugation are supported by analysis 
o f the LDL compositions. These confirm that the LDL in uraemic patients is 
triglyceride rich and cholesterol deplete compared with controls patients, a finding 
noted in previous studies of lipoprotein metabolism in ESRF [114,222] and 
characteristic of the composition of small dense LDL [56]. The abnormal LDL 
composition was seen in all three of the treatment groups, supporting the finding of a 
shift to smaller denser particles in PD, HD and pre-dialysis patients.
The two most important factors determining formation of small dense LDL in non- 
uraemic patients are plasma triglycerides and hepatic lipase. Thus to form atherogenic 
levels of small dense LDL in non-uraemic patients requires a plasma triglyceride 
>1.5mmol and hepatic lipase activity >15umolFA/ml/ln* (seen in males and post­
menopausal females) [56]. As stated previously, the current model for the formation 
of small dense LDL suggests that in the presence of hypertriglyceridaemia excess 
VLDLi is present, which takes part in neutral lipid exchange with LDL via cholesterol 
ester transport protein (CETP). Triglyceride is passed from the VLDL] to LDL in 
exchange cholesteryl ester which is transferred to VLDL, creating a triglyceride rich 
LDL particle which is hydrolysed by hepatic lipase, shiinking the particle and forming 
small dense LDL [56]. In keeping with the results of the studies in patients with 
glomerular disease and diabetes, the data from this study concurs with this hypothesis. 
Hypertriglyceridaemia is present, VLDLi concentration is increased, is cholesterol
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enriched and triglyceride deplete. LDL is cholesterol deplete and triglyceride enriched 
and hepatic lipase levels correlate with LDLIII concentration. Moreover previous 
authors have shown that CETP activity is increased in patients treated with PD [223]. 
It is therefore likely that the mechanisins underlying small dense LDL formation in 
uraemia are similar those proposed for non-uraemic populations.
Further support for this hypothesis is seen when examining the correlation between 
LDLIII concentration, triglycerides and hepatic lipase in the uraemic patients. The 
strong correlation between LDLIII concentration and plasma triglycerides in the 
patients confirms the importance of triglycerides in LDLIII formation in uraemia (a 
correlation that was seen in all three treatment groups), however this data also 
demonstrates the importance of reduced hepatic lipase (HL) activity in this population, 
with HL activity an independent determinant of LDLIII concentration on multivariate 
analysis. As a result there are differences in the triglyceride threshold at which 
atherogenic levels of LDLIII are formed. The univariate correlation between hepatic 
lipase is strongest in the groups with the highest triglycerides (PD & PreD i.e. where 
HL levels would be rate limiting) and not present in HD patients (the group with the 
lowest triglycerides, therefore the low triglyceride rather than HL is rate limiting). A 
plasma triglyceride of >1.5mmol in males or post-menopausal females is recognised 
as a level at which atherogenic levels of LDLIII are formed in normal populations (i.e. 
LDLIII concentration >100mg/dl) [56]. In this study however only 45% of patients 
with a plasma triglyceride >1.5mmol had a LDLIII concentration >100mg/dl 
compared with 73% of patients with a plasma triglyceride >2.0mmol/l. This suggests 
that in uraemia due to the rate limiting effect of the lower levels of hepatic lipase, 
patients require a higher triglyceride to form atherogenic levels of LDLIII.
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The basic lipoprotein results obtained were typical for this population, however not 
only were differences found between the dialysis modalities, in the concentration of 
LDLIII, but there were also marked differences in other aspects of the lipid and 
lipoprotein profiles. Patients on PD had far higher total and LDL cholesterol (a well 
recognised finding) [115,118], with similar triglycerides, VLDL-C, HDL-C and lipase 
activity. PD patients also had raised VLDLi and total LDL but not VLDLi when 
compared with those treated with HD. VLDLi and VLDLi are generally under 
independent metabolic control, VLDLi is associated with raised triglycerides [144] 
and tends to be overproduced in patients with insulin resistance [145] and following 
carbohydrate loading [146]. Production of VLDLi however is increased in patients 
with raised total and LDL cholesterol [56] and metabolic studies have shown that 
VLDLi production is also increased in proteinuria [171]. The dyslipidaemia pattern 
seen in the patients on peritoneal dialysis is therefore associated with excess VLDLi, 
and raised LDL rather than raised triglycerides from increased VLDLi. This would 
make carbohydrate loading from peritoneal dialysate dextrose absorption less likely to 
be responsible for difference in dyslipidaemia between these populations and favour 
the >5g/day peritoneal albumin loss that has been shown to occur in CAPD [224], as 
the most likely aetiology.
The incidence of cardiovascular disease in ESRF far exceeds that in comparable 
populations and accounts for 40-50% of reported causes of death amongst patients on 
renal replacement therapy [9]. In addition to dyslipidaemia, hypertension, fluid 
overload, left ventricular hypertrophy, hyperhomocystinaemia, diabetes mellitus and 
smoking all contribute to this increased risk [225]. Hypertriglyceridaemia has been
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shown to be an independent risk factor for cardiovascular disease in patients on RRT 
[134] whilst in the pre-dialysis population total cholesterol, triglycerides and LDL-C 
are increased in patients with caidiovascular disease compared to those without 
cardiovascular disease [8 ]. Triglycerides are physiologically linked to small dense 
LDL and low HDL, a combination known as the atherogenic lipoprotein phenotype 
[140], and it is likely that the increased small dense LDL observed in this study, 
contributes to the atherogenic risk of hypertriglyceridaemia in ESRF.
Despite the high morbidity and mortality from cardiovascular disease in renal failure, 
nephrologists have until recently, been reluctant to embark on aggressive lipid 
lowering therapy in uraemic patients . This is partly due to the general finding of 
normal cholesterol and LDL-C levels in uraemia and partly due to the lack of outcome 
evidence following lipid lowering therapy in patients with impaired renal function 
[226]. The finding of atherogenic levels of LDLIII in the context of normal plasma 
LDL-C highlights the need to look beyond the basic assessment of plasma levels of 
total and LDL-C when assessing the cardiovascular risk posed by dyslipidaemia in this 
population. The physiological link and strong correlation between fasting triglycerides 
and LDLIII concentration, can allow us to use triglycerides as a surrogate marker for 
LDLIII. Thus in our study using triglyceride of >2mmol/l to identify patients with 
LDLIII concentration >100mg/dl had a sensitivity of 8 6 % and a specificity of 79%.
In conclusion, atherogenic levels of LDLIII are formed in patients with end-stage renal 
failure. However, there is marked heterogeneity in LDLIII levels in this population, 
with a strong association between plasma triglyceride and LDLIII concentration, 
highlighting the physiological role of triglycerides in LDLIII formation and its
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possible use as a surrogate marker. Clearly further studies in uraemic patients are 
required to assess the risk posed by small dense LDL in this population and to assess 
the role of lipid lowering agents in a population who have dyslipidaemia with the 
atherogenic lipoprotein phenotype rather than hyperlipidaemia. Furthermore as 
nephrologists become more adept at slowing progression of renal failure and 
postponing dialysis, the qualitative change in LDL before ESRF highlights the need to 
address the cardiovascular risk from dyslipidaemia before the commencement of renal 
replacement therapy.
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CHAPTER 9 - 
General D iscussion  - The A therogenic  
Lipoprotein Phenotype in Renal D isease
This project has examined the metabolism of triglyceride rich lipoproteins in patients 
with chronic renal disease. We have concentrated on patients with nephrotic range 
proteinuria, a subset of patients who have an increased risk of coronary artery disease 
and a high risk of progression to end-stage renal failure. In this final chapter, we will 
review tln ee main aspects of the studies;
1. The origins and consequences of impaired metabolism of triglyceride-rich 
lipoproteins in renal disease, including the effect of hepatic lipase and disease state 
on the formation of small dense LDL in patients with chronic renal dysfunction.
2. The potential influence of the Atherogenic Lipoprotein Phenotype on coronary risk 
in chronic renal disease
3. Treatment of dyslipidaemia in chi’onic renal disease
ORIGINS AND CONSEQUENCES OF IMPAIRED METABOLISM OF 
TRIGLYCERIDE-RICH LIPOPROTEINS
Chapters 3 and 4 outline the possible origins and ultimate consequences of the 
impaired clearance of triglyceride rich lipoproteins in patients with proteinuria. This 
is summarised in fig 9.1. The data presented suggests that in this population, the 
VLDLi particles produced are smaller and relatively emiched in free cholesterol 
compared with the control population. These particles are also deficient in
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apolipoprotein CII, CIII and E, a deficiency that is present despite seeming to have 
adequate plasma levels of apolipoprotein CII and CIII. As a result, Hpolysis by 
lipoprotein lipase becomes less efficient and the smaller apolipoprotein deficient 
particles are less readily taken up by hepatic apoE receptors. The net effect is an 
increase in VLDLi, excess plasma triglyceride and increased concentrations of 
partially metabolised lipoprotein remnant particles. In this population, increased 
plasma concentration of VLDL2 is also present, an increase that is in part, related to 
impaired clearance of the particles [171]. In this context, it is likely that similar 
apolipoprotein defects are present on VLDLa contributing to the impaired clearance.
A similar increase in VLDLi was identified in the studies involving patients with 
diabetic nephropathy (chapter 7) and end-stage renal failure (chapter 8 ). In patients 
with type 2 diabetes, the plasma concentration of VLDLi is generally increased [145], 
due to an increase in production of triglyceride rieh lipoproteins. However the 
microalbuminuric and diabetic control patients in this study did not possess excess 
VLDLi. It is likely that this resulted from the good glycaemic control in all the 
diabetic patients studied. We suggest therefore that the excess VLDLi present in the 
proteinuric diabetic patients may have a similar origin to that found in the patients 
whose proteinuria resulted from glomerular disease. In the study involving patients 
with end-stage renal failure (ESRF - chapter 8 ), a clear reduction of in-vitro 
lipoprotein lipase activity was detected. Therefore, in this case, impaired activity of 
the lipase enzyme will be responsible for the excess VLDLi.
Although the origin of the excess VLDLi may differ depending upon the population 
studied, the consequences of the excess triglyceride rich lipoproteins are probably
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similar. In patients with excess triglyceride rich lipoproteins, VLDLi takes part in 
neutral lipid exchange via cholesteryl ester transfer protein (CETP). Thus triglyceride 
is passed to LDL in exchange for cholesteryl ester which is passed to VLDL (fig 9.1). 
The triglyceride in LDL is subsequently hydrolysed by hepatic lipase, shrinking the 
particle and forming small dense LDL.
Hepatic lipase activity is thought to be the second main factor (after plasma 
triglyceride) regulating production of small dense LDL [56]. The importance of 
hepatic lipase is illustrated by the presence of very low levels of small dense LDL in 
pre-menopausal women, a finding related to the low levels of hepatic lipase present in 
this population [144]. The influence of low hepatic lipase activity is further 
demonstrated in this project. In the patients with glomerular disease and proteinuria, 
normal hepatic lipase activity was detected. Thus the enzyme was not rate limiting and 
no relationship was identified between hepatic lipase activity and plasma LDLIII 
concentration. A different picture was seen in the patients with end-stage renal failure, 
where hepatic lipase levels were reduced. Here, hepatic lipase activity was rate 
limiting and independently related to plasma LDLIII concentration. It has been 
proposed that to form atherogenic levels of LDLIII, a plasma triglyceride >1.5mmol/l 
and hepatic lipase activity >15umolFA/ml/hi* is required [56]. As a result of the 
reduced lipase activity in end-stage renal failure, this triglyceride threshold was 
increased to 2mmol/l. Post-heparin lipase activity was not studied in the diabetic 
patients (due to the problem of giving intravenous heparin to patients with diabetic 
retinopathy), however we have infen*ed that part of the excess LDLIII in the diabetic 
patients resulted from patients with increased body mass index having increased 
activity of hepatic lipase.
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Therefore, in this project, we have outlined abnormalities in VLDLi which may 
account for the increased plasma concentration of triglyceride rich lipoproteins in 
proteinuric disease, the main consequences of which is the production of atherogenic 
lipoproteins. Although the deficiency of apolipoproteins on the VLDL particle can 
explain the delayed clearance of the particle, a number of factors need to be explored 
further. The high surface ratio of free cholesterol : phospholipid, is likely to inhibit 
post-secretory incorporation of apoC into VLDL, resulting in delayed lipolysis. 
However it has yet to be established why this high surface ratio is present. Data 
regarding production of free cholesterol (FC) production in this population is 
conflicting [188,189], and the high surface ratio could also occur in the context of 
normal FC production and incorporation, into a smaller VLDLi particle. Moreover, 
the cause of the apparently smaller VLDLi particles remains to be explained. This 
may be linked to the apparent plasma apoE deficiency, which also requires further 
investigation. ApoE is larger than both apoCII and apoCIII, and given that albumin is 
found in the urine (which is larger than all three apolipoproteins), it is certainly 
feasible for both apoC and apoE to be lost. However the plasma concentration of the 
apoC proteins did not seem to be reduced.
As a result we propose to continue our study of triglyceride rich lipoproteins in this 
population, in particular looking at;
1. Changes in the composition and size of VLDL particles
2. Fatty acid production from VLDL. In order to assess the ability of lipases to 
hydrolyse VLDL particles from patients with proteinuria
3. The transfer of apolipoproteins from VLDL to HDL, to explore further the effects
175
of changes in the surface components of VLDL.
4. Post-prandial apolipoprotein composition of chylomicrons, as clearance of
chylomicrons is normal in patients with proteinuria, but the mechanisms by which 
these triglyceride rich particles are cleared are similar to those seen in VLDL 
metabolism.
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THE ATHEROGENIC LIPOPROTEIN AND CORONARY HEART DISEASE 
IN CHRONIC RENAL DISEASE
It is now clearly established that proteinuria is associated with increases in both 
cardiovascular disease and coronary heart disease, with a 2-5 fold increase in the risk 
of MI or coronary death [3,7]. Furthermore this increased risk is independent of other 
cardiovascular risk factors including hypertension and plasma cholesterol [3,7]. To 
date, there is no data confirming the link between plasma triglyceride and coronary 
heart disease in patients with proteinuria, however the atherogenic lipoprotein 
phenotype is amongst the most common lipid disorders found in normal populations 
with coronary heart disease [227], and the presence of an atherogenic lipoprotein 
phenotype is associated with a 3-7 fold increase in the risk of coronary heart disease 
regardless of the level of LDL-C [227]. In the patients with proteinuria and 
glomerular disease that were studied in chapter 3, 74% possessed a plasma LDLIII 
concentration > 1 0 0 mg/dl, with the median remnant lipoprotein cholesterol level in the 
patients with proteinuria increased 2-3 fold, and a 5 fold increase in remnant 
lipoprotein triglyceride concentration. Even the patients with progressive renal failure 
(chapter 6 ), who had lower creatinine clearance when studied (and therefore reduced 
hepatic lipase activity) had a high prevalence of atherogenic levels of LDLIII, with 
57% possessing a plasma LDLIII concentration >100mg/dl. Therefore there seems 
little doubt that the atherogenic lipoprotein phenotype is extremely common in this 
population. It is difficult to imagine that in patients with persistent heavy proteinuria, 
that this dyslipidaemia is not going to have a profound effect on the incidence of 
coronary heart disease.
In type 2 diabetes, a clear link exists between raised plasma triglyceride and coronary
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heart disease [124], indicating a probable link between the atherogenic lipoprotein 
phenotype and coronary heard disease in this population. Type 2 diabetic patients with 
proteinuria have a 2-3 fold increase in death from cardiovascular disease compared 
with type 2  diabetic patients without proteinuria, an increase that is independent of 
systolic blood pressure and smoking [6 ]. 75% of the patients studied with type 2 
diabetes and proteinuria (chapter 7) possessed a plasma LDLIII concentration 
>100mg/dl. It is highly likely that this excess small dense LDL contributes to the 
increased incidence of vascular events that has been demonstrated in this population.
Finally, data in chapter 8  demonstrated that despite reduced hepatic lipase activity, 
non-diabetic patients with end-stage renal failure (ESRF) had an increased prevalence 
of the atherogenic lipoprotein phenotype. A plasma triglyceride of 2mmol/l proved to 
be an accurate marker of a plasma concentration of LDLIII >100mg/dl. Cohort data 
has shown plasma triglyceride to be an independent predictor of cardiovascular 
disease in ESRF [134], whilst cross-sectional data has suggested HDL-C to be an 
independent predictor of coronary heart disease in haemodialysis patients [135]. 
Therefore a clear link has been established between the atherogenic lipoprotein 
phenotype and vascular disease in ESRF.
Therefore across the differing groups of patients studied, the importance of the 
atherogenic lipoprotein phenotype in contributing to coronary heart disease has been 
outlined. Clearly this is not the only lipid abnormality present in many of these 
patients. Apart from increases in plasma cholesterol, IDL was increased in both 
proteinuric and ESRF patients. Increased plasma concentration of IDL is now 
recognised to contribute to atherosclerosis [228] and has been linked to increased
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vascular disease in ESRF [229]. This further ‘vascular risk factor’ simply serves to 
highlight the inadequacy of simple measurements of non fasting cholesterol in a 
population where premature cardiac death is so frequently found.
TREATMENT OF DYSLIPIDAEMIA IN CHRONIC RENAL DISEASE
The rationale behind using pharmacological treatment to ameliorate dyslipidaemia in 
chronic renal disease is firstly to reduce the incidence of coronary heart disease (CHD) 
and secondly to try and slow progression of chronic renal failure. To date there is no 
data to show that lipid lowering treatment with either a statin or a fibrate will reduce 
cardiovascular morbidity or mortality in a population with either proteinuric renal 
disease or advanced renal failure, as all the major lipid lowering trials have excluded 
these patients. There is however, extensive evidence to support the use of statins in 
particular, but also fibrates, in reducing morbidity and mortality from CHD in 
‘normal’ populations. In the context of secondary prevention, the 4S study showed 
that in a population with a mean plasma cholesterol of 5.5-8mmol/l, only 11 patients 
required treatment for 6  years with simvastatin to prevent one myocardial infarction 
(NNT = number needed to treat) [65]. This has been extended with two ftirther studies 
in patients with a plasma cholesterol within the normal range demonstrating that 
treatment with 40mg of pravastatin for 5 or 6  years, the NNT to prevent the combined 
end points of non-fatal myocardial infarction (MI) or CHD death are 33 and 27 
respectively [66,67]. Only the CARE study had a significant number of adverse events 
[6 6 ], an adverse finding not confirmed in the LIPID study, despite recruiting twice the 
number of patients and using virtually identical drug therapy to CARE [67]. Similar 
reductions in cardiac events have recently been demonstrated with the use of fibrates,
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with gemfibrozil providing a 22% reduction in cardiac events in men with CHD and a 
HDL-C <1 mmol/l (NNT=23 to prevent one death from CHD or non-fatal MI) [191]
The data in primaiy prevention is now equally extensive, with both statins and fibrates 
demonstrating a reduction in cardiac events in large scale prospective studies 
[64,68,70]. The first of these studies was the Helsinki Heart Study which 
demonstrated a 34% reduction in cardiac end-points after 5 years treatment with 
gemfibrozil (NNT=71) [70]. Within this study, the highest absolute cardiac risk was 
present in the sub-group with triglycerides >2.3 and HDL-C <1.06 (i.e. the patients 
who would have an excess of small dense LDL) [72]. The WOSCOPS study, using 
pravastatin 40mg for 5 years, demonstrated a 29% reduction in non-fatal MI or CHD 
death (NNT=40) [64]. Finally the AFCAPS/TEXCAPS study in a population with 
plasma cholesterol of 4.5-7 and HDL-C <1.2 demonstrated a 37% reduction in a 
broader end-point of fatal or non-fatal MI, unstable angina or sudden cardiac death 
(NNT=50), with the number needed to treat decreasing to approximately 40 if the 
HDL-C was <1.0mmol/l [6 8 ]. This wealth of data serves to illustrate the extent to 
which both statins and fibrates can reduce coronary artery disease in ‘normal’ 
populations. What therefore can we conclude about the role of these agents in renal 
disease ?
Patients with nephrotic range proteinuria have profound dyslipidaemia. It has been 
estimated that 89% of patients have a fasting plasma cholesterol >6.5mmol/l [104], 
with reports of 67% [104] and 71% [106] o f patients having a plasma triglyceride 
greater than 2mmol/l and 2.3mmol/l respectively. 74% of the patients studied in 
chapter 3 possessed atherogenic levels of LDLIII, with increased plasma
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concentrations of both remnant lipoproteins and IDL also present. In patients with 
proteinuria, statins have been shown to successfully reduce plasma cholesterol, 
triglyceride, apoB and LDLIII, but not remnant lipoproteins (chapter 5). The effects of 
statins are achieved by reducing cholesterol synthesis and up-regulating the LDL 
receptor, but also by increased removal of LDL precursors and decreased VLDL 
production [230]. In chapter 5, we found that in patients with proteinuria, fibrates 
reduce plasma cholesterol, with a more profound effect on triglyceride rich 
lipoproteins and both LDLIII and remnant lipoproteins. This is primarily achieved by 
reducing apoCIII synthesis, thus promoting efficient metabolism of triglyceride rich 
lipoproteins [152]. It is clear that the ability of these agents to improve dyslipidaemia 
is similar in both renal and non-renal disease.
The second aim of lipid lowering therapy is that of slowing progression of renal 
disease. The most extensive clinical data examining the role of dyslipidaemia in 
slowing progression of renal disease is in diabetic nephropathy where both cholesterol 
and triglyceride are independently associated with increased risk of renal failure 
[149,150,201]. In proteinuric glomerular disease there is increasing evidence, 
supported by the data in chapter 6 , that apoB containing lipoproteins contribute to 
renal failure progression [151,202]. However there are no large scale studies that have 
addressed the question of whether lipid lowering therapy will slow the progression of 
renal failure. Multicentre trials are clearly required to resolve this issue.
Given the efficacy of both statins and fibrates in improving lipid profiles in 
proteinuric renal disease and their proven benefit in reducing cardiac disease in non- 
renal populations, the main resistance to their use in proteinuria is likely to be related
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to a lack of data surrounding drug toxicity in this population. The large scale studies 
using statins are remarkable in their lack of significant side effects, and therefore to 
obviate the likely large reduction in caidiac disease in patients with proteinuiia, 
extensive and unexpected adverse effects would have to be seen following their use in 
this population. There was concern regarding the safety of the older fîbrate 
preparations, however adverse events were not significant in either the Helsinki Heart 
Study [70] or the recently published Veterans Affairs HIT study [191]. In this context 
it is significant that meta-analysis of lipid lowering therapies in patients with renal 
disease has not demonstrated an excess of adverse drug reactions [231]. The data 
presented in chapter 5 did show an increase in serum creatinine following fenofibrate 
treatment, an increase that has been noted in other studies, however further 
investigation did not show a decrease in creatinine clearance, and a reduction in GFR 
has not been demonstrated in patients with renal dysfunction, despite an increase in 
serum creatinine [197]. It seems likely that the effect of fenofibrate on serum 
creatinine results from an increase in creatinine production from muscle. It is 
noteworthy that previous dose response studies have noted that increases in serum 
creatinine are transient despite continued therapy [198].
Therefore in patients with chionic renal dysfunction, the two main questions are:
1. Who should we be aiming to treat ?
2. At what aspect of dyslipidaemia should we be targeting our treatment ?
There seems no doubt that treatment decisions should be tailored to individual 
patients. However within this a distinction should be made between primary and 
secondary prevention, no matter what the underlying renal pathology. A raised plasma
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cholesterol should be treated, but the data presented in this study strongly suggests 
that simply measuring plasma cholesterol is inadequate in order to fully assess the 
cardiovascular risk posed by the dyslipidaemia. Full fasting B quantification of lipids 
and lipoproteins should be analysed and close attention should be made to the plasma 
triglyceride and FIDL-C measurements. In patients with nephrotic range proteinuria or 
type 2 diabetics with nephi’opathy, a plasma triglyceride >1.5mmol/1 waiTants closer 
attention, whilst in ESRF consideration should be made to treating a plasma 
triglyceride >2mmol/l. Given the greater amount of data regarding coronary protection 
and safety, statins seem the logical first choice in renal disease, however the lipid 
profiles are likely to need aggressive treatment. It is worth noting that despite good 
lipid lowering in chapter 5, cerivastatin in a dose of 200microg failed to reduce 
LDLIII mass to <100mg/dl in any of the 10 patients who had an initial plasma LDLIII 
concentration > 1 0 0 mg/dl and failed to provide a reduction in lipoprotein remnants. 
Carefully monitored lowering of cholesterol and triglyceride with a combination of 
statin and fibrate may be required in this population in order to provide maximum 
cardiovascular risk reduction.
CONCLUSION
Heavy proteinuria is associated with increased risk of vascular disease. It is evident 
that simply looking at the plasma cholesterol and LDL-C does not allow full 
assessment of the cardiovascular risk posed by dyslipidaemia in this population. In 
addition to hypercholesterolaemia, raised plasma triglyceride is well recognised in 
nephrotic range proteinuria and is consequent upon delayed clearance of triglyceride 
rich lipoproteins. This results in production of small dense LDL and lipoprotein
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remnants. However excess production of LDLIII is not restricted to patients with 
nepluotic range proteinuria, with atherogenic levels of LDLIII prevalent in both 
diabetic nephropathy and ESRF. Thus the atherogenic lipoprotein phenotype is a 
common finding that is not necessarily expressed as an increase in LDL, but is 
nevertheless highly atherogenic. Despite significant lowering of lipids, lipoproteins 
and reductions in the concentration of LDLIII, atherogenic levels of small dense LDL 
remain following lipid lowering therapy in proteinuric renal disease. Increased 
remnant lipoproteins are also a component of the phenotype that responds to fibrate 
but not to statin therapy. The differing relationships between LDLIII reduction and (i) 
triglyceride reduction following fenofibrate and (ii) LDL-C reduction following 
cerivastatin suggest a potential role for combined therapy to achieve greater reduction 
in atherogenic lipoproteins. Cardiovascular protection in patients with chronic renal 
disease should be aimed at not only reducing total cholesterol but also at reducing 
concentrations of small dense LDL and remnant lipoproteins.
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